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SUMMARY
Comparative studies of non-steroidal anti-inflammatory 
drugs (NSAIDs) in rheumatoid arthritis indicate that patient 
response is variable and unpredictable. Although variability 
in pharmacokinetics might be implicated, no study has been 
able to demonstrate this. Changes in patient response to 
increments in dose or concentration have been difficult to 
detect, possibly due to the variable nature of the disease, 
to individual differences in disease severity and to the 
subjective nature of the rheumatological measurements.
In this thesis the response to increments in dose or 
concentration of two NSAIDs, fenclofenac and naproxen, were 
investigated in patients with rheumatoid arthritis. In both 
cases three doses were given to all patients in a randomised 
double-blind design. Attention was focused on the 
determination of pharmacokinetic variability and the utility 
of plasma concentrations in the explanation of clinical 
response. In addition, the disposition of indomethacin in 
plasma and synovial fluid was studied.
Analytical techniques were developed for the accurate 
measurement of plasma concentrations by high performance 
liquid chromatography and for the determination of the 
concentration of these drugs not bound to plasma proteins 
using equilibrium dialysis.
The variability in the pharmacokinetics of the NSAIDs 
was assessed by performing single dose studies. There was 
considerable variability in the clearance of both
xiii)
fenclofenac and naproxen. The clearance of fenclofenac 
appeared to be reduced in patients with raised alkaline 
phosphatase and with increasing age. The clearance of 
naproxen was also reduced in the elderly and appeared to be 
lower in female patients.
Linearity or non-linearity in the kinetics was 
determined from trough samples taken at steady state on each 
dose. The kinetics of fenclofenac (free plus bound) over the 
dose range 600 to 1800mg/day were consistent with linearity, 
but the kinetics of naproxen over the dose range 500 to 
1500mg/day were non-linear in all patients.
Protein binding studies confirmed that the non- 
linearity could be explained in terms of saturation of 
naproxen binding sites on plasma proteins. Saturation of 
binding also occured with fenclofenac but the increase in 
the free fraction with increasing total concentration was 
less dramatic for fenclofenac than for naproxen and did not 
appear to have a significant effect on the kinetics of total 
fenclofenac. There was, however, a linear increase in free 
concentrations.
The indomethacin study showed that there was some 
variability in the concentrations of indomethacin achieved 
in synovial fluid. There were also variations in the rate of 
input and output from synovial fluid. These factors may also 
be important in determining the variability in clinical 
response to NSAIDs. During the elimination phase a 
concentration gradient between plasma and synovial fluid was 
identified. The concentration in synovial fluid was in
xiv)
general at least twice that in plasma at later times and may 
explain the extended clinical effect produced by NSAIDs.
The relationship between dose or plasma concentration 
(total or free) of fenclofenac and naproxen and clinical 
response (Ritchie Articular Index, duration of morning 
stiffness, mean grip strength and the analogue pain score) 
was in general most appropriately described in terms of a 
simple linear model which took account of inter-individual 
disease severity (individual intercept). The improvement in 
symptoms (if any) which occured with increments in dose or 
concentration was described by a common slope.
In general knowledge of the inter-individual 
variability in total or free concentration at steady state 
added little to the explanation of the clinical response if 
the dose was known. As a result of the considerable inter­
individual variability in response, the average clinical 
improvement with increments in dose (or concentration) were 
not dramatic. Often the greatest improvement was observed 
between no treatment and the lowest dose. Further increases 
in dose were not associated with a proportional improvement 
in response. This suggested that the initial (no treatment) 
state was exaggerated (assessments carried out under non- , 
blinded conditions) or that the doses used currently in 
clinical practice are close to those necessary to achieve a 
maximum response.
If assessments carried out after withdrawal of previous
(XV)
therapy were included in the analysis, a hyperbolic or 
model was more appropriate in some cases. This was more 
apparent for naproxen (analysed in terms of dose or free 
concentration) than for fenclofenac. The relationship 
between total naproxen and response was still most 
appropriately described by a linear model as both response 
and concentration tended to plateau. In both studies the 
analogue pain score appeared to be the most sensitive 
measure of changes in response.
There were no serious side-effects experienced with 
either of these drugs. The small number of patients 
precluded any formal study of the relationship between side- 
effects and concentration.
In the absence of concentration related toxicity, the 
findings presented in this thesis suggest that if the dose 
of the NSAID is increased, on average an improvement in 
response can be expected. Drug concentrations measurements 
(in plasma) appear to be unnecessary in clinical practice. 
NSAID pharmacokinetic variability appears to contribute 
little to the total variability in clinical response to 
these drugs.
(xvi)
CHAPTER 1
GENERAL INTRODUCTION 
AND BACKGROUND
1.1 GENERAL INTRODUCTION
The work described in this thesis arose from a desire to 
optimise the therapeutic use of non-steroidal anti­
inflammatory drugs (NSAIDs) in the treatment of rheumatoid 
arthritis. The number of NSAIDs available to the 
rheumatologist has increased dramatically during recent years. 
The choice and dose of drug remains, however, relatively 
empirical. This may in part be a result of the lack of good 
data concerning the variability in the pharmacokinetics of 
these drugs, or conclusive data relating plasma or synovial 
fluid concentration and clinical response.
The withdrawal of benoxaprofen, after its use in 
the elderly was associated with fatal hepatic toxicity 
highlighted the potential risks associated with the use of 
drugs of this class. Indeed, one of the drugs studied in 
this thesis (fenclofenac) was discontinued recently because 
of a high incidence of skin rashes.
There is a need to investigate the variability in 
the pharmacokinetics of these drugs and to determine whether 
differences can be explained in terms of patient specific 
factors. Together with information regarding the 
relationship between concentration and clinical effect or 
toxicity, this would allow a more rational use of these 
drugs.
In this thesis Chapter 1 gives a general introduction.
The analytical techniques used to determine total and free 
drug concentrations are presented in Chapter 2. Chapter 3 
describes the traditional rheumatological assessments, the
assessments chosen for the subsequent studies and introduces
1
some of the newer objective measurements which might prove 
useful in the future. This is followed in Chapter 4 by an 
outline of the general approach used in the analysis of 
data.
Chapters 5 and 6 present two controlled studies of 
naproxen and fenclofenac in patients with rheumatoid 
arthritis to determine whether knowledge of inter-individual 
differences in the pharmacokinetics of these NSAIDs can 
contribute to the explanation of the clinical response. 
Chapter 7 presents a single dose study of a slow release 
preparation of indomethacin to elucidate the relationships 
between concentrations in plasma and synovial fluid.
The final chapter presents a general discussion of 
the results and clinical implications.
1.2 RHEUMATOID ARTHRITIS AND ITS TREATMENT
Rheumatoid arthritis is a chronic systemic disease 
characterised by inflammatory arthritis of the peripheral 
joints. The aetiology of the disease is largely unknown, 
although there appears to be some immunological basis for it 
which results in a chronic inflammatory response. There is 
evidence that the disease is an autoimmune disorder which 
has to be triggered by some genetic or environmental factor.
Inflammation is the normal response to tissue injury 
and is characterised by heat, redness, swelling, tenderness 
and pain. During the inflammatory response, chemical 
mediators such as 5-hydroxytryptamine (5-HT), slow- 
reacting substance of anaphylaxis (SRS-A), various 
chemotactic factors, bradykinin and prostaglandins are
2
liberated locally. Phagocytic cells migrate into the area 
and cellular lysosomal membranes may be ruptured, releasing 
lytic enzymes.
The inflammatory response in rheumatoid arthritis 
probably occurs due to the combination of an antigen (gamma 
globulin) with an antibody (rheumatoid factor) and 
complement, causing the local release of chemotactic factors 
that attract leucocytes. The leucocytes phagocytose the 
complexes of antigen, antibody and complement and in doing 
so release lysosomal enzymes. This leads to a continuous 
inflammatory reaction and eventually to extensive tissue 
damage.
The drugs available to treat rheumatoid arthritis are 
generally divided into two types:
1. NSAIDs which provide symptomatic relief by reducing 
the inflammation. For most patients, relief from pain and 
stiffness caused by inflammation develops within a week of 
treatment.
2. 'Second-line' drugs such as gold (sodium 
aurothiomalate) and penicillamine which appear to have some 
disease modifying effects which develop much more gradually 
over several months.
Steroids, have features of both types of drug 
and in addition claims have been made recently that some of 
the newer NSAIDs may have some disease modifying properties 
(eg benoxaprofen and fenclofenac). The use of steroids and 
'second-line' drugs is , however, restricted by the serious 
toxic effects that often develop during treatment. Thus 
emphasising the desire to obtain the maximum therapeutic 
effect from the less toxic NSAIDs.
1.3 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
1.3.1 Mechanism of action of NSAIDs
The NSAIDs are a diverse group of compounds (although 
in general they are all carboxylic acids) which share 
certain therapeutic actions and side-effects (Table 1.1). 
Salicylic acid had been used for a number of years to reduce 
the symptoms of inflammation, but until recently the mode of 
action was largely unknown. In 1971 Vane and others 
discovered that low concentrations of aspirin and 
indomethacin inhibited the enzymatic production of 
prostaglandins (Vane, 1971; Smith & Willis, 1971; Ferreira, 
Moncada & Vane, 1971). This, together with the evidence that 
prostaglandins contributed to the pathogenesis of 
inflammation led Vane to propose that inhibition of 
prostaglandin synthesis explains the therapeutic and some of 
the toxic effects of the NSAIDs. Prostaglandins generally 
act as vasodilators, and they potentiate the pain and oedema 
induced by other mediators such as bradykinin and histamine 
which are also released during inflammation.
Correlations between the relative anti-inflammatory 
potency in animal models of inflammation and the reduction in 
prostaglandin concentrations support the view that the major 
effect of these drugs can be accounted for by the inhibition 
of prostaglandin synthesis (Higgs, Moncada & Vane, 1980).
Two enzymes convert phospholipid derived arachidonic 
acid to a number of substances known as ^eicosanoids' (Figure 
1.1). The NSAIDs in general selectively inhibit the enzyme
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FIGURE 1.1 The formation of prostaglandins, thromboxanes 
and leucotrienes from arachidonic acid
A Cyclo-oxygenase pathway 
B Lipoxygenase pathways
eye 1o-oxygenase whieh eatalyses the eonversion of 
araehidonie aeid into endoperox ides and then by the aetion 
of isomerases to the prostaglandins and thromboxane. The 
seeond pathway is eatalysed by 1 ipoxygenase(s), araehidonie 
aeid is eonverted to an unstable hydroperoxy aeid and 
eventually to non-eyelysed hydroxy aeids (HETE), and 
leueotrienes. All tissues exeept red blood eel Is are eapable 
of produeing prostaglandins in response to injury. 
Prostaglandins are not stored, and their release refleets de 
novo synthesis. The eye 1o-oxygenase enzyme appears to be 
tissue speeifie; the poteney of inhibition by NSAIDs varies 
from tissue to tissue (Flower & Vane 1974). In addition 
different tissues produee different profiles of 
prostaglandin produets possibly due to different isomerase 
enzyme aetivities present in the tissue. The major 
prostaglandins identified in synovial effusions of patients 
with rheumatoid arthritis were PGE 2 , TXB 2 (the stable 
breakdown produet of TXA 2 ) and G-keto-PGF^# (the stable 
breakdown produet of PGI2 ). However, the ratio of the 
different eyelo-oxygenase produets showed considerable 
inter-subjeet variability indicating a heterogeneous 
cellular origin (Bombardieri et al, 1981). In addition, the 
extent of inhibition of prostaglandin synthesis by 
indoprofen ranged from 33% for G-keto-PGF^# to 90% for PGE2 .
Most NSAIDs are reversible inhibitors of eyelo- 
oxygenase and the effect of indomethaein on prostaglandin 
synthesis jo v ivo decreases as the drug is eliminated (Kane 
et al, 1978).
The NSAIDs also inhibit or interfere with a variety of 
other enzyme or cellular systems, and these effects may also 
contribute to their clinical effects. The concentrations 
required, however, tend to be considerably higher than those 
necessary to produce a therapeutic effect. Inhibition of 
the migration of leucocytes or monocytes into inflamed sites 
has been reported for some NSAIDs, doses required to 
reduce leucocyte migration are in general considerably 
higher than those which prevent oedema and the effects are 
species specific (Higgs et al, 1980).
Some NSAIDs appear to have a differential effect on 
leucocyte migration jji vivo. Indomethaein, aspirin and 
flurbiprofen enhance the accumulation of cells in 
inflammatory exudates at doses which significantly reduce 
prostaglandin production, but inhibit cell migration at 
higher doses (Higgs et al, 1980). This observation can be 
explained if the inhibition of eyelo-oxygenase diverts 
substrate towards the production of chemotactic lipoxygenase 
products, which then account for increased leucocyte 
migration. The subsequent inhibition of leucocyte migration 
at higher doses may be explained by a non-specific 
inhibition of araehidonie acid peroxidation.
In addition, prostaglandins released by macrophages in 
v itro appear to have a negative feedback effect on the 
production of lymphokines by T lymphocytes (Gordon, Bray & 
Mori e y , 1976). If a negative feedback on T cell function by 
prostaglandins is important _i_n vivo and if the enhancement 
of the production of chemotactic lipoxygenase products
occurs with the inhibition of eye 1o-oxygenase, NSAIDs, 
although alleviating the symptoms of inflammation, may 
enhance certain features of chronic inflammatory disease.
1.3.2 NSAIDs investigated in this thesis 
( i) Fenclofenac
Fenclofenac, a phenyl acetic derivative, was developed 
in the mid 1970's for the treatment of chronic inflammatory 
disorders. In animal models of inflammation, Atkinson & Leach 
(1976) found that the anti-inflammatory profile of 
fenclofenac was different from other common NSAIDs. 
Fenclofenac was only slightly effective in an acute 
inflammation model (rat carrageenan paw oedema), while it 
was relatively more effective in a chronic model of 
inflammation (adjuvant arthritis in the rat).
The efficacy of a standard 1200mg daily dose was shown 
to compare favourably with 150mg of indomethaein daily 
(Aylward et al, 1980) and to be more effective than 750mg of 
naproxen daily (Tiselius, 1980). In long term trials of 
fenclofenac the frequency of gastrointestinal side effects 
compared favourably with other NSAIDs (Smith, 1977). The 
observation that there was a reduction in the ESR during 
long term treatment suggested that fenclofenac possessed 
some disease modifying effects. One study indicated that 
there were significant improvements in both clinical and 
laboratory indices (eg C-reactive protein) after 6 months 
when no significant effects had been observed after 3 months 
(Berry et a l , 1980).
Fenclofenac, however, was withdrawn from clinical use 
by the Committee on Safety of Medicines, shortly after the 
completion of the study described in Chapter 5 because in 
their view, the use of fenclofenac was associated with an 
unacceptably high incidence of skin rashes. In earlier 
clinical studies, the incidence of skin rashes was 
approximately 14% during long term treatment (Smith, 1977).
( i i) Naproxen
Naproxen, a propionic acid derivative, was introduced 
in 1973 and has subsequently become a standard in this 
class of NSAID. Like other alpha substituted propionic 
acids, naproxen is a chiral compound. Only the S(+)- 
enantiomer is anti-inflammatory and an inhibitor of cyclo- 
oxygenase. The pharmaceutical preparation contains only the 
active isomer.
In rheumatoid arthritis, naproxen is effective and well 
tolerated. In a study of four propionic acid derivatives, 
naproxen (500mg/day) combined the greatest efficacy with the 
lowest incidence of side-effects (Huskisson et al, 1976). 
Naproxen is generally prescribed in doses of 500 to 1000mg 
daily (two divided doses).
(iii) Indomethaci n /
Indomethaein has been used in the treatment of 
rheumatoid arthritis for over 20 years. After, the discovery 
that the therapeutic action of indomethaein could be 
explained in terms of prostaglandin synthetase 
inhibition, it became a reference for comparison with newer 
agents. Side-effects tend to be more common for
indomethaein than for the newer NSAIDs. Headache was 
reported in over 10% of patients treated with indomethaein 
(Rhymer & Gengos, 1979). A relationship between central 
nervous system side effects and high peak concentrations of 
indomethaein has been noted (Baber et al, 1978).
Indocid-R, marketed as a 'slow release' preparation of 
indomethaein, has been designed to give flatter 
concentration profiles, theoretically minimising the side- 
effects often associated with high peak concentrations.
1.4 PHARMACOKINETICS OF NSAIDs
The important factors which determine the concentration 
of a drug in plasma are:
(a) the presence or absence of linear kinetics, and
(b) the extent of inter-subject variability in the 
kinetics.
The following background to the pharmacokinetics of 
NSAIDs concentrates on the specific drugs investigated in 
this thesis.
1.4.1 Absorption
In general the absorption of NSAIDs is rapid and 
bioavailability is close to 100%. Although food reduces the 
rate of absorption and the peak concentration, the overall 
bioavailability appears to be unaltered. This has been 
observed for fenclofenac (Henson et al, 1980) and naproxen 
(Runkel et al, 1972).
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The absorption of indomethaein after oral 
administration was complete as judged from material 
balance studies (Duggan et al, 1972). However, subsequent 
studies have suggested that indomethaein undergoes 
significant enterohepatic recirculation (Kwan et al, 1976). 
Published bioavailability studies must be interpreted 
with caution.
1.4.2 Metabolism
NSAIDs are generally eliminated entirely by hepatic 
metabolism, little parent drug is eliminated in the urine 
unchanged. In general the drugs are excreted as conjugates 
of the parent drug or any oxidative metabolites.
The oxidative metabolism of fenclofenac is illustrated 
in Figure 1.2. More than 93% of an oral dose has been
shown to be excreted in the urine (>93%) in the form of
conjugates of the parent compound and the hydroxylated 
metabolites (Hucker, Kwan & Duggan, 1980).
The only oxidative reaction identified for naproxen is
0-demethyl ation to give desmethyl naproxen (DMN). The parent
drug and DMN are conjugated, mainly with glucuronic acid 
(Figure 1.3) and the major metabolite recovered in urine is 
naproxen glucuronide (Runkel et al, 1972, 1976). These 
earlier metabolic studies suggested that about 10% of a dose 
was excreted unchanged in urine (Runkel et al, 1976), 
however, subsequent studies have indicated that negligible 
naproxen is excreted unchanged, and that naproxen is 
liberated from the glucuronide in urine while stored frozen
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FIGURE 1.3 The metabolism of naproxen
Key: N naproxen
DMN 6-0-desmethylnaproxen
(Upton et al, 1980b).
Indomethaein is metabolised extensively (Figure 1.4). 
0-demethy1 ation and N-dealkylation to give desmethyl (DMI), 
desbenzoyl (DBI) and desmethyl-desbenzoy1 (DMBI) metabolites 
followed by conjugation (Duggan et al, 1972). The major 
pathway is déméthylation followed by dealkylation.
1.4.3 Distribution and el imination
The clearance of NSAIDs is generally less than liver 
blood flow and is therefore affected by differences in 
protein binding and hepatic metabolic activity (Wilkinson & 
Shand, 1975). There is therefore scope for considerable 
inter-subject variability in the elimination of these drugs. 
The volume of distribution of NSAIDs is small and of the 
order of 10 to 20 1 due to the high degree of plasma protein 
binding. In general around 99% of the total drug in plasma 
is bound to protein.
(ii) Naproxen
The elimination half-life of naproxen in healthy 
volunteers is about 14 hours (Runkel et al, 1974 & 1976). In 
healthy young male volunteers, the clearance of total 
naproxen at steady state on 375mg twice daily was 
0.547+0.083 1/h (Upton et al, 1984). Early pharmacokinetic 
studies indicated that with single doses of naproxen over 
500mg, there was a less than proportional increase in the 
AUC with further increments in dose up to 4g (Runkel et al, 
1974 & 1976). In a study where radio 1abe1 led naproxen was
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FIGURE 1.4 The metabolism of indomethaein 
Key: I indomethaein
DMI desmethyl indomethaein
DBI desbenzoyl indomethaein
DMBI desmethyl-desbenzoyl indomethaein
given, recovery of drug in the urine indicated that this 
effect could not be due to reduced absorption of the larger 
doses (Runkel et al, 1974): there was little difference in 
the percentages of the various metabolites recovered in the 
urine.
Naproxen is bound principally to albumin. At a 
total concentration of 100pg/ml the percentage bound to 
human plasma and isolated human plasma albumin was 99% and 
96% respectively (Calvo & Dominguez-Gi1 , 1983). At a total 
concentration of 5pg/ml, however, the percentage bound was 
higher in isolated human serum albumin (99.91%) than in 
plasma (99.79%) (Piafsky & Borga, 1977). These workers also 
found that naproxen showed little affinity for (y^  ^cid 
glycoprotein (a^AGP).
Scatchard analysis of the binding of naproxen to 
solutions of human albumin, bovine serum albumin and human 
plasma indicate that naproxen is bound to at least two 
distinct binding sites (Calvo & Dominguez-Gi11 , 1983; Kaneo 
et al, 1981; Runkel et al, 1976).
The dose dependent kinetics of naproxen and other 
NSAIDs such as ibuprofen (Lockwood et al, 1983) have been 
explained in terms of the non-linear binding to plasma ,. 
proteins which occurs at concentrations achieved clinically. 
In vitro studies indicate that the percentage of free 
naproxen ranged from 0.37 at a total concentration of 
23^g/ml to 0.95 at a total concentration of 150;jg/ml (Runkel 
et al, 1974). Any changes in the binding to plasma protein 
will affect the apparent clearance of total drug and the
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volume of distribution.
( i i) Fenclofenac
There are few data on the pharmacokinetics of 
fenclofenac. Two studies have been published, one in healthy 
volunteers and the other in children with juvenile 
rheumatoid arthritis (Henson et al, 1980 & Makela et al, 
1983). In healthy male volunteers the mean elimination half- 
life was 27 hours and ranged from 20-38 hours. The mean 
apparent clearance of fenclofenac (j^SEM) was 0.38 (j^ 0.04)
1/h after a single 600mg oral dose. The hepatic extraction 
ratio was of the order of 0.007.
Up to 100pg/ml, the free fraction of fenclofenac was 
0.3%. Above this the free fraction increased with increasing 
total concentration (Brewster & Muir, 1978). There was a 
suggestion from the data in healthy individuals that there 
was a non-linear increase in plasma concentrations on 
multiple dosing as assessed by differences in observed and 
predicted concentrations at steady state. Although the 
elimination half-life was comparable the clearance and 
volume of distribution were apparently higher after multiple 
dosing, suggesting the presence of non-linear kinetics due 
to saturation of binding to plasma protein (Henson et al, 
1980) .
In 17 children aged 4-14years, fenclofenac was given in 
doses of 10-25mg/kg body weight (in two divided doses) for 
up to 3 weeks. The mean elimination half-life was 25.4 hours 
and ranged from 15-39 hours (Makela et al, 1983). There was 
a linear relationship between peak plasma concentrations and
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dose and between trough plasma concentration and dose.
(iii) Indomethaein
Alvan et al (1975) reported that the elimination of 
indomethaein could be approximated by a two compartment 
model and that this model was adequate to predict plasma 
concentrations at steady state after repeated dosing. The 
elimination half-life ranged from 2.6 to 11.2 hours and the 
plasma clearance ranged from 0.044 to 0.109 1/hr/kg. Despite 
variable kinetics suggested by the single dose study, plasma 
concentrations at steady state were quite similar between 
subjects. It was noted that terminal concentration time 
points did not decline exponentially, possibly due to 
enterohepatic recirculation and subsequently Kwan et al 
(1976) found that the two compartment model was inadequate.
A more complex model was proposed to account for 
enterohepatic recirculation. There was no evidence of dose 
dependent kinetics (Alvan et al, 1975).
1.4.4 Pharmacokinetics of NSAIDs in age and disease
There are no data on the kinetics of fenclofenac in 
elderly patients or in renal or hepatic disease.
Upton et al (1984) found there was no significant 
difference in the clearance of total naproxen in young and 
elderly healthy male volunteers at steady state. However, in 
the elderly group, reduced binding to plasma protein masked 
a 50% decrement in the intrinsic clearance of naproxen in 
the elderly as estimated by the unbound clearance. In young 
and elderly patients with osteoarthritis, age was associated
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with an increase in the elimination half-life of naproxen 
and higher total naproxen concentrations despite the fact 
that the albumin concentrations were similar (McVerry et 
al, 1986). Both of these studies indicate that there is a 
reduction in the intrinsic clearance of naproxen with age.
The elimination half-life of total naproxen was equal 
in healthy individuals and patients with moderate or severe 
renal failure (Anttila, Haataja & Kasanen, 1980). Serum 
concentrations of total drug tended to be lower in patients 
with severe renal failure, while concentrations of DMN were 
considerably higher. The clearance of free drug was not 
determined so it was established whether renal impairment 
was associated with a decrease in the intrinsic clearance. 
There was, however a correlation between the percentage of 
free drug (at a total concentration of 50pg/ml) and serum 
creatinine.
There was a reduction in the clearance of free drug in 
patients with alcoholic cirrhosis compared with healthy 
volunteers. On the basis of total drug, however, there was no 
evidence of any difference in the elimination between the 
two groups. Again lower albumin concentration in patients 
with cirrhosis masked a reduction in the intrinsic clearance 
of free naproxen (Williams et al, 1984).
There is some evidence that glucuronides of naproxen 
and ketoprofen are labile in plasma, and that reduced renal 
function will result in the accumulation of glucuronide and 
subsequent liberation of the parent drug (Upton et al,
1980b; Upton et al, 1982; Verbeeck, Wallace & Loewen, 1984).
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Benoxaprofen, one of the newer NSAIDs, was claimed to 
be an inhibitor of both eye 1o-oxygenase and the lipoxygenase 
enzyme (Walker & Dawson, 1979). Reports of the effect of age 
or renal impairment were conflicting but in general they 
suggested that the elimination of benoxaprofen was reduced 
with increasing age or decreasing renal function (Arnoff et 
al, 1982; Hamdy et al, 1982). In addition, these studies 
only investigated the clearance of total benoxaprofen, and 
it is likely that reduced protein binding in renal 
impairment or age would have masked an even greater 
reduction in the intrinsic clearance. Later reports of fatal 
cholestatic jaundice often associated with nephrotoxicity in 
the elderly led to the withdrawal of benoxaprofen from 
clinical use (Taggart & Alderice, 1982).
1.5 NSAID DOSE AND CONCENTRATION-RESPONSE RELATIONSHIPS
In the past decade, measurement of plasma 
concentrations of a number of drugs has become an integral 
part of routine clinical practice. Monitoring of salicylate 
was widely practiced by physicians in the treatment of 
rheumatic fever and has also been used to guide aspirin 
therapy in rheumatoid arthritis. However a recent controlled 
study has indicated monitoring salicylate offers no 
improvement over the standardised procedure of 
systematically increasing the dose until side effects appear 
or a dose of 6g/day is reached (Tugwell et al, 1984).
The rationale for monitoring plasma concentrations of
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drugs is based on several prerequisites, the most 
important of which is that there should be a better 
correlation between plasma concentrations and the 
pharmacological effect than between the administered dose and 
clinical response. Studies of the pharmacokinetics of NSAIDs 
have indeed indicated considerable inter-individual 
variability in the pharmacokinetics of these drugs which are 
eliminated almost exclusively by hepatic metabolism. Of the 
host of NSAIDs available, however, there is little or no 
information on minimum effective concentrations, therapeutic 
ranges or toxic concentrations.
A more rational approach to the use of NSAIDs is 
needed. Doses of these drugs are often increased by 
physicians and patients above those recommended. Although 
this suggests that patients achieve greater effect from the 
higher doses, the possibililty of toxicity cannot be ignored. 
NSAIDs are traditionally prescribed in fixed doses to 
patients of all ages despite the fact that renal impairment 
may reduce the elimination of these drugs. A drug that is 
not toxic in healthy adults may cause serious toxicity in 
the elderly due to accumulation of the parent drug or a 
particular metabolite.
It has been found in practice that despite the common 
mode of action of all NSAIDs some patients will respond to 
one but not another (Scott et al, 1982; Huskisson et al,
1976). In 1976 Huskisson and colleagues suggested that from 
the results of a study comparing four different propionic 
acid derivatives (ibuprofen, naproxen, ketoprofen and
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fenoprofen) there was considerable variation in individual 
responses to different drugs in terms of both effectiveness 
and the incidence of side effects. He proposed that:
"Since we cannot yet predict which patients will respond to 
a particular drug it may be necessary to try them all to 
find the best."
It is possible, however, that a poor clinical response 
may in part be due to pharmacokinetic variability and that 
there is more room for dosage adjustment than is normally 
practiced with NSAIDs. The results of studies to answer these 
questions have been inconclusive often due to inappropriate 
study design and variability in patient response.
There was no correlation between plasma concentration 
and clinical effect for phenylbutazone (Brooks et al, 1975; 
Orme et al, 1976) indomethaein (Ekstrand et al, 1980) or 
ibuprofen (Grennan et al, 1983). However these results are 
not altogether surprising as dose response relationships 
within an individual have in general been very difficult to 
detect. The results have been disappointing for a number of 
reasons:
a) Clinical response is often determined over a small range 
of doses, usually at the upper end of the dose range 
(Grennan et al, 1983). There was no difference in the 
response to three doses of indomethaein 45, 75 and 
100mg/day (Ekstrand et al, 1980) however this was not 
entirely unexpected as at a daily dose of 37.5mg, 
indomethaein was associated with a 60% reduction in the 
excretion of prostaglandins (Rane et al, 1978).
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b) There is considerable intra-individual variability
in the response measures and often too few patients have 
been studied to achieve significance (Orme et al, 1976).
c) The inter-subject variability in disease severity must be 
taken into account in the analysis of this type of data.
d) Patients should exhibit active disease, a 'flare' of 
symptoms when anti-inflammatory treatment is withdrawn 
should be demonstrated. Patients will not respond to 
an NSAIDs if there is no inflammation.
There was no difference in the pharmacokinetics of 
flurbiprofen and indomethaein at steady state in responders 
and non-responders (Capell, Konetshnik and Glass, 1977;
Baber et al, 1979).
To date, only one study has demonstrated a concentration- 
response relationship (Day et al, 1982). However, in this 
study there was no evidence that naproxen concentration gave 
an improved description of clinical effect over dose.
The propionic acid derivatives exist as stereo isomers, 
the pharmacological activity residing in the S(+)- 
enantiomer. With the exception of naproxen these drugs (eg 
ibuprofen, flurbiprofen, and ketoprofen) are given as 
enantiomeric mixtures. Metabolic chiral inversion of the 
inactive R(-)-enantiomer to the active isomer has been 
identified in man vivo (Hutt & Caldwell, 1983) for 
ibuprofen and benoxaprofen. On average, 63% of an 
administered dose of R (-)-ibuprofen is inverted to the S(+)- 
isomer (Lee et al, 1985). Inter-individual differences in 
the elimination of the respective isomers may also add to
20
the problems in the detection of a concentrâtion-response 
relationship if only total drug is measured.
The failure to establish a plasma concentration - 
response relationship for a number of NSAIDs might indicate 
that other factors determine the pharmacological response. 
NSAIDs must cross the synovial barrier to reach their site 
of action, and clinical effect might be more closely related 
to the concentration of total or free drug achieved in 
synovial fluid or synovial tissue.
The accumulation of acidic and non-acidic NSAIDs has 
been compared in acute and chronic animal models of 
inflammation (Graf, Glatt & Brune, 1975). There was a 
greater accumulation of the acidic NSAIDs in inflamed 
tissue. This could be explained in terms of an ion trapping 
effect (the lower pH in inflamed tissues will lead to a 
greater proportion of the acidic drugs in the un-ionised 
form, ie the drug will be more lipophilic) in addition to the 
higher degree of protein binding exhibited by acidic NSAIDs. 
Concentrations in inflamed joints were considerably higher 
than in controls. This observation has been proposed as the 
reason why non-acidic aspirin-like drugs have little anti­
inflammatory activity (Brune, Rainsford & Schweitzer, 198^). 
In rheumatoid arthritis, the 'levels' of oxyphenbutazone 
were significantly higher in patients with actively inflamed 
joints than in patients with little or no inflammation 
(Gaucher et al, 1983). It is more practical, however, to 
determine the concentration in synovial fluid. Studies in 
patients have found that synovial tissue concentrations were
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either similar to or less than concentrations in synovial 
fluid (Franke, Manz & Glynn, 1976; Jalava et al, 1977).
Simkin (1979) has proposed that the synovium behaves as 
a double barrier (previously regarded as a single barrier or 
simple 'dialysis membrane') between plasma and synovial 
fluid (Figure 1.5). It is proposed that passive diffusion 
through the interstitial space limits the overall trans- 
synovial exchange of most small molecules. The microvascular 
endothelium determines synovial permeability to proteins. In 
rheumatoid arthritis, microvascular changes may increase the 
permeability to proteins while interstitial changes 
(cellular hyperplasia, infiltration of inflammatory cells 
and deposition of fibrinous debris) restrict the synovial 
permeability to smaller water soluble molecules eg glucose 
and urea. However, the permeability of benzoyl alcohol, a 
small lipophilic molecule, was not reduced in the rheumatoid 
synovium (Simkin,1979).
Sholkoff et al (1967), investigating aspirin, were the 
first workers to conduct a kinetic study of an NSAID in 
synovial fluid. The majority of complete profile studies 
since then have been conducted on drugs with short half- 
lives, since anti-inflammatory activity was often noted to 
be sustained for longer than expected from knowledge of 
plasma concentrations (Wallis and Simkin, 1983). However, no 
study has investigated the relationship between NSAID 
concentration in synovial fluid and clinical response.
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FIGURE 1.5 'Tissue' model of synovial permeability 
proposed by ’Simkin (1979)
CHAPTER 2
ANALYTICAL TECHNIQUES
2.1 MATERIALS AND EQUIPMENT
2.1.1 Materials
Potassium dihydrogen phosphate and di-ethyl ether were of 
HPLC grade. Acetonitrile was HPLC grade with a far UV cut­
off of 210nm (90% transmission at 210nm). Bovine serum 
albumin was purchased from the Armour Pharmaceutical 
Company Ltd. All other reagents were of Analar grade.
Aqueous based reagents were made up in distilled water. HPLC 
mobile phases were filtered through either aqueous (Type AA 
0.8^) or organic (Type FA 1.0;j) filters supplied by 
Millipore and degassed by bubbling with helium.
Fenclofenac, [ 2- (2,3,5,6-tetrachlorophenoxy)phenyl ] 
acetic acid (TCPPA), 5-hyroxy fenclofenac and ^“^C- 
fenclofenac were kindly supplied by Reckitt and Colman. 
Naproxen, 6-0-desmethy1 naproxen (DMN) and 2-naphthylacetic 
acid were gifted by Syntex. Indomethaein was kindly supplied 
by Merck, Sharp and Dohme. Flufenamic acid was purchased 
from Sigma Chemical Company. Spectra/Por 2 dialysis membrane 
(molecular weight cut off 12,000-14,000) was purchased from 
Spectrum Medical Industries Inc.
2.1.2 Equipment
The HPLC system consisted of a Gilson model 302 pump and 
a Pye Unicam PU4020 UV variable wavelength detector. A 
Waters U6K manual injection system was used for the 
fenclofenac assay and a Waters Wisp autosampler was used for
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the naproxen and indomethaein assays. The output from the 
detector was collected by a Gilson HPLC Data Master system 
(Apple 2e microcomputer and Gilson Data Master module)
(Figure 2.1).
Equilibrium dialysis was carried out using a Dianorm^ 
system consisting of 20 Teflon 1ml cells contained in a 
rotating carrier unit (Figure 2.2). A Hewlett-Packard Liquid 
Scintillation Spectrometer was used to count ^-emission from 
^'^C-fenc 1 of enac. A Pye Unicam PU8600 UV/VIS 
Spectrophotometer was used in the estimation of total 
protein and albumin concentration.
2.2 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
2.2.1 Introduction
Reverse phase high performance liquid chromatography 
(HPLC) is ideally suited for the measurement of drugs and 
their metabolites in biological fluids. Earlier methods 
developed to measure NSAIDs depended on spectrofluorimetric 
techniques which in general are non-specific as these methods 
are not able to distinguish between the parent drug and 
metabolites or other NSAIDs. Before the advent of HPLC, gas 
liquid chromatography (GLC) gave specificity. However, 
sample preparation for GLC tends to be rather complex and 
laborious. The compound of interest has to be volatile, so a 
derivatisation step is often necessary for drugs containing 
highly polar substituents. Overall, HPLC is a much more
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/FIGURE 2.1 HPLC system
FIGURE 2.2 Dianorm^ dialyser
versatile system: sample preparation is shorter and simpler,
an infinite number of mobile phases may be used, various 
types of columns and packings are available and detection 
can be relatively specific with the use of variable 
wavelength UV absorbance and fluorescence detectors.
Sample preparation should be as simple as possible and 
yet a llow the specific assay of a drug in the presence of 
numerous biological components and other drugs. The extent 
of work-up is dependant on the specificity of the analytical 
technique and the relative amount of the drug present. 
Potentially interfering endogenous compounds need to be 
removed. If sample concentration is not necessary then 
protein precipitation using an organic solvent (usually 
acetonitrile) or a strong acid is a useful sample clean-up 
method. Sensitivity is then usually limited to the pg/ml 
range. Organic solvent extraction is useful for clean-up and 
sample concentration. The most appropriate organic solvent 
and aqueous phase pH can be chosen for a specific drug or 
metabolite depending on it's physico-chemical properties.
After standard doses of fenclofenac and naproxen, 
concentrations in plasma are relatively high compared to 
possible endogenous interference. With a specific HPLC set 
up, it is possible to analyse samples after a simple 
precipitation step. Indomethacin, however, is present in 
plasma in much lower concentrations (two orders of magnitude 
less) so it is necessary to carry out an acid extraction 
into an organic solvent in order to clean up the sample and
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concentrate it.
In all cases the aqueous component of the mobile phase 
was acidic giving ion suppression of all of these drugs (pKa 
3-4.5). The selectivity of each assay was determined by the 
use of different columns, slight alterations in the 
proportions of water and acetonitrile and the specific UV 
wavelengths for maximum absorption for the particular drug.
A summary of the final HPLC conditions for the measurement 
of fenclofenac, naproxen and indomethacin is given in Table2.1.
2.2.2. Assay for the measurement of fenclofenac in p 1asma
A specific, simple and rapid HPLC assay was developed 
for the determination of total fenclofenac in plasma.
Previous methods reported for the measurement of fenclofenac 
included GLC (Henson et al, 1980) and a rather laborious 
HPLC method requiring 1ml of plasma sample and the use of a 
solid phase extraction procedure (Flockhart & Binns, 1979).
The phase I metabolite of fenclofenac (5-hydroxy 
fenclofenac) could be quantified using this method. The 
assay described here for the determination of fenclofenac is 
a modification of a procedure used for other NSAIDs 
(Nielsen-Kudsk, 1980). The extraction of the drug is 
achieved by simple precipitation of plasma proteins with 
acetonitrile containing the internal standard, TCPPA, (a 
structural analogue of fenclofenac). The structures of 
fenclofenac and the internal standard are shown in Figure 
2.3.
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Fenclofenac
COOH
Cl
TCPPA
COOH
FIGURE 2.3 Chemical structures of fenclofenac and the 
internal standard, TCPPA
(i) Preparation of solutions
Ail solutions of fenclofenac and TCPPA were prepared in 
acetonitrile. Stock fenclofenac (Irag/ml) was prepared by 
dissolving 10mg of fenclofenac in 10ml acetonitrile. Working 
standards of 1, 10 and 100pg/ml were prepared by appropriate 
dilutions of this stock. Stock TCPPA (500pg/ml) was prepared 
by dissolving 10mg of TCPPA in 20ml of acetonitrile. 
Acetonitrile for precipitation was prepared by dilution of 
this stock to give 5pg/ml.
(ii) Preparation of plasma standard curves
Plasma standards, 2, 5, 10, 20, 50, 100 and 150pg/ml 
were prepared from standard fenclofenac working standard 
solutions. After evaporation of the acetonitrile at room 
temperature the residue was reconstituted in 0.1ml of 
plasma.
(iii) Extraction of plasma
The addition of 0.5ml of acetonitrile containing the 
internal standard (5pg/ml) to duplicate 0.1ml samples of 
plasma resulted in the formation of a precipitate. After 
brief centrifugation the supernatant was decanted into 
a clean polypropylene tube. Aliquots (10-50^1) of the 
supernatant were injected directly onto the column.
(iv) Chromatographic conditions
The mobile phase was a mixture of 50% acetonitrile and 
50% distilled water acidified to pH3 with orthophosphoric 
acid. This mixture gave a good separation of fenclofenac 
from the TCPPA when pumped through a 12.5cm Hypersil 5p ODS
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reverse phase column at 2ml/min with a pressure of 1000psi. 
The retention times of fenclofenac and the TCPPA were 4.6min 
and 6.7min respectively. The metabolite 5-hydroxy 
fenclofenac had a retention time of 2 minutes, but as this 
coincided with plasma constituents it was not possible to 
detect the very low concentrations expected. The detector 
was set at 215nm, the wavelength of maximum UV absorbance 
for fenclofenac. The detector attenuation was set at 0.05 
AUFS. Sample chromatograms of standard and patient samples 
are shown Figure 2.4.
(v) Quantitation
Quantitation of fenclofenac concentrations in patient 
samples was achieved by calculating the peak height ratio 
(PHR) of fenclofenac to the internal standard. Plots of 
PHR against fenclofenac concentration were linear (Figure 
2.5). The lower limit of detection defined as two times 
baseline noise was 0.5pg/ml.
(vi) Assay precision
Low, medium and high quality control (QC) samples were 
run with each assay. Patient samples and QCs were analysed 
in duplicate. All samples from individual patients were 
analysed on the same day to reduce intra-subject 
variability.
The results of analysis of quality control samples on the 
same day and on different days is shown in Table 2.2.
(vii) Stability of fenclofenac
Solutions of fenclofenac in acetonitrile were stable
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FIGURE 2.5 Typical calibration line for fenclofenac over the 
concentration range 2-150ug/ml
TABLE 2,2 Precision of
Quality Number 
Control of samples
fenclofenac HPLC assay
mean SD
concentration
(pg/ml)
%CV
Intra-assay
Low (20pg/ml) 5 20.1 0.502 2.5
Inter-assay
Low (25pg/ml) 8 27.6 0.930 3.4
Medium (5 0pg/ml) 8 49.4 1.07 2.2
High (100pg/ml) 8 101 3.59 3.6
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at 4°C. There was no evidence of breakdown of fenclofenac 
over a four month period. Long periods of storage at -20°C 
and freezing and thawing of plasma samples did not influence 
the analysis of fenclofenac,
3.2.3 Assay for the measurement of tota1 naproxen and DMN 
in piasma
A number of HPLC methods have been published for the 
measurement of naproxen in plasma using UV detection (Upton 
et al, 1980a; Nei1sen-Kudsk, 1980; Shimek, Rao & Wahba- 
Khalil, 1982) some simpler than others, and some offering 
greater sensitivity. Since sensitivity was not a problem for 
total naproxen measurements (as with fenclofenac), 
precipitation of plasma proteins with acetonitrile was found 
to be the most appropriate sample preparation method. The 
method developed was similar to that used to analyse 
fenclofenac except from the use of a more appropriate 
internal standard, a different reversed phase column, a 
slight modification of the mobile phase and a different UV 
wavelength. The phase I metabolite DMN was also separated 
from endogenous interference. The structures of naproxen,
DMN and the internal standard 2-naphthylacetic acid (a 
structural analogue of naproxen) are shown in Figure 2.6.
(i) Preparation of solutions
All standard solutions were prepared in acetonitrile. 
Stock naproxen (Img/ml) was prepared by dissolving 20mg in 
20ml. Serial dilutions of the stock were prepared to give
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CHNaproxen
COOH
CH6-desmethyl naproxen
COOH
HO
2-naphthylacetic acid
COOH
FIGURE 2.6 Chemical structures of naproxen, DMN and the 
internal standard, 2-naphthylacetic acid
working standards of 0.1, 1, 10 and 100pg/ml. Stock 2-
naphthylacetic acid (100pg/ml), was prepared by dissolving 
10mg in 100ml of acetonitrile. This stock was diluted in 
acetonitrile to give a concentration of 0.4pg/ml. Stock DMN 
(Img/ml) was prepared by dissolving 10mg in 10ml. Working 
standards (1 and 10pg/ml)were prepared from dilutions of 
this stock in acetonitrile.
(ii) Preparation of plasma standards
Plasma standards containing naproxen, 2, 5, 10, 20, 50, 
100 and 150pg/ml and DMN, 0.5, 1.0, 2, 5, 8 and 10pg/ml 
were prepared from naproxen working standards. After 
evaporation of acetonitrile at room temperature the residue 
was reconstituted in 0.1ml of plasma. A plasma blank was 
also taken through the assay.
(iii) Extraction
The addition of 0.5ml of acetonitrile containing the 
NAA (0.4pg/ml) to duplicate 0.1ml plasma samples resulted in 
the formation of a protein precipitate. After brief 
centrifugation the supernatant was decanted into a clean 
tube and 35pl aliquots were injected directly onto the 
column.
(iv) Chromatographic conditions
A 25cm Spherisorb 5p ODS reverse phase column was 
necessary to achieve a good separation of naproxen from 
endogenous interference as naproxen is more polar than 
fenclofenac. In addition it was necessary to increase the 
proportion of acidified water in the mobile phase so that
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naproxen was retained to some extent and separated from a 
small interfering peak with a similar retention time. The 
mobile phase was 60% water acidified to pH3 with 
orthophosphoric acid and 40% acetonitrile. The flow rate was 
2.5ml/min giving a pressure of approximately 3000psi. The 
retention times of DMN, naproxen and NAA were 2.6, 4.3 and
6.0 minutes respectively. The absorbance of the eluent was 
monitored at 230nm and the attenuation was set at 0.05 AUFS. 
The metabolite was well separated from any endogenous 
interference, however under these conditions DMN could only 
just be detected in patient single dose study samples. 
Examples of plasma standard and patient samples are shown in 
Figure 2.7.
(v) Quantitation
The peak height and peak area ratios were calculated 
for naproxen or DMN to the internal standard. Plots of PAR 
or PHR against naproxen or DMN concentration were linear 
over the concentration range of interest (Figure 2.8). In 
most cases analysis yielded similar results, however if 
there were slight problems with the chromatography or 
interference, peak areas were subject to larger errors 
(especially at lower concentrations). A comparison of 
concentrations determined by the PHR and PAR methods is 
given in Table 2.3. The lower limit of detection was 
0.5pg/ml for naproxen and 0.08pg/ml for DMN.
(vi) Assay Precision
Naproxen low, medium and high quality control samples
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TABLE 2.3 Comparison of the use of peak height ratio (PHR) 
and peak area ratio (PAR) to determine naproxen 
concentration
Naproxen
PAR
concentration
PHR
(pg/ml)
Difference
(PAR-PHR)
42.0 42.5 -0.5
48.0 49.5 -1.5
60.0 60.5 -0.5
60.6 60.5 0.1
95.2 93.5 1.7
69.0 71.0 -2.0
55.0 54.5 0.5
46.2 46.5 -0/3
35.2 36.2 -1.0
12.3 12.3 0.0
6.8 6.9 -0.1
3.4 3.5 0.1
60.0 58.0 2.0
37.8 38.5 -0.7
23.2 22.2 1.2
32.5 34.5 2.0
39.2 40.0 0.8
30.5 30.7 -0.2
3.6 3.6 0.0
3.3 3.4 -0.1
mean
SD
0.07
1.06
TABLE 2.4 Precision of naproxen HPLC assay
Intra-assay Inter-assay
Quali ty 
Control
mean 
cone. 
(pg/ml)
SD %CV mean 
cone. 
(pg/ml)
SD %CV
Low (5.0) 4.4 0.179 4.1 4.9 0.36 7.2
Medium (30) 27.5 0.793 2.9 29.2 1.203 4.1
High (130) - - - 129 3.97 3.1
mean of six samples at each concentration
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were run with each assay. The low quality control sample 
also contained DMN.
The results of the analysis of naproxen in quality 
control samples analysed on the same day and on different 
days are given in Table 2.4. The inter-assay coefficient of 
variation for DMN at a concentration of 1.5pg/ml was 7.6%. 
All samples from the same patient were analysed on the same 
day to reduce intra-subject variability.
(vii) Stability of naproxen and DMN in acetonitrile and 
plasma
Naproxen was stable in stock solutions for a number of 
months. Concentrations in plasma samples which had been 
thawed and defrosted were not altered. It has been reported 
that the hydrolysis of the naproxen conjugates may occur in 
samples of naproxen stored at -20°C for two months (Upton et 
al, 1980b), theoretically leading to a 10% increase in the 
measured total naproxen concentration. In this study all 
samples were frozen immediately and assayed at least 1 month 
later. It is not known whether this breakdown of the 
conjugate occured in these samples. •
As DMN is sensitive to light and moisture, stock 
solutions were protected from light and were stable for a 
few months. Working standards were prepared freshly.
3.2.4 Assay for the measurement of indomethacin in plasma 
and synovial fluid 
It was necessary to develop a sensitive and specific
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assay for indomethacin in order to analyse the relatively 
low concentrations of indomethacin in plasma and synovial 
fluid that were expected. Numerous methods for the analysis 
of indomethacin in plasma have been published (Skellern & 
Salole, 1975; Soldin & Gero, 1979; Astier & Renat, 1982; 
Mehta & Calvert, 1983). Most reported a limit of detection 
of 100ng/ml; the method of Astier & Renat quoted a limit of 
20ng/ml. The following assay was developed after 
experimenting with a number of these reported methods.
( i)Development of the assay.
It was most appropriate to start with the method which 
claimed the lowest sensitivity (Astier & Renat, 1982). The 
extraction method was found to be more complex than was 
necessary. The initial precipitation of proteins with 
acetonitrile was found to be no better than a simple acid 
extraction into ether. In addition, smaller plasma volumes 
could be used (0.4ml instead of 1ml). Initially 
phenylbutazone was investigated as an internal standard, 
however there were problems with stability: it is oxidised
and hydrolysed on contact with air. Even if the evaporation 
of the organic layer was carried out under nitrogen there 
was still some considerable breakdown of phenylbutazone. The 
reduction in the phenylbutazone peak was associated with the 
appearance of an additional peak in the chromatogram. 
Flufenamic acid was used as an internal standard instead 
since it was considerably more stable. The structure of 
indomethacin and flufenamic acid are shown in Figure 2.9.
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indomethacin
COOH
Flufenamic acid
COOH
NH
FIGURE 2.9 Chemical structures of indomethacin and 
the internal standard, flufenamic acid
A number of reversed phase columns were tested.
Although slightly greater sensitivity could be obtained with 
a shorter column (12.5cm Hypersil 5p ODS or Waters Nova pak 
C^g) better resolution from interfering endogenous materials 
or other NSAIDs could be obtained with a longer column (25cm 
Spherisorb 5p ODS). Plasma from patients with rheumatoid 
arthritis contained considerably more potential interference 
than plasma from healthy individuals. Recovery of 
indomethacin and the flufenamic acid were reduced in 
extracts of synovial fluid compared to plasma, possibly due 
to the greater viscosity and stickiness of the synovial 
fluid. To take account of this problem separate plasma and 
synovial fluid standards were prepared for each assay. The 
patients' own plasma and synovial fluid samples taken at 
'zero time' were used because slight interferences at a 
similar retention time to that of indomethacin varied from 
patient to patient. The conditions of the final assay method 
are given below.
(ii) Preparation of solutions
Indomethacin and flufenamic acid were made up in 
acetonitrile. Flufenamic acid was prepared by dissolving 20mg 
in 20ml of acetonitrile to give a stock solution of Img/ml. 
This stock was diluted to give a working standard 
of 20pg/ml. Stock indomethacin was prepared by dissolving 
20mg in 20ml of acetonitrile. Working standards of 1, 10 and 
100^g/ml were prepared by serial dilutions of the stock. A
0.2m solution of potassium di-hydrogen phosphate was prepared
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by dissolving 6.8g in 250ml of water.
(iii) Preparation of plasma and synovial fluid standards
Plasma standards, 0.025, 0.05, 0.10, 0.20, 0.50, 1.0,
2.0 and 5pg/ml indomethacin were prepared together with 
synovial fluid standards up to Ipg/ml using the patients' 
zero time samples.
( iv) Extraction
Duplicate plasma or synovial fluid samples (0.4ml) were 
acidified with 0.4ml of potassium di-hydrogen phosphate 0.2M 
(pH 4.5) after the addition of 50pl flufenamic acid 
(20pg/ml). After brief vortex mixing, 5m 1 of di-ethyl ether 
was added, the tubes were capped and placed in an orbital 
shaker for 15 minutes. Following brief centrifugation, the 
organic layer was transferred to a clean conical tube and 
evaporated under a stream of air at 30°C. The residue was 
reconstituted in 120pl of mobile phase and 60pl was injected 
onto the column.
(v) Chromatographic conditions
The mobile phase, a mixture of water acidified to pH3 
with acetic acid (45%) and acetonitrile (55%), was pumped 
through a 25cm Spherisorb 5p ODS column at 2ml/min giving a 
pressure of 3000psi. A pre-column was used to protect the 
analytical column. It was repacked regularly with Lichroprep 
RP18 packing material. The UV detector was set at a 
wavelength of 260nm and the attenuation was 0.005 AUFS. 
Samples were introduced onto the column using a Waters Wisp 
autosampler. Under these conditions the retention times of
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indomethacin and flufenamic acid were 4.9 and 6.6 minutes 
respectively. Typical chromatograms are shown in Figure 2.10.
(vi) Quantitation
Plots of peak area ratio (PAR) of indomethacin to the 
internal standard against the concentration of indomethacin 
in plasma or synovial fluid were linear over the 
concentration range of interest (Figure 2.11). Separate 
standard curves for the range 0.025 to 0.5pg/ml and 0.2 to 
5.0pg/ml were used for quantitation to prevent excessive 
weighting of the higher concentration points. The limit of 
detection of the assay was 10ng/ml for both plasma and 
synovial fluid.
(vii) Recovery of indomethacin
For plasma the recovery of indomethacin and flufenamic 
acid was approximately 90% but at lower indomethacin 
concentrations there was a slight reduction in the recovery 
(Table 2.5). The recovery from synovial fluid tended to be 
less than that from plasma in the same patient.
(viii) Precision
Low, medium and high quality control samples were run 
with each assay. The results, together with the intra- and 
inter-assay coefficients of variation, are given in Table 2.6, 
Quality control samples of synovial fluid spiked with 
indomethacin could not be prepared due to the lack of blank 
samples. All plasma and synovial fluid samples from the same 
patient were analysed on the same day to reduce 
intra-subject variability.
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FIGURE 2.11 Typical calibration lines for indomethacin
TABLE 2.5 Percentage extraction of indomethacin 
flufenamic acid from plasma
and
Quali ty 
Control
indomethacin 
% extraction
flufenamic acid (IS) 
% extraction
ratio
I/IS
Low
(0.05pg/ml)
87.9
(6.5)
91.6
(4.1)
0.96
(0.04)
Medium 
(0.4pg/ml)
86.3
(2.4)
90.6
(4.0)
0.96
(0.04)
High
(4. 0jjg/ml )
90.3
(2.8)
90.8
(4.0)
0.99
(0.04)
SD is given in parenthesis
TABLE 2.6 Precision of indomethacin HPLC assay
Quality
Control
Intra-assay Inter-assay 
mean SD %CV mean SD %CV 
cone. conc.
(pg/ml) (pg/ml)
Low 0.049 0.0024 
\
4.8 0.045 0.0023 5.1
Medium 0.392 0.0142 3.6 0.400 0.0142 4.9
High 4.01 0.146 3.6 4.06 0.132 3.2
mean of eight samples at each concentration
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(ix) Stability of indomethacin in stock solutions and samples 
Indomethacin, protected from light, was stable in stock 
solutions for a number of weeks.
2.3 EQUILIBRIUM DIALYSIS
2.3.1 Introduction
A number of methods have been described to study the 
binding of drugs to plasma proteins. These may be divided 
into separation methods (ultrafiltration,ultracentrifugation, 
equilibrium dialysis and gel filtration) and non-separation 
methods (spectroscopy, optical rotatory dispersion and 
circular dichroism). The choice of technique depends on the 
type of binding information required. Separation techniques 
yield information on the affinities and number of binding 
sites, while the spectroscopic methods allow the qualitative 
nature of the interaction between the drug and protein 
molecule to be studied.
Several improvements in the technique of equilibrium 
dialysis have been made since it was first used in the 
1940's (Davis, 1943 and Klotz, 1946). Procedures have been 
standardised (use of dialysis systems such as Dianorm) and 
equilibrium times are much shorter as a result of improved 
dialysis membranes. Equilibrium dialysis has often been used 
as a reference for other separation methods, although there 
are a number of problems associated with all of these 
methods (eg perturbations of the equilibrium between the
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bound and free drug or dilution of protein concentration) 
(Kurz, Trunk & Weitz, 1977).
In equilibrium dialysis a protein solution (eg plasma 
or serum) is separated from a buffer solution by a semi- 
permeable membrane. A drug added to the system will 
equilibrate across the membrane according to the affinity of 
the drug-protein interaction, the concentration of drug and 
the amount of protein. When equilibrium has been reached the 
concentration of the free drug on either side of the 
membrane will be equal. With the Dianorm^ dialyser, the 
volume of plasma and buffer are equal.
It is normal when using radio label led tracer to count 
aliquots of both the buffer and plasma after dialysis. The 
fraction of drug not bound to plasma proteins is then:
f ^ = CPM (buffer) / CPM (plasma) ............... 2.1
However, during most dialyses, there is a shift of water 
from the buffer to plasma due to the osmotic pressure 
created by protein molecules. This volume shift should be 
taken into account if it is greater than 10% and especially 
if the free fraction of drug is small (Jin -Ding, 1983). 
Table 2.7 shows the effect of different degrees of volume 
shift on the free fraction determined by the above method. 
Hypothetical observed and actual free fractions are given 
for a range similar to that observed for fenclofenac. For 
example if there,is a 10% shift in volume from buffer to 
plasma, and f^ is 0.01, there will be a 10% error in 
calculating f^. The over-estimation of the free fraction.
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TABLE 2.7 The theoretical error in the estimation of the 
free fraction determined from the ratio of 
radioactivity in buffer to that in plasma after 
equilibrium dialysis if volume changes are not 
taken into account (according to the method of 
Jin-Ding, 1983)
F 0.0001
Free fraction 
0.001
(fu)
0.01 0.1
0.95 0.0526 0.0526 0.0521 0.0474
0.90 0.1111 0.1110 0.1100 0.1000
0.85 0.1764 0.1763 0.1747 0.1588
0.80 0.2500 0.2498 0.2475 0.2250
F is the ratio of final protein concentration to initial 
protein concentration.
Fractional error in calculating f^ = (l-F)(l-f^)/F
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will become larger the greater the volume shift and the 
lower the actual free fraction.
The free drug concentration measured directly in buffer 
is independent of any shift in water from buffer to plasma 
as the number of binding sites, and therefore the amount of 
drug bound, remains constant. Even if there is a volume shift 
this causes no additional error in the determination of the 
free fraction if the initial total drug concentration is 
used in the calculation.
The total concentration at the end of dialysis is not 
the same as the initial concentration due to the 
distribution of the free drug into twice the initial plasma 
volume. However if the free fraction is very small this has 
only a minute effect on the total concentration. The 
concentration of protein in plasma before and after dialysis 
may be measured to take account of the effect of volume 
changes on the determination of the free fraction.
Care must be taken in assembling the dialysis cells as 
any slight leak of protein can cause significant over­
estimation of the free fraction especially for a drug which 
is highly protein bound. If a drug is 99% bound, a 0.5% leak 
of protein could lead to a 50% over-estimate of the free 
drug concentration and the free fraction. The absence of 
protein in dialysate should be confirmed by a sensitive 
protein assay (Lowry et al, 1951).
The extent of the volume shift can vary greatly 
depending on the drug, the membrane, the buffer and the
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duration of dialysis. The extent of the volume shift can be 
reduced by the use of as short a dialysis time as possible, 
a relatively thick membrane or the addition of a high 
molecular weight compound (eg dextran) to the buffer (Lima 
et al, 1983). These workers also found that the volume shift 
was much smaller for highly bound drugs (eg clofibrate) when 
compared to drugs which are less extensively bound (eg 
lignocaine).
For a drug that is highly protein bound it is important 
to have a specific assay to determine the free fraction or 
free concentration of the drug (Yacobi & Levy, 1975). It is 
therefore better to measure the drug directly than to use a
radiolabel which is perhaps only 98-99% pure. The free
fraction will often be over-estimated when the total 
concentration (and the free fraction) is very small (the 
radiolabelled tracer is a larger percentage of the total 
drug concentration).
2.3.2 General methods for equilibrium dialysis
(i) Dialysis buffer
The phosphate buffered saline was prepared as follows: 
Stock sodium dihydrogen phosphate (dihydrate) (0.02M)
3.12g in IL water........Solution A
Stock disodium hydrogen phosphate (0.02M)
5.68g in 2L water........Solution B
IL of buffer was prepared by dissolving 7.84g of sodium 
chloride in a mixture of 200ml of solution A and 800ml of
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solution B. The buffer was adjusted to pH7.4 using 2N sodium 
hydroxide.
(ii) Preparation of dialysis membrane
The following washing procedure was used to prepare 
Spectra/Por 2 dialysis membrane prior to each dialysis.
1. The appropriate length of dialysis tubing was soaked 
in distilled water for at least 15 minutes.
2. The membrane, once pliable, was cut along the entire 
length and opened up.
3. The membrane was rinsed 5 times with distilled water.
4. After draining off the distilled water, the membrane 
was soaked for 15minutes in dialysis buffer.
5. The buffer solution was renewed and the membrane was 
soaked overnight at 4°C.
6. The membrane was cut into pieces of the appropriate 
size and the buffer was changed once again just 
prior to assembling the dialysis cells.
(iii) Dialysis cell assembly, filling and emptying 
Each cell is made up of two halves, the lid and the
base. Each half-cell has three stoppered holes, two close 
together are for filling, one accepts the pipette tip and 
the other acts as an air vent. A single hole on the opposite 
side of the chamber allows the cell to be emptied. The cells 
are assembled with stoppers inserted into the single 
emptying hole. The drained membrane is placed on the lid and 
any creases are smoothed out. The base is then placed on 
top, ensuring that the inlet and outlet holes on both cells
46
are in line (Figure 2.12). The assembled cell is inverted 
before stacking in the cell carrier stand. Each cell is 
separated by a spring loaded cell spacer. The cells should 
be stacked so that all the stoppers are aligned in a row.
The cells are secured tightly in position before filling.
With the cell carrier unit mounted in the filling 
clamp, 1ml of plasma was added to the left-hand side of the 
cell and 1ml of buffer was added to the other side (Figure 
2.13). The two sides of the cell were filled in quick 
succession using a Gilson pipette. Adjacent stoppers on each 
half cell were inserted simultaneously. The four assembled 
cell units once filled were mounted in the drive unit 
(Figure 2.2) and the unit was immersed in a water bath set 
at 37°C. Gentle rotation of the cells about an axis 
perpendicular to the membrane ensures thorough mixing (the 
actual total volume of each half cell is 1.36ml, if a 
maximum volume of 1ml is used complete mixing can occur).
At the end of the dialysis, the the cell unit was 
placed in the filling clamp. With the emptying hole in a 
horizontal position, the plug was removed and replaced by a 
PTFE emptying tube. With the end of the tube in a test tube, 
the cell stack is turned round so that one of the filling 
stoppers can be removed and the Gilson pipette was used 
to blow the fluid out of the cell and into the test tube,
(iv) Cleaning cells
After the cells had been emptied, they were dismantled 
and layed flat up in a drip tray containing a dilute Decon
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FIGURE 2.12 Assembling a dialysis cell
4
n
FIGURE 2.13 Filling the dialysis cells
solution. The cells were soaked in this solution for 1 hour 
and rinsed overnight with running water. The cells were 
rinsed finally in distilled water before placing in a drying 
cupboard. The cells were completely dry before use.
(v) Measurement of tota1 plasma concentration
Total protein concentration in plasma before and after 
dialysis was determined by an improved Biuret method 
(Yatzidis, 1977). The Biuret reagent was prepared as 
follows: 3.8g cupric sulphate, 6.7g disodium EDTA, 17.5g 
glycine and 14.0g sodium chloride were dissolved in 750ml of 
water. Sodium hydroxide(40g) was added slowly and the 
solution was finally made up to one litre. If stored at 4°C 
in a plastic container the reagent was stable for at least 
one month. Standards of 25, 50, 75 and 100g/l were prepared 
from a stock solution of bovine serum albumin. 5m 1 of the 
Biuret reagent was added to 0.1ml of standard or duplicate 
plasma sample and to 0.1ml of water for the reagent blank. 
After mixing, the tubes were allowed to stand at room 
temperature for 5 minutes. The absorbance of standards and 
samples at 545nm was determined after the instrument had 
been zeroed using the reagent blank. With this reagent, the 
optical density of a 50g/ml albumin standard gave an 
absorbance of 0.25 absorbance units.
2.3.3 Determination of fenclofenac plasma protein binding 
The free fraction of fenclofenac was determined in 
patient trough plasma samples. For a few patients blank
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plasma obtained at the start of the study was spiked with 
fenclofenac up to 800pg/ml. Quantitation of the free 
fraction was achieved by using radiolabelled fenclofenac 
as a tracer.
(i) Radiochemical purity of — C-fenclofenac
Radiolabelled fenclofenac was used to quantitate the 
free fraction of fenclofenac in plasma samples. It was 
necessary to confirm the radiochemical purity before 
proceeding with protein binding studies. The radiochemical 
purity of ^'^C-fenclofenac was determined using thin layer 
chromatography (TLC) with two different solvent systems.
The first 'lot' of ^'^C-fenclofenac was dissolved in 
0.1ml of 2N sodium hydroxide and then made up to 1ml with 
dialysis buffer (stored at 4°C). The radiochemical purity at 
this time was 98-99%. However during preliminary experiments 
there was a gradual increase in the free fraction for any 
total drug concentration over a two month period. The 
radiochemical purity was checked again and was found to be 
only 90%. It appears that there was some breakdown of 
fenclofenac or loss of label during storage in alkali 
solution at 4°C. The results of analysis using this label 
were discarded.
New ^^C-fenc1 ofenac was obtained, and this time it was 
dissolved in organic solvent, 35:65 ratio of ethyl acetate 
to ethanol. The radiochemical purity was 98%. From inter­
assay measurements of quality control samples a number of 
months apart it was obvious that the radio 1 abe 1 led drug was
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considerably more stable in the organic solvent. The ^^C- 
fenclofenac had a specific activity of 45.7pCi/mg.
The concentration of ^^C-fenclofenac in the stock 
solution was 2.19mg/ml (radioactivity 100pCi/ml). 15pl of 
this stock was diluted to 25ml with dialysis buffer 
immediately before each dialysis experiment (final 
concentration 1.3ng/ml, 0.06pC i/ml and 133200dpm/ml).
(i i) Quantitation of radioactivity
The radioactivity in samples of buffer and plasma at 
the end of dialysis was measured by liquid scintillation 
counting. 10ml of liquid scintillation fluid was added to 
500pl samples in plastic scintillation vials. After mixing, 
the vials were counted for five minutes at the appropriate 
energy setting for emission of ^ particles from Since
colour or chemicals will cause quenching of emitted 
particles it was necessary to count the samples on the 
external standard channel ratio (ESCR) setting so that the 
plasma sample counts could be corrected to the equivalent in 
buffer. A quench curve was determined for each set of 
samples using haemolysed plasma. A constant amount of 
radioactivity was added to each vial and varying proportions 
of plasma and buffer. The percentage efficiency of counting 
was expressed relative to the sample containing buffer alone 
and the % efficiency was plotted against the ESCR to give a 
quench curve (Figure 2.14). Plasma caused a reduction of 1 
to 5% in the counting efficiency in comparison to buffer.
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FIGURE 2.14 An example of a quench curve for ^^C-fenclofenac 
in plasma
(iii) Conservation of mass
The absence of non-specific binding of ^'^C-fenc 1 ofenac 
was tested by carrying out a dialysis of buffer 
containing radiolabelled drug against blank buffer. At the 
end of dialysis the sum of the radioactivity on both sides 
of the cell was equivalent to the activity in the initial 
buffer. This demonstrated that there was no binding of ^^C- 
fenclofenac to the membranes or cells.
(iv) Time to reach equilibrium
The time to reach equilibrium was determined by 
carrying out dialysis experiments for 2, 3, 4 and 6 hours 
using a range of concentrations from 25 to 500^g/ml.
The results of these experiments are given in Table 2.8.
From the free fraction measurements it appeared that 
equilibrium had been reached by 3 hours. Thereafter the 
slight rises in the free fraction over the concentration 
range could be attributed to the gradual shift of water from
the buffer to the plasma side of the membrane. Subsequent
dialysis were carried out over 3 hours.
(v) Effect of pH and temperature
The binding of fenclofenac was unaltered in plasma over 
the pH range 6-9. The free fraction was equivalent whether 
determined at 37°C or at 25°C.
(v) Calculation of the free fraction and free concentration 
The counts per minute (cpm) for plasma and buffer were 
first corrected for background radioactivity (approx. 25cpm), 
determined by counting buffer or plasma with no
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TABLE 2.8 The free 
dailysis
fraction of fenclofenac after various 
times
Total 
conc. 
(pg/ml)
2
Dialysis Time 
3
(hours)
4 6
25 - 0.30 0.34 0.40
50 0.42 0.33 0.36 0.40
100 0.46 0.40 0.44 0.56
200 0.70 0.65 0.63 0.76
300 0.96 0.86 0.90 1.03
400 1.07 1.02 1.09 1.12
500 1.24 1.20 1.28 1.41
TABLE 2.9 Inter-assay precision of fenclofenac free 
fraction determination by equilibrium dialysis
Plasma 
conc. 
(pg/ml)
Free fraction 
mean SD
(X102)
%CV
1.3 0.28 0.020 7.3
51.3 0.34 0.015 4.5
200 0.66 0.030 4.5
400 1.05 0.046 4.3
six observations at each concentration
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radioactivity present. After correcting the plasma cpm for 
quenching using the ESCR the free fraction (f^) was 
calculated according to Equation 2.1.
In a number of dialysis experiments, the pre and post 
dialysis plasma protein concentration was measured. It was 
found that dilution of plasma did not exceed 10% so it was 
considered unnecessary to correct for this volume shift. The 
free concentration (Cu) was calculated from the free 
fraction and the total fenclofenac concentration (C) 
determined by HPLC:
Cu = f ^  . C ............................................ 2.2
( vi) Precision
At least one quality control sample was taken through 
each dialysis experiment. The inter-assay precision is given 
in Table 2.9 for a range of total fenclofenac concentrations,
2.3.4 Determination of naproxen plasma protein binding
The binding of naproxen was investigated in patient 
trough samples at steady state. In addition, binding data 
were obtained over a wider concentration range by dialysis 
of blank patient plasma (taken at the end of an initial 
wash-out period) against dialysis buffer spiked with 
naproxen from 25-500pg/ml.
The only radiolabelled naproxen available was ^H- 
naproxen. Tritium has less specific activity than '^^ C and is 
therefore not ideal as a tracer for binding experiments 
especially when the free fraction is very small. The
53
radiochemical purity of the compound provided was only 95% 
so it was considered inappropriate to use it. Instead, the 
concentration of naproxen in dialysate was measured directly 
by HPLC.
(i) Preparation of solutions
Stock naproxen (20mg/ml) for the preparation of spiked 
dialysis buffer was prepared by dissolving 200mg of naproxen 
in 10ml of acetonitrile. 0.5ml of this stock was evaporated 
at 30°C and the residue was reconstituted in 20ml of fresh 
dialysis buffer (500pg/ml). Dilutions of this solution in 
dialysis buffer were prepared to give naproxen 
concentrations of 25, 50, 75, 100, 150, 200, 300 and 
400^g/ml.
For the HPLC determination of naproxen in dialysate, 
stock solutions of naproxen (Img/ml), DMN (Img/ml) and 2- 
naphthyl acetic acid (500mg/ml) were prepared as given in 
section 2.2.3. Dilutions of stock naproxen were prepared to 
give working standards of 0.1, 1 and 10jLig/ml. The internal 
standard was diluted to give working standards of 0.2 and 
0.05/ig/ml.
(ii) HPLC determination of free drug concentration in
dialysate
(a) Extraction
At the end of a dialysis experiment duplicate 200^1 
samples of dialysate were extracted into 2.5ml of di-ethyl 
ether after acidification with 200^1 of 0.2M potassium di­
hydrogen phosphate (pH 4.5) and addition 50^1 of the internal
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standard ( 0.2pg/ml for dialysis of blank plasma against 
spiked buffer, and 0.05pg/ml for trough samples). After 
mixing on an orbital shaker for 15 minutes and brief 
centrifugation, the organic layer was transferred to a clean 
tube and evaporated at 30°C under a stream of air. The 
residue was reconstituted in 120pl of mobile phase and 30^1 
aliquots were injected onto the column. In the experiments 
to determine binding parameters (total concentration 25- 
500^g/ml), post dialysis buffer from 200 and 300pg/ml total 
concentrations were diluted 1 in 2 with dialysis buffer and 
buffer from dialysis of 400 and 500^g/ml total concentration 
were diluted 1 in 4 before extraction.
(b) Standards
Standards of 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1.0, 2.0 
and 5.0jjg/ml were prepared in dialysis buffer using the 
working standards. For the measurement of free naproxen 
concentrations in trough samples the top four standards 
were omitted and DMN was also added at the same 
concentrations.
(c) Chromatography and quantitation
The chromatographic conditions were identical to those 
used to measure total naproxen concentrations (section 
2.2.3.) except that the detector attenuation was set at 0.01 
AÜFS. Sample chromatograms are shown in Figure 2.15. 
Quantitation was by the peak area ratio (PAR) method. 
Standard curves of PAR against naproxen concentration were 
linear. Separate standard curves for the range 0.01 to
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FIGURE 2.15 Typical chromatograms of DMN (1), internal
standard (2) and naproxen (3) extracted from 
buffer after dialysis
A
B
Blank dialysis buffer extract 
Dialysis buffer standard extract:
naproxenS0ng/ml 
DMN 50ng/ml 
Buffer extract after dialysis against a 
patient plasma trough sample, naproxen
^ ____________________
0.2pg/ml and 0.2 to 5jug/ml were used for quantitation to 
prevent excessive weighting of the higher concentration 
points.
(d) Precision
Buffer quality control samples were analysed with each 
assay, the coefficients of variation are given in Table 
2.10.
(iii)Conservation of mass
Table 2.11 gives the results of an experiment to 
determine whether naproxen bound non-specifically to 
membranes or cells. Dialysis of plasma samples spiked with a 
range of naproxen concentrations from 25 to 800jjg/ml for 3 
hours indicated that there was no loss of naproxen due to 
non-specific binding. At the end of the dialysis naproxen 
concentrations in plasma and dialysis were measured by HPLC 
and the protein concentration before and after dialysis was 
determined. After correction for a 10% volume change, the 
total amount of naproxen was not different from the initial 
amount added to the dialysis cell. In all subsequent 
dialysis experiments only the concentration of naproxen in 
dialysate was determined.
(iv) Time to reach equilibrium
Dialysis of spiked plasma samples at 50 and 200ug/ml 
for 1, 2, 3 and 4 hours indicated that equilibrium was 
possibly reached by as early as 1 hour. The 3 and 4 
hour results, however, were more comparable so it was 
considered that the 3 hour dialysis time would be ideal
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TABLE 2.10 Precision of free naproxen measurements by HPLC, 
Spiked buffer and buffer after dialysis against 
spiked plasma.
Inter-assay Intra-assay
Quality
Control
(pg/ml)
mean 
conc. 
(pg/ml)
SD %CV mean 
conc. 
(pg/ml)
SD %CV
BUFFER
0.025 0.0261 0.0017 6.6 .
0.250 0.242^ 0.0094 3.9 - - -
0.500 0.482^ 0.0228 4.7 - - -
PLASMA
50 0.034% 0.0030 8.8 0.0364 0.0018 5.0
100 0.146 % 0.0109 7.5 0.135 % 0.0022 2.0
mean of 9 samples 
mean of 8 samples 
mean of 7 samples 
mean of 4 samples
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TABLE 2.11 Conservation of naproxen during dialysis
Initial total Post dialysis Final total % at end 
amount of Buffer Plasma amount of of dialysis 
naproxen conc. conc. naproxen^
(pg) (pg/ml) ipg/ml) (pg)
25 0.015 24 26.4 1.06
50 0.040 46 50.6 1.01
75 0.077 66 73 0.97
100 0.154 88 97 0.97
150 ' 0.748 134 148 0.99
200 1.39 174 193 0.96
300 3.00 271 303 1.01
400 5.15 350 390 0.98
600 16.1 526 595 0.99
800 51.6 696 806 1.01
^ The amount of naproxe n recovered at the end of dialysis i;
calculated taking into account a 10% increase in the volume
of plasma during dialysis
(Tab 1 e 2.12).
(v) The effect of adding naproxen to the plasma or buffer
Since the volume of plasma collected at the end of the 
initial washout was limited, it was more practical to spike 
the dialysis buffer with naproxen than to spike the plasma.
It is possible that this would affect the time to reach 
equilibrium so a comparison was made between the free 
concentration over a range of total concentrations 
initially in either buffer or plasma. Table 2.13 shows that 
after a 3 hour dialysis the free concentration was 
consistent whether the drug was present initially in buffer 
or plasma.
(vi) Calculation of the bound concentration and free fraction 
The concentration of naproxen bound (Cb) to plasma
proteins at the end of the dialysis was calculated as 
follows :
Cb = C - 2.CU ...........................................2.3
where C is the total concentration in plasma and Cu is the 
free concentration in dialysis buffer.
The total concentration (C') of naproxen in plasma 
after dialysis:
C  = C - Cu ............................................. 2.4
and the free free fraction (f^) of naproxen at the end of 
dialysis :
f^ = Cu / C ............................................. 2.5
(vii) Volume shifts during dialysis
The degree of volume shift due to the movement of water
59
TABLE 2.12 Naproxen concentration in plasma (P) and buffer 
(B) after various dialysis times
Initial
plasma
Dialysis Time (hours)
conc
P
1
B P
2
B P
3
B P
4
B
50 42 0.052 42 0.048 42 0.045 41 0.045
200 186 0.395 186 0.367 180 0.395 178 0.386
All concentrations are in pg/ml
TABLE 2.13 Comparison of free drug concentrations in 
dialysate after a three hour dialysis with 
the drug initially in the plasma (1) and 
buffer (2)
Initial 
total drug
Naproxen concentration in dialysate
concentration 1 2
50 0.034 0.035
100 0.159 0.144
200 1.32 1.40
400 4.92 5.15
All concentrations are given in pg/ml
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from the buffer to the plasma side of the membrane was 
assessed by measuring the total protein concentration before 
and after 3 hour dialysis experiments. The ratio of post 
dialysis to pre-dialysis protein concentration (F) was 
calculated for 200 samples (Figure 2.16). The mean value of 
F was 0.909 + 0.025 (%CV = 2.8): on average, the volume shift 
was just under 10%.
(viii) Effect of pH
There was no change in the binding of naproxen in 
plasma over the pH range 5-9 consistent with a previous 
study of naproxen binding to bovine serum albumin (Kaneo et 
al, 1981)
( ix) Precision
At least one quality control plasma sample was taken 
through the dialysis and HPLC assay. There was a limit to 
the number of quality control samples included in one 
dialysis experiment since there were only a total of 20 
cel Is.The inter and intra-assay precision for plasma 
concentrations of 50 and 100^g/ml are shown in Table 2.10.
In addition the inter-assay precision of buffer taken 
through.the HPLC assay is given.
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FIGURE 2.16 The distribution of the volume shift during 
dialysis of 200 samples
CHAPTER 3
RHEUMATOLOGICAL ASSESSMENTS
3.1 INTRODUCTION
In general the clinical assessment of antirheumatic 
drugs is largely subjective, or at best, semi-objective. The 
number of different measures available reflect the relative 
inadequacy of any one particular measure.
The more objective assessments of antirheumatic drug 
effect are based on relatively crude measurements of the 
degree of inflammation. They have not changed dramatically 
for a long time and consist of measures of joint tenderness, 
the time to walk a set distance, digital joint circumference 
and grip strength. These measurements tend to be variable 
and therefore lack sensitivity. In previous studies 
investigating dose or concentration relationships, digital 
joint size and walking time have proved to be the least 
useful of these semi-objective measurements (Orme et al, 
1976; Baber et al, 1979; Ekstrand et al 1980 & Day et al, 
1982). In addition they have often been shown to be no 
better than purely subjective measures such as the patients' 
own assessment of pain or the duration of morning stiffness.
If a response to NSAIDs is to be used to measure the 
effect produced by different doses or concentrations, it 
should be fairly sensitive and subject to as little 
measurement error as possible to allow comparisons of small 
changes. Unfortunately, the degree of variability 
associated with rheumatologica1 assessments results not only 
from the crude and rather subjective nature of the measures
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but also a result of the variable nature of the disease, 
differences in individual perceptions of pain and changes in 
mood which may affect attitudes towards disease.
Newer approaches which provide a more objective measure 
of the degree of inflammation, such as ^^Technetium 
pertechnetate (^^Tc) uptake and thermography have not been 
used widely because they are time consuming, require special 
equipment and rarely provide better results than the older 
more subjective methods. These techniques however can only 
be applied to specific joints. Recently, De Silva et al 
(1986) compared two of these more objective techniques with 
subjective measurements of pain and inflammation in the 
knee. They showed that there was some correlation between 
objective and subjective methods, but in most cases the 
correlation coefficients were less than 0.5. Correlations 
were much better for ^^Tc uptake than for the 'heat 
distribution index' (HDI) which has previously been shown to 
correlate better with clinical assessment than with the 
usual thermographic index (Salisbury et al, 1983). Grennan 
et al, 1983 found that infrared thermography was less 
sensitive than an articular index or analogue pain score 
when one week of ibuprofen treatment was compared to 
placebo. However, it had previously been suggested that the 
clinical indices of disease activity achieve their maximum 
improvement more rapidly than changes in the thermographic 
indice (Bacon et al, 1976) with NSAID treatment. The 
usefulness of these types of assessments in studies
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investigating dose or concentration-response relationships 
has yet to be established.
Biochemical measurements have proved to be 
unsatisfactory in the assessment of NSAID effects. Reduction 
in the ESR, C-reactive protein, globulin and rheumatoid 
factor and increases in albumin, haemoglobin and iron have 
only been observed during long-term treatment with second- 
line antirheumatic drugs (Amos & McConkey, 1981).
A further development in objective assessment in 
rheumatoid arthritis is the use of an ambulatory monitoring 
technique (MacGregor , 1981). A 'physiological cost index' 
(PCI) which relates the walking (RHI(w)) and resting
(RHI(r)) heart rates to the walking speed, thus
RHI(w) - RHI(r) (beats/min)
PCI (beats/m) = .....................................  3.1
Walking speed (m/min)
In a study comparing a NSAID with placebo, there was a 
reduction in the PCI in 8 out of 10 patients. Thus the 
patients expended less energy in walking the same distance 
when they were receiving the NSAID. This type of monitoring 
device is useful as it is objective and can be worn by the 
patient at home.
The more traditional and commonly used rheumatological 
measures were used in the assessment of the disease in the 
subsequent clinical studies. These methods are described and 
discussed here in some detail.
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3.2 RITCHIE ARTICULAR INDEX
A measure of joint tenderness should give a good 
indication of the degree of joint inflammation. However, no 
totally satisfactory method has yet been described. One of 
the most commonly used methods was introduced by Ritchie et 
al in 1968. It is simple and quick to perform.
3.2.1 Scoring procedure
The tenderness of each joint or group of joints is 
scaled from 0-3 to give the index a degree of 
discrimination. If there is no pain the score is zero. A 
score of one is given if the patient complains of pain, two 
if the patient also winces and three if the patient 
withdraws. The tenderness of the cervical spine, hip joint, 
talo-calcaneal and midtarsal joints are elicited by passive 
movement. The joints treated as a single unit are the 
temporo-mandibular joints, the joints of the cervical spine, 
the sterno and acromio-c1 avicu1ar joints, the metacarpal- 
phalangeal and proximal interpha 1 an'gea 1 joints of each hand, 
and the metatarsal-phalangeal joints of each foot. A number 
of joints are omitted either because they are rarely 
involved or because they may be painful for some other 
reason. These are the distal interpha1angea1 joints of the 
hand and foot, joints of the lumbar spine, sacro-iliac 
joints and the proximal interpha1angea1 joints of the toes. 
The total possible score is 78. An example of an articular 
tenderness score is shown in Table 3.1.
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3.2.2 Intra and inter-observer variability
The Ritchie Articlar Index is associated with a fairly 
small degree of intra-observer variability, but a large 
degree of inter-observer variability. Index differences as 
much as 20 (total possible score of 78) between two 
observers assessing the same patient may not be taken as 
significant (Ritchie et al, 1968). This is a result of the 
difference in the amount or position of pressure exerted on 
the joint by different assessors and may also be related to 
the attitude of the patient towards the assessor. Thus it is 
important that measurements of joint tenderness should be 
made by the same observer throughout an entire study.
3.2.3 Comparison with other articular indices
The Ritchie Articular Index correlates well with the 
articular index of the Co-operating Clinics Committee of the 
American Rheumatism Association (1965) (r = 0.89) which 
scores the number of active joints according to tenderness 
on pressure, pain on passive movement and swelling. The 
Lansbury index records the number of active joints and is 
weighted for joint size, so that the hip is given greater 
weight than a joint in the finger (Lansbury & Haut, 1956; 
Lansbury, 1968). This gives a measure of joint involvement 
but there is no grading of tenderness, so it is unlikely to 
discriminate between different doses or concentrations of 
NSAIDs.
The Ritchie Articular Index is often modified by
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allowing the proximal interpha1angea 1 and metacarpal- 
phalangeal joints to be scored individually rather than as a 
unit. This obviously weights the index to some extent if 
patients have disease mainly limited to the hands (Day et 
al, 1982; Palmer et al 1981). It is likely that the 
variability in the measurement will increase in parallel 
with the increase in the total possible score.
The use of an instrument which applies a standard 
pressure might reduce inter-observer variability. The spring 
gauge dolorimeter can be used to determine the subjective 
pain threshold in an inflamed joint. The degree of 
tenderness is scored on a 10-point scale (McCarty, Gatter & 
Phelps, 1965). More recently, a simpler dolorimeter has been 
described which was more sensitive than a modified Ritchie 
Articular Index in measuring the degree of joint tenderness 
as the tenderness is scored on a continuous scale (Langley 
et al, 1983). These instruments, however, cannot 
be applied to all joints. It appears that the best approach 
is to have the same observer throughout a study and use 
simple digit pressure.
3.3 GRIP STRENGTH
Although grip strength appears to be a more objective 
measure of inflammation and pain, it is also affected by the 
patient/observer interaction and by the patients degree of 
motivation. In addition patient grip will be dependent on
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the degree of muscularity or loss of function due to joint 
or tendon damage.
3.3.1 Measurement of grip strength
The patient is asked to grip a small bag which is 
usually inflated to 30mmHg. The pressure corresponding to 
the maximum sustained grip is recorded on a pressure gauge. 
The mean of at least two observations of each hand 
is determined.
3.3.2 Intra and inter-observer variability
A study by Lee et al (1974) indicated there was a large 
degree of inter-observer variability in the measurement of 
grip strength. Mean differences of up to 20mmHg occured with 
different observers. The mean intra-observer variability was 
of the order of 9mmHg.
3.3.3 Diurnal variation
Grip strength showed a dramatic diurnal variation in 
patients and also in healthy volunteers (Wright, 1959). Grip 
strength was weakest in the early hours of the morning, 
gradually improved during the morning, was maintained for a 
few hours and then fell off during the evening. Lee et al 
(1974) found a significant improvement in grip strength at 
midday and in the evening when compared to the morning, but 
the improvement was small and of the same order of magnitude 
as the intra-observer error. It is probable that the
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difference in these two studies in terms of the magnitude of 
the diurnal variation was due to differences in the severity 
of the disease in the two patient groups. More recently a 
study of flurbiprofen in rheumatoid arthritis has also 
indicated a significant circadian rhythm associated with 
grip strength (Kowanko et al, 1981). In this study, patients 
carried out their own assessments at home throughout the day 
during treatment periods. Analysis of variance indicated 
that there was a significant diurnal variation in both grip 
strength and finger joint size. It is therefore important to 
determine grip strength at the same time of day throughout a 
study.
3.3.4 Newer approaches
A group of workers in New Zealand has developed a grip 
strength analyser which gives a dynamic measurement of grip 
strength function. Pressure-time recordings allow the 
determination of several aspects of grip. These include the 
power (related to the rate of grip development), work done 
(the area under the pressure-time curve) and maximum grip 
strength (Myers, Grennan & Palmer, 1980; Palmer et al,
1981). The measurement of power and rates of grip release 
and grip development showed greater percentage changes than 
maximum grip strength and power in a study of sodium 
mec1 ofenamate compared with placebo (Palmer et al, 1981). 
They suggest that the dynamic parameters are likely to be 
affected by joint stiffness and swelling whereas the static
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parameters (eg maximum grip strength) probably more closely 
reflect muscle power.
3.4 PAIN RATING SCALES
There are numerous types of scales which can be used to 
determine either pain levels or the degree of relief from 
pain (Figure 3.1). They range from 'simple descriptive 
scales' to visual analogue scales. Numerical scales fall 
somewhere in between the two extremes.
3.4.1 Simpie descriptive scale
The simple descriptive scale, to which numerical values 
can be given, uses 4 or 5 points eg nil, mild, moderate, 
severe, very severe. This type of scale is easily understood 
by the patient but there are not many categories available 
and it is likely that this approach will lack sensitivity in 
detecting small changes. It is therefore unlikely to be of 
use in determining dose or concentrâtion-effeet 
relationships. An improvement in discrimination can be 
achieved, however, by using a numerical rating scale marked 
from 0 - 1 0  or 0 - 2 0 .
3.4.2 Visual analogue scales
A visual analogue scale should theoretically allow for 
even greater discrimination. A 10cm line represents a 
continuum of pain from no pain to the worst pain ever 
experienced. The patient is asked to make a mark on the line
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FIGURE 3.1 Various pain rating scales
at a position between the two extremes which represents the 
perceived level of pain. Joyce et al (1975) found that the 
visual analogue scale was more sensitive than a four point 
scale in discriminating between the analgesic effect of two 
doses of dihydrocodiene in patients with rheumatic 
disorders.
The design of the visual analogue scale, however, has 
been shown to affect the final result. Scott & Huskisson 
(1979a) investigated the performance of horizontal and 
vertical analogue pain scales. They found a uniform 
distribution of results on a horizontal scale whereas there 
was a clustering of results if a vertical scale was used. 
These scales were associated with descriptions. However 
similar results have been obtained with scales without 
descriptions. In contrast, Downie et al (1978) found that 
there was no appreciable difference between a horizontal or 
vertical scale. On balance, however, the uniformity of 
results across a horizontal scale gives the method greater 
sensitivity.
Other workers investigating pain scales have suggested 
that a numerical rating scale may be used more accurately 
than an analogue scale (Downie et al, 1978). They suggest 
that this may be because it provides a compromise between 
the simple descriptive scales in terms of discrimination and 
the analogue scale where the freedom of choice may be 
confusing to the patient.
Another factor which has to be considered if these
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measurements are repeated over a period of time is whether 
the patient should be allowed to see their previous scores. 
Joyce et al (1975) found little difference in visual 
analogue pain scores whether or not patients were allowed to 
see their previous score. Another study has suggested that 
it is important for patients to observe their previous score 
as patients tend to overestimate their pain with the passage 
of time (Scott & Huskisson, 1979b). They are able to correct 
their scores when shown their initial starting point.
3.4.3 Comparison of pain scales
A number of studies have investigated the degree of
correlation between various pain rating scales. Downie et al 
(1978) found there was good correlation between four 
different scales, 4 point descriptive scale, 0-10 numerical 
scale rating and the visual analogue scale used both 
horizontally and vertically. However the 11 point scale and 
the horizontal analogue pain scale appeared more precise. 
Another study compared the performance of three different 
scales; a 4-5 point pain scale, a horizontal analogue pain
scale and a 6 point pain relief scale (Littman, Walker and
Schneider, 1985). These were used in the assessment of 
various analgesic drugs. This study again showed that there 
was a good correlation between the various pain rating 
scales. In this case the descriptive pain relief scale 
appeared to be more sensitive than the analogue pain scale 
which in turn was more sensitive than the descriptive pain
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intensity scale. It is not surprising that 4 point pain 
intensity scales are not very sensitive since if a patient 
starts with moderate pain there is only one step available 
between the baseline pain category and no pain. The pain 
relief scale allowed for a greater degree of flexibility.
3.5 DURATION OF MORNING STIFFNESS
Often the major problem facing patients with rheumatoid 
arthritis is morning stiffness. The duration of morning 
stiffness or the time taken to 'limber up' is a useful 
measure to test the effect of antirheumatic drugs. It is, 
however, important that the patient can distinguish between 
stiffness and joint pain (Steinberg, 1978). The recording of 
morning stiffness, however, has rarely been found to be a 
sensitive measure of disease activity.
More objective measures of the degree of morning 
stiffness may provide improved sensitivity in this 
assessment than is available by simply asking 'how long 
does it takes you to get going in the morning?'. Using an 
improved hand grip assessment, Myers and collègues have been 
able to demonstrate that stiffness is reflected in the power 
developed during the establishment of hand grip (Myers, 
Wilson & Palmer, 1981).
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3.6 COMPOSITE SCORES AND PATIENT PREFERENCE
It is popular in trials of anti-inflammatory drugs to 
sum a number of effect parameters to obtain a composite 
index. This allows an overall view of the success or failure 
of a treatment when there is possibly improvement in some 
parameters but not in others. These composite scores may 
also increase the statistical efficiency of the study as 
this type of composite score will tend to normalise 
individual patients' clinical effect. However the clinical 
significance of a statistically significant effect may be 
difficult to determine if the relative weighting of each 
component in the composite score is not taken into account.
A concentration-effect relationship has been demonstrated 
for naproxen using a composite score of several response
indices (Day et al, 1982).
Patient preference or order of preference for a 
particular treatment is often a useful measure as it is 
related to the efficacy of the treatment and to the severity 
of side-effects.
3.7. SUMMARY OF ASSESSMENT METHODS USED IN THIS THESIS.
An example of the assessment forms used in the studies
presented in this thesis is given in Appendix I. The 
assessments were almost identical for the studies of 
fenclofenac and naproxen. One clinical metrologist carried
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out the assessments for the fenclofenac study and another 
did the assessments for the naproxen study. The assessments 
used in dose and concentrations response analyses were 
carried out at the same time of day throughout each study.
1. The Ritchie Articular Index was determined as described 
in section 3.2.1.
2. The duration of morning stiffness was stated by the 
patient and recorded in minutes.
3. Mean grip strength was determined from the mean of two 
observations of each hand. The patient was asked to grip 
a small bag inflated to 30mmHg. The pressure was recorded 
on a gauge scaled in 2mmHg increments.
4. Global pain was determined using:
a) 1 0 cm horizontal visual analogue scale.
b) 4 point descriptive scale. The four categories 
were none, mild, moderate and severe.
5. 4 point descriptive scale of the therapeutic effect as 
assessed by the patient and by the clinical metrologist. 
The categories were none, fair, good and very good.
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CHAPTER 4
DATA ANALYSIS
4.1 INTRODUCTION
This chapter describes the general approaches used in 
the analysis of data generated from the studies described 
later in this thesis. There were several models used to 
describe the data:
1. Pharmacokinetic models, to describe the time 
course of drug concentrations.
2. Pharmacodynamic models, to determine the 
relationship between drug concentration and 
response.
3. Models to describe the binding of drugs to plasma 
proteins.
The analysis of data in terms of a model allows the 
relationship between at least two variables to be 
quantitated and in some cases the parameters of a model may 
be used in a predictive manner. In this thesis, model 
parameters were determined by the method of 'least 
squares'. Individual patient data sets were analysed to 
obtain parameter values for the relevant model. In some 
cases, however, it was more appropriate to analyse all data 
simultaneously to determine the average parameter values and 
their variability within the patient population. In this 
situation the programs GLIM (Baker & Nelder, 1978) and 
NONMEM (Beal & Sheiner, 1980) were used.
Standard statistical tests such as simple linear 
regression. Students't-test and analysis of variance were
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applied where appropriate.
4.2 PHARMACOKINETICS
Pharmacokinetics is the study of the time course of 
drugs in the body. In this thesis, emphasis was placed on 
the investigation of inter-individual differences in the 
processes of of absorption, distribution, metabolism and 
excretion which help in the understanding of the 
pharmacological effect of a drug assuming that the clinical 
response is in some way related to the plasma concentration, 
Factors such as age and disease can have considerable 
effects on the pharmacokinetics of some drugs. This in turn 
may be reflected in differences in clinical response or 
toxicity.
4.2.1 Compartmenta1 models
The concentration-time profile of a drug in plasma is 
commonly represented by a system of compartments. These 
compartments do not necessarily have any physiological or 
anatomical meaning. It is imagined that a drug is 
distributed throughout one or more compartment 'spaces' and 
that the drug concentration in any one compartment is 
homogeneous. The rates of transfer between compartments are 
assumed to obey first order kinetics. The parameters 
determined using this type of analysis may be used 
subsequently to predict the plasma concentration of a drug
at any time after multiple doses assuming that the kinetics 
are linear.
The one compartment model describes the concentration of 
drug in plasma (C) at any time (t) in terms of a single 
exponential :
C = ^  (4.1)
where k^is the elimination rate constant which can be 
expressed as a half-life:
t-y = In 2 / k g ........................ (4.2)
and C 0 is the initial concentration of the drug after 
intravenous administration. The volume of distribution is:
V = Dose/C 0 ...... ................ (4.3)
and the clearance (defined as the volume of plasma which is
cleared per unit time) is:
Cl = V .kg .............................. (4.4)
In all studies described in this thesis, however, the 
drug was given orally. Values of clearance and volume of 
distribution are therefore approximations as absorption is 
uncertain, hence the terms apparent clearance (Cl/F) and 
apparent volume of distribution (V/F) are used. If the 
distribution of the drug from plasma and highly perfused 
tissues is rapid in comparison to the rate of absorption, " 
the profile in plasma will approximate to a one compartment 
model (Figure 4.1a). The equation describing the 
concentration-time profile is:
C = A ( e" g - kg t ^ ................... (4.5)
which can be expressed in terms of the Bateman function:
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FIGURE 4.1 One and two compartment pharmacokinetic models
A One compartment model 
B Two compartment model
c = kaFD (e-ket_e-kat) ...........(4.6)
V(ka-kg)
where D is the dose and is the absorption rate constant. 
If the distribution phase is more prolonged then the 
kinetics of the drug after oral administration may be 
described better by a two compartment model (Figure 4,1b). 
The equation describing the concentration-time profile is 
given in Appendix II.
The absorption of a drug after oral administration has 
generally been described by a first order rate constant 
despite the fact that gastrointestinal absorption of drugs 
involves several processes which may or may not be first 
order (eg. dissolution of the tablet formulation, different 
rates of absorption from different parts of the 
gastrointestinal tract and gastric emptying). Some 
investigators have found that the absorption of certain 
drugs after oral administration may be better described as a 
zero order process (analogous to a short constant rate 
infusion of the drug) (McNamara, Coburn & Gibaldi, 1978; 
Whitfield, Kaul & Clark, 1978). A comparison of the type of 
profile obtained using zero order or first order input is 
given in Figure 4.2.
The pharmacokinetic models used in the analysis of 
NSAID plasma concentration-time data were either one or two 
compartment models with first or zero order absorption. The 
equations for the models (Models 1-4) are given in Appendix
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II. In all cases a time lag (time after administration when 
the drug is first detected in plasma) was incorporated in 
the pharmacokinetic model. In order to fit concentrations in 
synovial fluid, two models were proposed (Models 5 and 6 in 
Appendix II, Figure 4.3). Model 5 assumed that 
concentrations in synovial fluid could be described in terms 
of the kinetics of the peripheral compartment of a two 
compartment model. Model 6 assumed that the synovial fluid 
represented a distinct, relatively small compartment which 
did not affect the kinetics of the drug in plasma.
4.2.2 Physiological Models
The clearance of drug from the blood can be expressed 
as the product of blood flow to the eliminating organ (Q) 
and the extraction ratio (E) of the drug across the organ:
Cl = Q E .................................. (4.7)
The extraction ratio is dependent on three physiological 
variables; blood flow, the ability of the organ to remove 
the drug and the degree of plasma protein binding. The most 
commonly used model is the 'well stirred' model (Wilkinson & 
Shand, 1975). When applied to drugs which are eliminated 
entirely by hepatic metabolism the clearance of total drug 
is :
Cl == Q
0 ^ ^u C^int'
(4.8)
where f^ is the free fraction of the drug in blood and 
Clint' is the intrinsic clearance. The intrinsic clearance
Dgut
SO
gut
FIGURE 4.3 Pharmacokinetic models proposed to describe the 
concentration of drug in plasma and synovial 
fluid
A Model 5 
B Model 6
is a measure of hepatic drug metabolising activity and is 
related to the enzymatic parameters, and
Clint* = ^max,i ...........1.............(4.9)
^m, i
when the system is operating under linear conditions, ie 
when the unbound concentration of the drug in liver is less 
than (Pang, Rowland & Tozer, 1978). Using this model
there are two extremes. The model predicts that the clearance 
of drugs with a low extraction ratio will be sensitive to 
changes in the binding and intrinsic clearance. However, the 
clearance of drugs with a high extraction ratio will be 
dependent on the liver blood flow. For low extraction drugs 
the clearance of total drug (Cl^ ,pj) and free drug (CL^pj) are
(T) ^u Clint' ........................(4.10)
Cl (p) = Clint' .......................... (4.11)
The other parameter which can be considered in the apparent 
volume of distribution, in physiological terms the volume of 
distribution given by:
V = Vg + (fg/f?)  (4.12)
where Vg is the volume of blood, Vrp is the volume of 
tissues, fg is the free fraction in blood and f^ is the free 
fraction in tissues.
4.3 ANALYSIS OF PLASMA PROTEIN BINDING DATA
The binding of drugs to plasma proteins is usually 
assumed to obey the law of mass action. The interaction
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, nP:.Cu
Cb = \   i.....   (4.13)
Kdi + Cu
between a drug molecule and a protein molecule can therfore 
be described in terms of a Langmuir isotherm:
1 = 1
where Cb is the concentration of drug bound, Cu is the free 
concentration of drug, n is the number of classes of binding 
sites, and  ^ and nPj^  are, respectively the dissociation 
constant and the number of equivalent binding sites of the 
ith class of sites.
Examination of the literature of the binding of a 
particular drug to plasma proteins will provide a range of 
quite diverse parameter values for affinities and number of 
binding sites (Kragh-Hansen, 1981). Some examples of binding 
of NSAIDs are given in Table 4.1. Although this may in part 
be due to differences in the analytical technique it is also 
a result of errors in the analysis of the data (Vallner, 
Perrin & Wold, 1976). In the past, binding parameters were 
obtained by graphical analysis after linearisation of the 
Langmuir equation eg Klotz and Scatchard Plots. In all cases 
both independent and dependent variables are subject to 
error. If there is one high affinity site and one or more 
classes with lower affinity, the graphical representations 
are curved, and separation of the various binding parameters 
is more difficult. Often the intercepts and slopes obtained 
from graphical methods are quoted as the parameter values, 
this will result in errors if the affinity of the high 
affinity site are not much larger than that for the low
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affinity site (Vallner et al, 1976).
The use of computer procedures should have improved the 
quantitation of binding parameter values. However most 
procedures determine the parameters through a least squares 
fit of the data based on the Scatchard equation. 
Alternatively the data are fitted simply in the form of the 
Langmuir equation so that the error in the free 
concentration (independent variable) is assumed to be small 
and independent of the error in the bound concentration.
Free and bound concentrations are determined in general from 
the total concentration (which is known fairly accurately) 
and will therefore be correlated.
Other statistically correct least squares procedures 
have been proposed such that the free or bound concentration 
is analysed in terms of the total concentration (Perrin, 
Vallner & Wold, 1974; Priore & Rosenthal, 1976).
Despite the fact that these mass action models have 
some physiological basis, the parameter values reported may 
have no relevance if the data analysis was inappropriate. 
Often there are too few data points to be able to get a good 
estimate of the parameters. In addition some workers suggest 
that the value of 'n' should be fixed in order to reduce the 
number of parameters to be estimated.
Simpler mathematical functions have been fitted to 
binding data. These methods of analysis do not assume any 
specific molecular behavior but merely describe the observed 
data so that predictions of free concentrations or free
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fractions may then be determined (Behm & Wagner, 1981;
Monot et al, 1983),
In this thesis, binding data were fitted to the
Langmuir isotherm for two independent binding sites:
nP-i.Cu , nPg.Cu 
Cb = _ L _   ^ .................. (4.14)
Kdi Cu ^d2 ^ Cu
where Cb and Cu are the bound and free drug concentrations 
and nP^ and nP 2 are the binding capacities of two classes of 
binding sites with equilibrium dissociation constants of K 
and K r e s p e c t i v e l y .
Rearrangement of this equation in terms of total 
concentration results in a cubic equation which cannot be 
solved easily. As a compromise the free concentration was 
considered as the dependent variable. When the Langmuir 
equation is rearranged, the free concentration is given by 
the positive root of a quadratic equation (Appendix III). 
This treatment is more appropriate than fitting bound in 
terms of free for drugs which are highly bound. The 
percentage error in the determination of the free fraction 
is much greater than for the bound fraction for a drug like 
naproxen or fenclofenac. For naproxen the coefficient of 
variation for free drug concentration ranged from 7.5 to
8 .8 , however expressed in terms of bound drug the 
coefficient of variation ranged from 0.006 to 0.011. The 
possibility of correlation between bound and free 
concentration is only likely when the free fraction exceeds 
10%.
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4.4 ANALYSIS OF CLINICAL RESPONSE DATA
The classical models to explain dose or concentration- 
effect relationships were based on the Langmuir isotherm 
assuming a reversible drug receptor complex:
Effect =   (4.15)
ECs0% + C
where C is the concentration or dose, E^^% is the maximum 
effect and ECgg^ is the concentration or dose producing 50% 
of E^^%. This model, often referred to as the E^^% model, 
has been used widely to describe drug effects in isolated 
tissues.
A number of models have been proposed for the analysis 
concentrâtion-effeet relationships vivo (Holford & 
Sheiner, 1981). The simplest model which can be used to 
describe clinical response in terms of concentration is a 
linear model:
Effect = A + B. C ........................ (4.16)
where A is the baseline measurement and B is the slope of 
the line relating the effect to concentration. This model 
can be derived from the the E^^^ or hyperbolic model if , 
concentrations are assumed to be low in relation to EC^g^. 
The E^ax model is able to describe drug effect over a wide 
concentration range and can be modified to allow for a 
baseline effect:
Effect = ^max • ^ + Eg  (4.17)
GC50% + ^
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where Eg is the baseline value, assuming that baseline 
measurements have the same error as the other measurements.
The log-linear model is an approximation to the E^^% 
model in the range 2 0  to 80% of the maximum response:
Effect = B.log(C) + I ................... (4.18)
where I is an arbitary constant with no physical meaning.
The model is unable to predict the absence of an effect when 
there is no drug present.
If the drug effect is examined over a dosage interval, 
the clinical response may be described in terms of 
concentration using an integrated pharmacokinetic / 
pharmacodynamic model (Sheiner et al, 1979). In this thesis, 
however, the response was compared with a single steady 
state concentration obtained on different doses so that this 
type of integrated model was not possible.
4.5 PARAMETER ESTIMATION
This section outlines the general principles of least 
squares regression analysis together with the details of the 
specific computer programs used to determine the parameter 
values of the particular model. Non-linear regression was 
used to estimate individual parameters of the particular 
pharmacokinetic or binding model and the programs GLIM 
(linear models) and NONMEM (non-linear models) were used to 
simultaneously analyse data from a large number of 
individuals.
4.5.1 Least squares regression analysis
In both linear and nonlinear least squares regression 
analysis, the total variation in the dependent variable may 
be partitioned into that due to the model (the explained 
variation) and the remaining residual error (the unexplained 
variation). The assumptions are:
a) the error in the independent variable is negligible
b) the valuesof the dependent variable are sampled from a 
normal distribution
c) the variance of the dependent variable is constant.
The best estimates of the model parameters are those which 
minimise the residual sum of squares or the objective (Obj) 
value:
Obj = ^  (y i-y i ) ^ .................... (4.19)
where y is the observed value and'y is the fitted value of 
the dependent variable. This is the objective for ordinary 
least squares regression. If the error in the independent 
variable is known (eg the error in the measurement of drug 
concentration) an appropriate weighting scheme may be 
applied. In general the dependent variable is weighted by  ^
the reciprocal of the fitted value itself or the fitted 
value squared (Boxenbaum, Riegelman & Elashoff, 1974). This 
is able to cope with the experimentally observed error in 
the measurement of drug concentrations over a wide range, 
since the absolute magnitude of the error tends to increase 
as the concentration increases. The objective value will
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take account of the weighting scheme used:
(Yi - Yi)
Obj H I ___ H I  ......................(4.20)
Wtj^
4.5.2 General Linear Interactive Model ling (GLIM)
The program GLIM (Baker & Nelder, 1978) was used for 
the simultaneous analysis of dose or concentration-response 
data from all patients (Chapters 5 & 6 ).
Simple linear regression assumes that all values of y 
are mutually independent. It is inappropriate for the 
analysis of data which contains more than one observation 
from a single individual. GLIM is able to handle this type of 
data. The linear model may involve one or more independent 
factors or variables and account is taken of the fact that 
some of the observations are associated (ie from the same 
individual). The parameters of the linear model are those
which minimise the residual sum of squares and as for simple
linear regression the parameters are unique for any given 
set of data. In it's simplest form the program can be used
for analysis of variance.
A hierarchical series of linear models were proposed to 
test the effect of dose or concentration (total or free) on 
a particular clinical response measurement. The models 
tested are illustrated in Figure 4.4. The full model 
describes the response in a individual(effect^) in terms of a 
unique intercept (a^) and slope (b^):
1. Effect^ = aj, + b^.C ......................(4.21)
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FIGURE 4.4 Linear models investigated to describe dose or 
concentration-response data
A Effect^ = a^ + b^.C
B Effect^ = a^ + B.C
C Effect^ = a^
AUJ
Concentration
B
UJ
Concentration
u
o>
UJ
Concentration
The reduced models tested were:
2. Effect- = a- + B.C .......................(4.22)
where the slope (B) is common for all individuals, and
3. Effect • = a^ ..............................(4.23)
where the slope is zero.
GLIM was also used to test the factors which affect the 
free fraction of fenclofenac (Chapter 5).
Selection of the most appropriate model
The addition of parameters to the model will lead to a 
reduction in the residual sum of squares and an apparent 
improvement in the fit. However, the most appropriate model 
is the simplest model (ie the model which keeps the number 
of parameters as small as possible) that still gives a good 
description of the data. Statistically the best model is 
selected on the basis of the F-ratio test. The reduction in 
the residual sum of squares is tested in relation to the 
decrease in the number of degrees of freedom (ie increase in 
the number of parameters). This is often referred to as the 
F-to-enter statistic or the F-to-remove statistic, depending 
on whether the simplest or the most complex model is used as 
the starting point, and is based on the General Linear Test
(Netter & Wasserman, 1974). The F value is calculated:
SSQ(R)-SSQ(F) SSQ(F)
F — - ■ — —— ■ ■ " - / — — —— —— *#****####*# (4*24)
df(R)-df(F) df(F)
where SSQ(R) and SSQ(F) are the residual sum of squares for 
the reduced and full model, df (R) and df(F) are the degrees 
of freedom for the reduced and full model. The significance
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of F is determined for df(R)-df(F), df(F) degrees of 
freedom. If F is not significant the full model is rejected 
in favour of the reduced model. The 'goodness of fit' can be 
assessed by calculating the coefficient of determination 
(Cdet):
r- = explained variation ,. g c \
det — .......................  .........
total variation
4.5.3 Nonlinear regression
Nonlinear least squares regression analysis was used to 
fit individual patient data sets (concentration-time data or 
protein binding data) to the models described in the 
previous section. Unlike linear regression, there is no 
unique solution for nonlinear regression. The nonlinear 
fitting procedure used in the analysis of data was a 
modification of the Marquardt algorithm (Marquardt, 1963) 
and was implemented on a Nodecrest mini computer. The non­
linear model, in the form of a Fortran subroutine and 
initial estimates of the parameters of the model were 
provided.
(i)' Goodness ojE fit'
Examination of residual values, the difference between 
the observed and fitted value of the dependent variable (y^- 
y^), can give an indication of the 'goodness of fit'. Plots 
of the residual values against the fitted values of y can be 
very useful and may indicate that a weighting scheme is 
necessary. In addition plots of the residuals against the
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independent variable can provide information on how well the 
model appears to fit the observed data. If there are 
systematic patterns in the residuals then it is possible 
that the model is inappropriate. The coefficient of 
determination gives an indication of the overall 'goodness 
of fit',the value of should be as large as possible.
However a high value should always be considered in the
context of any trends in the residuals.
(ii)Selection of the most appropriate model
There are various methods that can be used to determine 
the best model if different models are to be compared. If 
one model is a submodel of another within an ordered 
hierarchy (eg comparison of a one and two compartment 
pharmacokinetic model) the General Linear Test should be 
applied and the F ratio is calculated according to equation 
4.24 (Netter & Wassweman, 1974). If there are not sufficient 
data points in relation to the number of parameters, the 
full model will often have to be rejected even if 
examination of the residuals suggests that the full model 
gives a better description of the data.
If the models to be compared have the same number of 
parameter values (or if one model is not a submodel of the 
the other) the General Linear test cannot be applied. In 
this situation other criteria may be considered (Akaike, 
Schwartz etc). In this thesis the Akaike Information 
Criterion (AIC) was used (Akaike, 1973). The AIC is derived 
from information theory:
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Aie = N. In(SSQres) + 2.P  (4.26)
where N is the number of data points, SSQres is the residual 
sum of squares and P is the number of parameters. The lowest 
value of the AIC indicates the best fit. There is however no 
statistical test for the difference in the AIC value.
4.5.4 NONlinear Mixed Effects Model (NONMEM)
NONMEM is a computer program which can be used to fit 
data from a large number of individuals to any non-linear 
model (Beal & Sheiner, 1980). As with GLIM account is taken 
of the fact that all data points are not mutually 
independent. The program has generally been used to 
determine population pharmacokinetic parameters of certain 
drugs using data collected during routine clinical 
monitoring (small number of samples from a large number of 
patients) (Sheiner, Rosenberg & Marathe, 1977). In addition 
the relationship between patient specific factors and the 
parameters of the model can be investigated.
NONMEM was used to analyse dose/concentration - effect 
relationships and to determine parameter values for binding 
of naproxen to plasma proteins. The program provides 
estimates not only of the mean parameters of the structural 
model (9's) ie. the population mean parameter values of the 
binding model or effect model, but also of the inter-subject 
variability of each of these parameters (tj's ), and the 
intra-subject variability (measurement error or model 
misspecification) (e). There are different types of error
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models; additive, proportional or log (Beal, Boeckmann & 
Sheiner, 1985). The program also provides the approximate 
error in the estimate of the structural and variance 
parameters. The best estimates of the structural and 
variance model parameters are those which minimise the 
objective value for a given set of data. It is possible to 
test the influence of patient factors on the parameters of 
the structural model.
In the analysis of dose and concentration - response 
relationships the and Linear models described in
Section 4.4 were tested. The log or proportional error model 
was used for the inter-individual variance in the structural 
parameters :
ln9jç- = In&k + rjy^ i .................. (4.27)
where is the value of 9j^  in the individual i. This 
assumes a log normal distribution of the structural model 
parameters. The constant (additive) error model was used for 
the intra-individual error:
Y i  = Y i  +  ( 4 . 2 8 )
An example of a 'PRED' and control file are given in 
Appendix IV for the E^^% model.
Naproxen plasma protein binding data were fitted to the 
Langmuir isotherm for two independent binding sites given in 
Section 4.3 rearranged in terms of the free concentration 
(Appendix III). In addition the data were also analysed 
taking account of patient specific factors which might be 
expected to affect the binding. The constant error model was
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used for the inter-individual variance in the structural 
model parameters:
»ki = »k + % ki ...................... (4-2 9)
This assumes that the structural model parameters are 
normally distributed within the population. A log or 
proportional model was used for the intra-individual error 
(error in the measurement of free concentration):
Iny^ = Iny^ + e ......................... (4.30)
which assumes that the coefficient in the measurement of 
free concentration is constant over the concentration range. 
An example of the a 'PRED' and control file are given in 
Appendix IV.
Selection of the most appropriate model
Comparison of different models is based on the 
objective value. If one model is a submodel of another the 
difference in the objective value is distributed with
degrees of freedom equal to the difference in the number of 
parameters (structural and variance model parameters). If the 
models do not conform to a hierarchy the best model is 
chosen on the basis of the objective value, the error in the 
estimate of the parameters and on the examination of the 
residual plots against the dependent (observed or predicted) 
and independent variable. If there is any trend in the 
residuals, the model may be inappropriate.
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CHAPTER 5
FENCLOFENAC, PHARMACOKINETICS 
AND CLINICAL RESPONSE
5.1 INTRODUCTION
This chapter presents a dose ranging controlled study 
of fenclofenac in patients with rheumatoid arthritis. 
Attention was directed towards the determination of the 
variability in the pharmacokinetics of fenclofenac and the 
general aim was to evaluate whether knowledge of total or 
free drug concentrations could contribute to the explanation 
of clinical response or toxicity.
There has been no properly controlled trial of 
fenclofenac over the recommended dosage range (600 to 1800mg 
daily in two divided doses) and little attention has 
been directed towards the measurement of plasma 
concentrations and the relationship between concentration 
and clinical response. In juvenile arthritis, it appeared 
that a concentration of at least 100pg/ml (at steady state) 
was necessary for a satisfactory response (Makela et al, 
1983). While there appeared to be a relationship between 
dose and clinical response, a more confident prediction of 
response could be obtained with additional information 
provided by a drug concentration measurement. Clinical 
assessments, however, were not blinded.
The specific aims of this study were to determine the 
following :
a) The relationship between the dose of fenclofenac and 
plasma concentration (free and total).
97
b) The relationship between fenclofenac clearance and 
any specific patient factor such as age, sex or 
severity of disease,
c) The relationship between fenclofenac dose and/or 
plasma concentration (free and total) and clinical 
response and/or toxicity.
5.2 PATIENTS AND METHODS
5.2.1 Study design
The overall study design is outlined in Figure 5.1. 
After the initial washout period, patients were given a 
single dose of fenclofenac (600mg) and blood samples were 
taken over the subsequent 48 hours. From this point the 
study was 'double blind'; each patient was given three doses 
of fenclofenac, 600, 1200 and 1800mg daily, for 12 days at a 
time. Doses were randomised according to a a Latin Square 
design. The standard rheumatological assessments given in 
Chapter 3 were carried out by the same observer throughout 
the study.
5.2.2 Patients
Eighteen outpatients with 'definite' or 'classical' 
rheumatoid arthritis (Ropes et al, 1959) complied with the 
protocol and completed the study (three 3x6 randomised 
treatment blocks). Twelve patients were female and six 
patients were male. Their disease duration ranged from 4
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months to 20 years (median 3.5 years) and their ages ranged 
from 22 to 74 years (median 56 years). All individual 
patient demographic features and previous NSAID treatment 
are given in Table 5.1. None of the patients was receiving 
corticosteroids or any other second line antirheumatic drug 
and patients were only included in the study if the 
withdrawal of anti-inflammatory therapy for at least 3 days 
resulted in a symptomatic 'flare'. Table 5.2 gives an 
indication of the disease severity after this initial 
washout period.
5.2.3 Single dose study
Patients were allowed a light breakfast (at least 2 
hours before the dose) on the morning of the single dose 
study. Lunch was allowed 3 hours after the dose. Two 300mg 
tablets of fenclofenac were taken with 100ml of water at 
approximately 10am. Blood samples were taken from an 
indwelling intravenous cannula before the dose and at 0.25, 
0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 
hours thereafter.
All blood samples were collected into heparinised tubes 
and after centrifugation at 2000rpm for 5 minutes, the 
plasma fraction was separated and stored at -20°C. 
Fenclofenac concentration was determined as outlined in 
Chapter 2.
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5.2.4 Randomised treatment period
The randomised treatment period continued for 6 weeks 
(Figure 5.1). Fenclofenac (300mg) and placebo were identical 
in appearance. On each dose two tablets were taken three 
times a day, at 10.00, 15.00 and 22.00 hours, thus:
Total daily dose (mg) Morning Afternoon Evening 
600 F + P  P + P  F t p
1200 F + F P + P F + F
1800 F + F  F + F  F + F
where F is 300mg fenclofenac and P is matching placebo. Thus 
the 600 and 1200mg doses were given in two divided doses 
every 12 hours, while the 1800mg dose was given in three 
divided doses at unequal intervals. A three day wash-out 
period was included after each dose.
Rheumato1ogia1 assessments were carried out and blood 
samples were taken for the measurement of fenclofenac 
concentrations and for standard biochemical and 
haematological screens. These assessments were carried out 
at the end of the initial washout period and at the end of 
each treatment period as close to 10am as possible. Trough 
samples (10am) were taken after 5 and 14 days of each 
treatment period. Additional assessments and were carried 
out after the washout periods between treatments and at the 
end of the study at 3pm. Corresponding blood samples for the 
measurement of fenclofenac were obtained. Blood samples for 
drug analysis were handled as above for the single dose 
study.
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5.2.5 Data analysis
(i) Single dose study
Individual single dose concentration-time data were 
fitted to one and two compartment models with either a first 
or zero order input function using ordinary nonlinear least 
squares regression analysis (Chapter 4).
The relationship between the clearance of fenclofenac 
and any specific patient factor was investigated using 
general linear regression and correlation techniques.
(ii) Dose and concentration - response analysis
The clinical response measures used in these analyses 
were the Ritchie Articular Index, duration of morning 
stiffness, mean grip strength and analogue pain score. The 
simple 4-point verbal pain scale and the patients' and 
physicians assessment of the therapeutic effect were too 
insensitive to show any change from dose to dose, and were 
not used in this analysis.
Two-way analysis of variance was used to test for time 
or treatment order effects. A summed efficacy score was 
obtained by ranking the rheumato1ogica1 measures across 
baseline and dose from 1 to 4 and taking the sum of the 
ranks for all measures. Friedman two-way analysis of 
variance was used to test for dose related changes in each 
individual rheumatologica1 measure and in the summed 
efficacy score.
Various linear and non-linear models were investigated 
to describe the relationship between dose or concentration
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and clinical response. The models and the statistical
analysis are presented in Chapter 4.
Changes in biochemical or haematological indices with 
dose were investigated using Friedman two-way analysis of 
variance.
(iii) Protein binding studies
It was possible to investigate the binding of 
fenclofenac to plasma proteins over a wide range of plasma 
concentrations in five patients (14-18). Plasma, taken at
the end of the initial washout period was spiked with cold
fenclofenac to give concentrations over the range 1.3- 
800pg/ml. The free fraction was determined by carrying out 
equilibrium dialysis against buffer containing radiolabelled 
drug as described in Chapter 2.
Free and bound concentrations were fitted to the 
classical binding isotherm with two classes of binding sites 
using weighted non-linear least squares regression analysis 
(Chapter 4). The free concentration as the independent 
variable was weighted proportional to the reciprocal of the 
fitted concentration (1/c^). Initial estimates of the 
parameters were obtained by plotting the data in the form of 
a modified Scatchard plot (bound/free vs bound).
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5.3 RESULTS
5.3.1 Pharmacokinetics
(i) Single dose study
An example of a representative patient's concentration­
time data (patient 4) fitted to 4 possible pharmacokinetic 
models (Models 1-4, Appendix II) is given in Figure 5.2. For 
this patient the one compartment model is obviously 
inappropriate as terminal concentrations are not fitted 
well. The effect of using either zero order or first order 
input are clearly shown. The AIC values for all individual 
patient data fitted to the four models are given in Table 
5.3. Using this fitting criterion, in general the two 
compartment model with a zero order input was on balance the 
best model to describe the data. The zero order input 
allowed a better fit of both the peak and the terminal 
concentrations. Table 5.3 also indicates that in most cases, 
the AIC was smaller or equal for fits to the one or two 
compartment models with zero order input (Models 2 and 4).
It is more appropriate to compare hierarchical 
models using the F ratio test. Table 5.4 gives various 
'goodness of fit' criteria for Models 2 and 4. The F ratio 
test indicated that for only 6 out of the 18 patients, the 
fit to the two compartment model was significantly better 
than the one compartment model. The residuals plots, 
however, showed that the one compartment model failed to fit 
the terminal concentration points and often the peak
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f i g u r e 5.2 Representative patient (4) fenclofenac
concentration-time profile fitted to one and 
two compartment models with first order or zero 
order absorption
TABLE 5.3 Comparison of AIC values for fenclofenac
concentration-time data fitted to one and two 
compartment models with first order and zero order 
absorption (Models 1-4, Appendix II)
Patient One compartment model Two compartment model
number first order 
MODEL 1
zero order 
MODEL 2
first order 
MODEL 3
zero order 
MODEL 4
1 74 68 75 65*
2 100 97 94 78*
3 73* 74 75 76
4 100 93 90 67*
5 45 47 46 46
6 84 80 86 81
7 63 62 57 56 *
8 63* 77 64 80
9 73 59 70 48*
10 68 67 68 62*
11 63 62* 75 66
12 97 106 97 75*
13 65 55 65 54*
14 82 79 82 80
15 77 77 53 52*
16 88 81 90 79*
17 74* 80 80 81
18 70 68 45 38*
AIC is the Akaiki Information Criterion 
* the lowest AIC for the comparison .of the four models
1 06
TABLE 5.4 Comparison of 'goodness of fit' for individual
fenclofenac concentrâtion-time data fitted to one 
and two compartment models with zero order 
absorption.
Patient One compartment 
MODEL 2 
Cdet SSQres
mode 1 
df
Two compartment 
MODEL 4 
Cdet SSQres
model
df
1 0.946 72 10 0.967 44 8
2 0.933 563 10 0.986  ^ 114 8 **
3 0.937 154 9 0.941 144 7
4 0.941 205 12 0.991 31 10 **
5 0.992 20 9 0.994 14 7
6 0.941 260 9 0.955 198 7
7 0.975 66 9 0.987 34 7
8 0.957 203 9 0.959 193 7
9 0.986 51 9 0.996 16 7 *
10 0.989 53 11 0.994 29 9
11 0.981 46 10 0.996 47 8
12 0.877 690 11 0.899 67 9 **
13 0.984 28 10 0.988 20 8
14 0.958 161 10 0.965 132 8
15 0.988 99 11 0.998 14 9 **
16 0.972 133 11 0.980 90 9
17 0.951 173 10 0.916 136 8
18 0.986 75 10 0.999 6 8 **
Key: df = degrees of freedom
SSQres = the residual sum of squares
Cdet ” coefficient of determination
* p<0.05
** p<0.01 two compartment model significantly better than the 
one compartment model (F ratio test).
1 07
concentrations were not fitted well.
Parameter values determined from fits to one and two 
compartment models with zero order input are given in Table 
5.5 and 5.6. Examination of the parameter values for the 
data fitted to either model suggests that there is
considerable inter-subject variability in the kinetics of 
fenclofenac. The variability in T^^g and T may reflect the 
fact that patients were not fasted before the single dose 
study. For the two compartment model the wide range of 
values for O'and ^^ 21 in part be a result of too few data
points to give a good estimate of these parameters: the SE 
of the estimate of these parameters was often large. The 
variability in apparent clearance was approximately 50%. 
Closer examination of clearance values indicated that the 
majority of patients had a clearance in the 0.33-0.74 1/hr 
range: 3 patients had a clearance in the 1.23-1.49 1/hr 
range (patients 3,5 and 13).
Correlations between fenclofenac clearance and age, 
creatinine, ESR or alkaline phosphatase were tested using 
simple linear regression. No significant relationships were 
found, but there was a possible decrease in clearance with 
increasing age (p<0.083) and with an increase in alkaline 
phosphatase (p<0.091) (Figure 5.3). There did not appear to 
be any sex related differences in clearance.
(ii) Steady State
There was a proportional increase in mean trough 
concentrations from 600 to 1200mg/day, the mean trough on the
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f i g u r e 5.3 Correlation between fenclofenac apparent
clearance and patient factors, age and alkaline 
phosphatase
highest dose being slightly lower due to the different 
dosing regimen. Mean total trough concentrations are shown 
in Figure 5.4a. There was considerable inter-individual 
variability in 12 hour trough concentrations at steady state 
(Figure 5.4b), with an overlap in concentrations achieved 
between individuals over the dosage range. For some 
patients, trough concentrations at steady state on the 
highest dose were lower than those achieved by other 
patients on the lowest dose.
The validity of the two compartment model to describe 
the pharmacokinetics of fenclofenac was further tested by 
examining the difference between trough concentrations 
predicted from the individual pharmacokinetic parameters and 
observed trough concentrations at steady state on each dose. 
The steady state equations for the one and two compartment 
models with zero order absorption are given in Appendix II. 
Allowance was made for the unequal dosing intervals on the 
highest dose. Predicted and observed trough concentrations 
were compared using a paired t-test. Figure 5.5 presents the 
mean prediction errors (j^ SD) using the one or two 
compartment model parameter values. At all dose levels the 
one compartment model gave significantly biased 
(underpredicted) estimates of trough concentrations. The two 
compartment model was less biased; only trough 
concentrations predicted for the lowest dose were 
significantly underpredicted.
The Friedman two-way analysis of variance was used to
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f i g u r e 5.4 Total fenclofenac trough concentrations at 
steady state on each dose
A Mean concentrations 
B Individual concentrations
1 I one compartment model 
two compartment model
IIII
I
iÜ-40
"100"^ 600 1200 1800
Dose (mg/day)
FIGURE 5.5 Mean error (j^ SD) in the prediction (predicted-
observed) of individual total fenclofenac trough 
concentration at steady state using either one 
or two compartment model parameter estimates
test for any trends in the prediction errors (using the two 
compartment model) over the dose range to determine whether 
the kinetics of fenclofenac were linear. The analysis showed 
that there was no significant trend in the prediction errors 
over the dose range, indicating that total fenclofenac 
kinetics were indeed consistent with linearity.
This suggests that the binding of fenclofenac to 
plasma proteins is constant over the concentration range 
encountered in this study. One would therefore expect to 
observe a linear increase in the free concentration. Median 
free trough concentrations were 180, 406 and 565ng/ml on 
600, 1200 and 1800mg respectively. Indicating that on 
average there was a linear increase. However from the plot 
of individual free concentrations against dose (Figure 5.6), 
the increase in free concentration was far from linear in 
3 patients (14, 15 and 18) indicating perhaps, saturation of 
hepatic metabolic pathways.
(iii) Binding Studies
Figure 5.7 shows the free fraction of fenclofenac in 
trough samples plotted against total concentration. In most 
patients the free fraction remained relatively constant 
across the dose range but the free fraction increased 
with increasing total concentration in one or two patients.
The relationship between the free fraction of 
fenclofenac, total fenclofenac and albumin was investigated 
by multiple linear regression using GLIM (Chapter 4). The 
models tested to describe the free fraction (f^) of
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on each dose plotted against total fenclofenac 
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fenclofenac using GLIM are given in Table 5.7. The best 
model on the basis of the F ratio test was:
fy = A + b-.Ctot .............................. (5.1)
The coefficient of determination for this model was 0.905. 
This indicates that each subject had an individual slope
(b^) for the change in f^ with increasing and a common
intercept (A). The regression equation for the average 
patient was:
f ^  (xl0"3) = 3 . 7 4  + 0.024.Ctot ............ (5.2)
and ranged from:
fg (X10-3) = 3.74 - 0.059 .Ctot ............. (5.3)
to :
f^ (X10-3) = 3.74 + 0.256.Ctot ............. (5.4)
This relationship indicates that in general there was a 
slight increase in the free fraction with increments in 
concentration; in some patients, the increase was more 
dramatic. It may have been expected that albumin would 
explain this difference but it did not.
Fenclofenac bound and free concentrations over the 
total concentration range of 1.3-500jug/ml were fitted 
well to the Langmuir isotherm for two independent classes of 
binding sites. An example of an individual set of data 
plotted in the form of Scatchard and also fitted to the 
double Langmuir isotherm with free concentration as the 
dependent variable is shown in Figure 5.8. The individual 
parameters and the coefficient of determination are given in 
Table 5.8. The mean parameters for patients were: the
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FIGURE 5.8 Fenclofenac binding data for a representative 
patient (14)
A Scatchard plot
B Data fitted to the Langmuir isotherm with free 
concentration as the dependent variable
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maximum number of binding sites, nP^  ^ and n? 2 , 366 and 3434pM 
respectively and the dissociation constants, K a n d  K^ 2 ' 
1.87 and 56pM respectively for the high and low affinity 
sites. Assuming albumin is the only binding protein, the 
number of each type of binding site on each albumin molecule 
can be determined. The molecular weight of albumin was taken 
as 69,000 and the mean values of n^ and n 2 were calculated 
as 0.63 and 7.4 respectively. These parameters indicate that 
there is concentration dependent binding below 100pg/ml. 
However, the non-linearity becomes more apparent above 
100pg/ml with saturation of the primary binding site. The 
change in the free fraction with total concentration 
predicted from the median binding parameters is shown in 
Figure 5.9 together with observed free fraction in the 18 
patients at steady state.
5.3.2 Dose and concentration-response relationships
There were no significant time or treatment order 
effects. Samples taken at the end of each wash-out period 
indicated that fenclofenac was still present in plasma at 
significant concentrations, mean concentrations (SO) were 
12.5(7.6), 20.6(19.1) and 3 3.6 (2 3.5 ) pg/m 1 at the end of the 
wash-out period after 600, 1200 and 1800mg respectively.
This was not surprising considering the long terminal 
elimination half-life determined from the single dose study. 
However, it meant that these assessments could not be used 
in the analysis to check for any week to week variability
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f i g u r e 5.9 The change in the free fraction of fenclofenac 
with increasing total concentration predicted 
from the mean binding parameters is given 
together with the free fraction determined in 
patient samples at steady state
in the disease severity. In addition these assessments were 
carried out in the afternoon and therefore could not really 
be compared with those carried out in the morning. Since the 
doses were continued for 12 days it is unlikely that these 
residual concentrations would have affected the attainment 
of steady state in terms of concentration and clinical 
response.
Four patients showed little, if any, improvement in 
symptoms at any dose. Corresponding trough concentrations 
were 52, 82, 79 and 100pg/ml on the highest dose. All other 
patients showed an improvement in at least three of the 
effect measurements when receiving 1800mg/day. All patients 
with trough concentrations above 100pg/ml on 1200 or 1800 
mg/day showed an improvement in all effect measurements when 
compared to baseline values.
A summary of the clinical effect data is given in Table 
5.9 and Figure 5.10 giving an indication of the considerable 
variability in the response measurements. A result of both 
inter and intra-subject variability. Friedman two-way 
analysis of variance indicated that there were no 
significant differences from dose to dose for any of the 
four response measurements. The 600mg dose was not 
significantly different from baseline. When the data were 
taken as a whole the analogue pain score was the only 
assessment which appeared to show a dose related effect. As 
patients sometimes showed an improvement in one response 
measure but not in others, a summed efficacy score was
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calculated. This however did not reveal a dose response 
relationship.
Corresponding dose or 12 hour trough fenclofenac 
concentrations (total and free) and clinical response data 
(Ritchie Articular Index, mean grip strength, duration of 
morning stiffness and analogue pain score) were analysed 
using the linear modelling program GLIM (Baker & Nelder, 
1978). The data were fitted to the three possible linear 
models described in Chapter 4 (Equations 4.21-4.23) , 
referred to as Models 1-3, and compared using the F ratio 
test. Three or four data points per individual (depending on 
whether or not baseline measurements were included) for 
eighteen patients were analysed simultaneously for each 
response index.
Table 5.10 shows the effect of fitting the response 
data in terms of total concentration to Models 1-3. Despite 
the large range of values for the individual slope parameter 
obtained by fitting the data to the full model (Model 1), 
this model was rejected in favour of the simpler linear 
model (Model 2). This was due to the large amount of 'noise' 
or intra-subject variability in the response measurements. 
The reduced model, however, took account of inter-subject' 
variability by allowing an individual intercept (severity of 
disease before treatment) and a common improvement slope for 
all individuals. This model was tested against Model 3, to 
determine the significance of the slope: the subject effect 
accounted for a large percentage of the total sum of
1 1 9
TABLE 5.10 Comparison of different linear models to 
describe fenclofenac total concentrâtion- 
response data (baseline data omitted)
RITCHIE ARTICULAR INDEX 
Linear model SSQres df^,df2 F value p value C^^t
Total SS 4747
Model 1 647 0.864
Model 2 1083 17,18 (1) 0.71 NS 0.772
Model 3 1199 1,35 (2) 3.75 ' NS 0.747*
DURATION OF MORNING STIFFNESS
Linear model SSQres dfj^,df2 F value p value Cdet
Total SS 753800
Model 1 104800 0.861
Model 2 144100 17,18 (1) 0.40 NS 0.809*
Model 3 164100 1,35 (2) 4.86 <0.05 0.782
Linear models :
1. Effect^ = + b^.C
2. Effect^ = a^ + B.C
3. Effect^ = a^
model for comparison is given in parenthesis 
* denotes the most appropriate model
1 20
TABLE 5.10 Comparison of different linear models to 
describe fenclofenac total concentrâtion- 
response data (baseline data omitted)
MEAN GRIP STRENGTH
Linear model SSQres df 2^ ,df 2 F value p value Cdet
Total SS 96720
Model 1 6079 0.937
Model 2 11690 17,18 (1) 0.98 NS 0.879
Model 3 12540 1,35 (2) 2.54 - NS 0.870*
ANALOGUE PAIN SCORE
Linear model SSQres df 2^ ,df 2 F value p value ^det
Total SS 287
Model 1 61 0.787
Model 2 81 17,18 (1) 0.35 NS 0.719*
Model 3 94 1,35 (2) 6.05 <0.05 0.671
Linear models:
1. Effect^ = a^ + b^.C
2. Effect^ = a^ + B.C
3. Effect^ = a^
model for comparison is given in parenthesis 
* denotes the most appropriate model
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squares, particularly for grip strength.
With baseline measurements included, the slope of 
improvement was significant for all response indices when 
analysed against dose, total or free concentration (Table 
5.11). The coefficient of determination was slightly higher 
for the fit in terms of total concentration than for dose or 
free concentration, especially when the dependent variable 
was the duration of morning stiffness.
When baseline values were removed the results were 
slightly different (Table 5.12). The slopes were 
considerably flatter and the median intercepts were 
different from those observed, especially for free 
concentration. As an example, when analogue pain score was 
analysed in terms of total concentration, the slope was -2.7 
and -1.7cm/pg/mlxl0“  ^ when baseline data was included and 
excluded respectively. The slope was only significant for 
the duration of morning stiffness in terms of dose and total 
concentration and for the pain score in terms of dose, total 
and free concentration. There was a trend towards an 
improvement in the articular index with increasing total 
concentration but this was not significant. The data for 
total concentration are presented in Figure 5.11 together' 
with the average slope of improvement determined with 
baseline measurements excluded.
The SSQres are presented in Table 5.13 for each 
response index fitted to Models 1 and 2 with dose, total 
and free concentration as the independent variable. Dose
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FIGURE 5.11 Individual total fenclofenac concentration- 
response data. The bold continuous line gives 
the average slope of improvement
TABLE 5.13 Comparison of the residual sum of squares
(SSQres) for clinical response data fitted to the 
full and reduced models in terms of dose, total 
or free concentration
DOSE TOTAL FREE
ARTICULAR INDEX
Model: 1 580* 647 661
2 1112 1083* 1134
MORNING STIFFNESS
Model: 1 84060* 104800 105400
2 140800* 144100 154300
GRIP STRENGTH
Model: 1 4940* 6079 5990
2 11490* 11690 12120
PAIN SCORE
Model: 1 57* 61 60
2 82 80* 82
* the lowest SSQres for the comparison between dose, total 
and free concentration
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gave the lowest SSQres when data were fitted to the full 
model. In general, the SSQres was lowest for concentration 
when data were fitted to Model 2. In addition, the 
difference in SSQres between Model 1 and Model 2 was always 
less for concentration than for dose, indicating that 
concentration does explain some of the inter-individual 
variability in the response.
Plots of the residuals (y^-y^) against the predicted 
effect or concentration indicated that with .grip strength 
and the duration of morning stiffness, baseline values were 
not fitted well assuming a linear model. With all data 
included, baseline measurements were overpredicted for grip 
strength and underpredicted for the duration of morning 
stiffness. There did not appear to be any trends in the 
residuals with the other rheumatological measures. These 
discrepancies indicated that either it was inappropriate to 
include the baseline values (carried out under non-blinded 
conditions) or that the data should more appropriately be 
fitted to an model (Holford & Sheiner, 1982).
These data (baseline measurements were included) were 
fitted to a linear and a nonlinear (E^^x) model using the 
program NONMEM (Equations 4.16 & 4.17). A comparison of the 
®max linear model was made on the basis of the
difference in the objective values (Table 5.14). The best 
improvement in the objective value using the E^a* model was 
that associated with the analogue pain score analysed in 
terms of total and free concentration.
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The final NONMEM parameter estimates for the E^^% model 
are summarised in Table 5.15. Intersubject variability (ie 
the variance parameters) and the residual intra-subject 
error were very large. The standard errors of most parameter 
estimates were also relatively large. was most poorly
estimated. The structural model parameters (SE in the 
estimate) were best defined for analogue pain score eg. for 
total concentration E^^% was 5.0 (0.9)cm , was
69 (27)pg/ml and Cg was 6.8 (0.3) cm. For all effects in terms 
of dose, total or free concentration, the residual 
unexplained variability was large and a reflection of the 
the known variability in some of these response measures 
(Chapter 3). The residual error, which is also is also due 
to model mispecification and true intra-subject 
variability, was slightly larger when data were fitted to 
the linear model.
5.3.3 Side-effects , biochemistry and haematology
Side-effects reported are given in Table 5.16. These 
were minor in nature and consisted of gastrointestinal, 
central nervous system and dermatological complaints. None 
were so serious as to require discontinuation of treatment 
or withdrawal from the study. There did not appear to be any
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TABLE 5.15 NONMEM parameter estimates (SE) for fenclofenac 
dose, total and free concentrâtion-response 
data fitted to the E^^x model
RITCHIE ARTICULAR INDEX
Parameter Dose Tota 1 Free
®max -12(5) -14(7) -11(8)
var 0.33 (0.91) 0.33 (0.34) 0.34 (0.39)
^^50% 507 (829) ^ 42(59)^ 113(146)C
var ID ID ID
C0 23(3) 24(3) 23(3)
var 0.095(0.058) 0.100 (0.047) 0.100 (0.056)
e 36 (14) 33 (12) 35 (12)
DURATION OF MORNING STIFFNESS (minutes)
Parameter Dose Tota 1 Free
^max -163 (325) -241(64) -112(49)
var ID ID 0.57 (0.92)
8^50% 534 (1850) ^ 79 (67) b 10(8) c
var 10 (24) 0.18 (0.13) 0.21 (0.21)
218 (45) 218 (32) 217(40)
var 0.28 (0.31) 0.18 (0.13) 0.21(0.21)
e 4330 (4170) 6310 (3480) 5640 (4680)
Key:
y  var
V e
var variance parameter for the preceding structural
parameter
e = the resid ual error
ID = parameter was indetermi nate
a = units are mg/day
b = units are pg/ml
c = units are ng/ml
ves as estimate of the inter- individual coefficient
of variation in the structural model parameter 
gives the estimate of the random additive error
1 29
TABLE 5.15 NONMEM parameter estimates (SE)for fenclofenac 
dose, total and free concentration-response 
data fitted to the E^^x model
MEAN GRIP STRENGTH (mmHg)
Parameter Dose Tota 1 Free
^max 54 (61) 39 (14) 26 (8)
var ID 0.79(0.69) 0.70 (0.65)
8^50% 2730(51900)3 76 (67) b 144 (108)C
var ID ID ID
C0 100(2) 100(10) 99(10)
var 0.12(0.06) 0.14 (0.05) 0.14(0.06)
€ 288 (109) 269 (87) 281(90)
ANALOGUE PAIN SCORE (cm)
Parameter Dose Tota 1 Free
®ma X -4.1(2.4) -5.0 (0.9) -3.3(1.0)
var 0.52 (1.14) ID 0.56 (0.47)
8^50% 795(1360) ^ 69 (27) b 105 (113) c
var ID 2.47 (1.51) ID
C0 6.7 (0.3) 6.8(0.3) 6.8(0.3)
var ID ID ID
6 1.9(0.5) 1.9(0.5) 1.9(0.5)
V
V e
var gives as estimate of the inter-individual coefficient 
of variation in the structural model parameter 
gives the estimate of the random additive error in 
the response
1 30
TABLE 5.16 Side effects reported on each dose and associated 
total fenclofenac trough concentrations. Patient 
number is given in parenthesis.
Side effect
600
Dose (mg/day) 
1200 1800
Indigestion 13(5)
Vomiting
Drowsiness
Headache 51 (15)
Dizzy spells 51(6)
Haematuria
Hot flushes 41(14)
Slight rash 
Mild skin irritation 
Blotches on skin
20 (5) 
81 (16)
29 (13)
71(9)
93(3)
101 (12)
52(5),108(6)
78 (7)
93(1) 
140 (2)
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total concentration. In addition, patients with very high 
free concentrations (due to non-linear binding above 
100pg/ml) reported no adverse effects.
Biochemical and haematologica 1 indices which showed a 
change from baseline are given in Table 5.17. There appeared 
to be a dose related increase in creatinine, although values 
remained within the normal range. This effect may be of some 
clinical significance as creatinine concentrations tend on 
the whole to be lower in patients with rheumatoid arthritis 
due to a reduction in its production (Nived et al, 1983). 
There was also some evidence of a dose related reduction in 
the white blood cell count, but again values remained within 
the normal range. There was a reduction in bilirubin, red 
blood cell count and platelet count, but these changes did 
not reach significance. There was a significant reduction in 
alkaline phosphatase on the highest dose. The reduction was 
most dramatic in patients with high initial values. These 
patients also attained relatively high trough fenclofenac 
concentrations.
5.4 DISCUSSION
Despite the observation that the binding of fenclofenac 
to plasma proteins is concentration dependent over the range 
of total concentrations encountered in this study, 12 hour 
total trough concentrations were consistent with linear 
kinetics. Even below 100pg/ml there was a slight increase in
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the free fraction with increasing total concentration, in 
contrast to previous observations (Brewster & Muir 1978). 
Three patients showed a dramatic non-linear increase in the 
free drug concentration over the three doses (Patients 14,
15 and 18). Assuming that the clearance of free drug 
remains constant, there should be a linear increase in 
free concentrations and a non-linear increase in total 
concentrations. These results suggest that in some patients 
there might be saturation of hepatic metabolism. In terms of 
total concentration this effect may be masked in part due to 
saturation of binding sites on plasma protein.
The elimination half-life determined from the single 
dose study ranged from 11 to 33 hours (median 20 hours).
This average value is slightly shorter than the elimination 
half-life determined in healthy volunteers (mean 27 hours, 
range 20-38 hours, Henson et al; 1980). The median clearance 
(range) of total drug in patients was 0.62 (0.33-1.49) 1/h, 
higher than that found in healthy volunteers with a mean 
(SD) of 0.38 (0.12)1/h. It is possible, however, that 48 
hours was too short a sampling time to get an accurate 
estimate of the elimination half-life or clearance and this 
may explain the underprediction of trough concentrations at 
steady state.
The variability in fenclofenac clearance 
(coefficient of variation was approximately 50%) determined 
from the initial single dose studies (Table 5.6) is 
reflected in the range of trough concentrations at steady
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State (Figure 5.4). For a drug such as fenclofenac with a 
low extraction ratio, the elimination is dependent on the 
free fraction of drug in the blood and the intrinsic 
clearance of free drug (Wilkinson & Shand; 1975). In 
general, the free fraction of fenclofenac was fairly 
consistent between patients for a given total concentration, 
but the free fraction was much higher in one patient with a 
very low albumin concentration (30g/l) and non-linear 
binding was evident at much lower total concentrations. 
Rheumatoid arthritis is a disease not only of the joints but 
is also associated with dramatic systemic effects. 
Alterations in the production and catabolism of plasma 
proteins occur, and it is possible that there are changes in 
the configuration of these protein molecules. The higher 
value of clearance determined in this study may be a result 
of lower albumin concentrations in patients with rheumatoid 
arthritis compared to healthy individuals, but there was no 
correlation between total fenclofenac clearance and albumin 
concentration. It would be interesting to compare the 
relationship across a wider range of albumin concentrations.
These results suggest that factors affecting the 
intrinsic clearance of fenclofenac may be important 
determinants of the total clearance. There was a trend 
towards a decrease in the apparent clearance of total 
fenclofenac with increasing age and alkaline phosphatase. 
Alkaline phosphatase is often raised in patients with 
rheumatoid arthritis. Indeed, at the beginning of this
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study, alkaline phosphatase was above the normal range in 7 
of the 18 patients.
Serum alkaline phosphatase is composed of isoenzymes 
derived from the liver, bone and the intestine. In normal 
adults 50% is synthesised in the liver and 50% is derived 
from bone, reticuloendothelial and vascular sources. A 
correlation between alkaline phosphatase and the number of 
osteoblastic cells in bone has been reported (Teaford & 
White; 1964). The raised levels in patients with rheumatoid 
arthritis may be due to effects of the disease on bone or on 
the liver. It may be assumed that the decrease in 
fenclofenac clearance is related to a diffuse effect of the 
disease on the liver, also associated with an increased 
production of alkaline phosphatase. Together with a 
significant reduction in white cell count and the previous 
observations that during long term treatment there was a 
reduction in the ESR (Akyol, Anderson & Thompson, 1977) 
these observations lend substance to the proposal that 
fenclofenac possesses some disease modifying activity. 
Indeed, in animal studies fenclofenac was more effective 
against chronic immunologically-mediated inflammation than 
against acute inflammation (Phillips, 1980).
There was a decrease in alkaline phosphatase with dose 
which was most dramatic in patients with high initial 
levels. This effect has been noted in studies with 
benoxaprofen (Jones, 1982). It was proposed that this was 
due to an effect on the production of alkaline phosphatase
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by osteoclasts, directly or indirectly. Raised alkaline 
phosphatase in rheumatoid arthritis, however, has been shown 
to be of hepatic origin (Mills & Sturrock, 1982). There was, 
however, no evidence that the clearance of fenclofenac 
increased over the treatment period in the patients who 
showed the most dramatic reduction in alkaline phosphatase.
Despite the observed inter-subject variability in the 
pharmacokinetics of fenclofenac, clinical response was 
explained equally well by dose as by total concentration 
irrespective of the model used (linear or non-linear). This 
is probably due to the marked 'noise' or intra-subject 
variability in clinical response. Although some patients 
showed little or no improvement, others showed a dramatic 
response to fenclofenac. The more complex linear model 
(Model 3) which describes the data in terms of an individual 
intercept and slope had to be rejected in favour of the 
simpler model (Model 2). If there was a relationship between 
total concentration or free concentration and clinical 
response across the patient group, the full model should 
have been more appropriate for explaining the response in 
terms of dose but not for response in terms of total or free 
concentration. The full model was not significantly better 
for dose, but in general, the increase in the SSQres was 
greatest for dose as a result of removing the individual 
slope parameter. Although comparison of the results of the 
GLIM analysis with and without baseline measurements 
indicated that the data would be more appropriately fitted
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to an model, the variability in the data often resulted
in the rejection of the more complex non-linear model in 
favour of the simple linear model. In addition, the 
parameters were always poorly defined and therefore not very 
meaningful.
Across the concentration or dose range encountered 
clinically, the simplest linear model predicts an 
improvement in clinical response with increments in dose or 
concentration within an individual patient for at least two 
clinical effect parameters. Due to the lack of response in 
some patients, the slope of improvement (which is an average 
value for all patients) is not very dramatic (Table 6.10): 
reduction in morning stiffness of 25 minutes; reduction in 
the analogue pain score of 0 .6 cm, both as a result of 
increasing the dose from 1 2 0 0  to 1800mg.
If one considers the fit to the model, which is
perhaps more realistic, the concentration necessary to 
achieve 50% of the maximum reduction in the analogue pain 
score, C 5 0 1  (SE) was 795 (1360)mg/day, 68.9 (26.7)^g/ml and
105 (113)ng/ml for dose, total and free concentration 
respectively; ie, somewhere between the 600 and 1 2 0 0 mg 
doses. And the maximum reduction in the pain score was 4, 5 
and 3cm for dose total and free concentration respectively.
In conclusion, these results suggest that fenclofenac 
could have been given in doses above 1 2 0 0 mg/day with the 
expectation that on average there would be an improvement 
in symptoms. Despite the considerable inter-subject
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variability in the kinetics of fenclofenac, these results 
indicate that knowledge of plasma concentrations (total or 
free) adds little to the explanation of clinical response. 
Although subjectively most patients with trough total 
concentrations above 1 0 0 pg/ml showed an improvement in 
symptoms, the analysis did not indicate minimum effective or 
toxic concentrations.
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CHAPTER 6_
NAPROXEN, PHARMACOKINETICS 
AND CLINICAL RESPONSE
6.1 INTRODUCTION
In the last chapter, knowledge of concentration was 
found to offer little advantage over dose in the description 
of the clinical response to fenclofenac in patients with 
rheumatoid arthritis. Increments in dose or concentration, 
however, were associated with reductions in the duration of 
morning stiffness and the analogue pain score. This was 
investigated further with another NSAID, naproxen and this 
chapter presents the results of a dose ranging controlled 
study of naproxen in patients with rheumatoid arthritis. The 
general approach was the same as that described in the 
previous chapter for fenclofenac. Attention was directed 
towards the determination of the variability in the 
pharmacokinetics of naproxen and the general aim was to 
evaluate whether knowledge of total or free drug 
concentrations could contribute to the explanation of 
clinical response or toxicity.
Two previous controlled studies have investigated the 
relationship between dose and clinical response (Luftschein 
et al, 1979; Day et al, 1982). Luftschein and colleagues 
found a significant linear improvement with dose in only 2 
of 1 2  outcome measures (joint swelling and a joint pain and 
tenderness score). A concentration response relationship was 
not investigated. Day et al (1982) gave three doses of 
naproxen (250, 750 and 1500mg/day) to 24 patients (some were
stable on gold or penicillamine). They were able to
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demonstrate a linear dose response relationship in 5 of 9 
clinical response measures (joint count, patients' pain 
assessment, activities of daily living, grip strength and 
patients' and doctors' global assessments). Using a 
parametric ranking technique, there appeared to be a linear 
relationship between the percentage of responders and trough 
total concentration. However the advantage of knowledge of 
concentration over dose could not be tested.
The specific aims of this study were to investigate the 
following:
a) The relationship between the dose of naproxen and 
plasma concentration (total and free).
b) The relationship between naproxen clearance and any 
specific patient factor.
c) The relationship between the dose of naproxen and/or 
the plasma concentration (total and free) and 
clinical response and/or toxicity.
6.2 PATIENTS AND METHODS
6.2.1 Study design
The basic study design was identical to that described 
for fenclofenac (Chapter 5) and is outlined in Figure 6.1. 
The doses of naproxen were: 500, 1000 and 1500mg/day. 
Rheumatologica 1 assessments were identical to those used in 
the study of fenclofenac (Chapter 3, Appendix I).
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figure 6 . 1  study outline
6.2.2 Patients
Eighteen outpatients with 'definite' or 'classical' 
rheumatoid arthritis (Ropes et al, 1959) complied with the 
protocol and completed the study. This completed 3 
randomised blocks of 6 for the order of the three doses. 
Thirteen patients were female and five were male. Their ages 
ranged from 43 to 74 years and the disease duration ranged 
from 6 months to 23 years. Individual patient 
characteristics are given in Table 6.1 together with 
previous NSAID therapy. None of the patients was receiving 
corticosteroids or any other second line drug. Patients were 
included in the study only if there was a 'flare' after the 
withdrawal of their previous NSAID for at least 3 days. 
Patient 18, however stopped taking piroxicam one week before 
the start of the study. Table 6.2 presents the 
rheumatological measures at the end of this initial wash-out 
period and gives an indication of the severity of the 
disease.
6.2.3 Single dose study
The initial wash-out period was followed by a single 
1000mg dose study (4x250mg tablets). The conditions being 
indentical to those of the fenclofenac study. A control 40ml 
blood sample was taken from all patients before the dose to 
determine naproxen binding parameters (Chapter 3). 
Subsequently, 1 0 ml samples were taken at the times given for 
fenclofenac up to 48 hours. All blood samples were handled 
and stored as described for fenclofenac (Chapter 5). Total
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and free naproxen were determined as outlined in Chapter 2.
6.2.4 Randomised treatment period
During the randomised treatment period each dose of 
naproxen was given for 12 days at a time. Naproxen (250mg) 
and placebo were identical in appearance. On each dose, 
patients took three tablets two times a day; at 1 0 . 0 0  and 
2 2 . 0 0  hours.
Rheumatological assessments were carried out and blood 
samples were taken for the measurement of naproxen 
concentrations (total and free) and for standard biochemical 
and haematological screens throughout the study as detailed 
for fenclofenac (Figure 6.1). Blood samples for drug 
analysis were handled as above for the single dose study.
6.2.5 Data analysis
(i)Single dose study
Total or free concentrâtion-time profiles were fitted 
to one and two compartment models with first order or zero 
order absorption (Models 1-4, Appendix II) using non-linear 
least squares regression analysis (Chapter 4). The most 
appropriate model was chosen on the basis of the criteria 
given in Chapter 4. For total concentration the error was 
assumed to be constant, while the free concentration was 
weighted proportional to the reciprocal of the fitted 
concentration (1 /c^).
(ii) Binding studies
Binding data were fitted to the Langmuir isotherm with
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two independent binding sites using non-linear least squares 
regression analysis (Chapter 4). Free concentration as the 
dependent variable was weighted as above.
(iii) Dose and concentrâtion-response analysis
The rheumatological assessments used in these analyses 
were the same as those used in Chapter 5. Data analysis 
techniques were identical to those for fenclofenac.
6.3 RESULTS
6.3.1 Pharmacokinetics and protein binding
(i) Total naproxen pharmacokinetics
Total concentration-time profiles after a single dose 
of 1 0 0 0 mg naproxen were in general fitted well to a two 
compartment model with a zero order input (Table 6.3). 
Parameter estimates are presented in Table 6.4. Apparent 
clearance ranged from 0.22 to 1.22 1/h (median 0.58 1/h).
The parameter values, however, could not be used to predict 
total trough concentrations at steady state on each dose.
There was a non-linear increase in total naproxen 
trough concentrations. Mean concentrations (jfSD) were
36.5 (+7.1), 49.2 ( + 8.0) and 56.4 (+9.5) pg/ml on 500, 1000 and 
1500 mg/day respectively. Individual trough concentrations 
are presented in Figure 6.2a. The non-linear increase was 
consistent for all patients. The variability in total 
concentrations was small compared to the range of clearance 
determined from the single dose study.
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TABLE 6 .3 Comparison of AIC values for total naproxen
concentration-time profiles fitted to Models 1-4
One compartment model Two compartment model
Patient first order zero order first order zero order
1 1 0 1 1 0 0 * 1 1 0 103
2 135 123 131 116*
3 118 1 0 1 99* 106
4 132 1 2 0 132 119*
5 1 2 2 104 1 2 2 99*
6 1 0 2 1 0 1 136 78*
7 114 114 96* 1 0 2
8 127 134 1 2 1 * 136
9 152 174 174 123*
1 0 115 1 2 0 119 104*
1 1 1 2 2 106 117 89*
1 2 1 1 1 93 128 78*
13 106 96* 109 1 0 0
14 1 1 1 * 116 131 130
15 131 119* 132 124
16 135 1 0 0 117 8 8 *
17 103 103 8 6 83*
18 135 1 2 2 139 119*
indicates the lowest AIC value for comparison of the
four models
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f i g u r e  6.2 Individual total and free naproxen trough
concentrations at steady state on each dose, 
Female nonsmoker (•) and smoker (O) , male 
nonsmoker (a ) and smoker (a ) .
* patients receiving cimetidine
(ii) Free trough concentrations at steady state
The relationship between the dose of naproxen and the 
free drug concentration was linear: mean trough 
concentrations ( + SD) were 34.2 (+15.2), 63.9 (+25.9) and 
95.1(+40.6) ng/ml on 500, 1000 and 1500 mg/day respectively.
Individual free trough concentrations are presented in 
Figure 6.2b. The variability in total concentrations was 
small in comparison to the variability in free drug 
concentrations. The free concentration of naproxen tended to 
be higher in females and lower in smokers. In addition, the 
free concentration was considerably higher in two patients 
who were receiving cimetidine throughout the study (Figure 
6.2b). The differences were not so dramatic for total 
concentration (Figure 6.2a).
The free fraction in trough samples ranged from 0.032% 
at a total concentrations of 25pg/ml to 0.4422% at a total 
concentration of 75^g/ml (Figure 6.3): the percentage of 
naproxen bound to plasma albumin over this concentration 
range exceeded 99.5%.
(iii) Protein binding studies
To explain the kinetics of naproxen it was necessary to 
determine the free concentration-time profile. Instead of 
measuring the free naproxen concentration in each of the 
single dose study plasma samples, the binding of naproxen 
was investigated over a much wider concentration range by 
spiking the control plasma taken after the initial wash-out 
period with naproxen to give concentrations over the range 
25 to 500pg/ml using equilibrium dialysis (Chapter 2). This
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FIGURE 6.3 The free fraction of naproxen plotted against 
the total concentration in trough samples at 
steady state on each dose.
allowed the estimation of the parameters of an appropriate 
binding model assuming that the interaction obeyed the law 
of mass action. The parameters could then be used to 
determine the free concentration corresponding to a 
particular total concentration.
The individual binding data plotted in the form of a 
modified Scatchard plot (bound/free against bound) indicated 
that naproxen was bound to at least two distinct binding 
sites. The binding parameters, determined graphically were 
used as initial estimates for the non-linear least squares 
regression analysis.
The binding data for a representative patient, plotted 
in the form of Scatchard and fitted to the Langmuir equation 
rearranged in terms of free concentration, are given in 
Figure 6.4. A summary of the individual binding parameters 
(expressed in pg/ml naproxen) are presented in Table 6.5.
The mean binding capacities for the high and low affinity 
sites were 73 (+15) and 473 (+53)pg/ml respectively. The 
dissociation constants were 0.060 (+0.025) and 6.2 (+1.5)pg/ml 
for the high and low affinity sites respectively. The 
standard error in the estimate of some of the individual 
parameters (especially the dissociation constant for the 
high affinity site) was often large. The variability in the 
mean parameter values may in part, therefore be a result of 
poorly defined individual parameter estimates.
By fitting the data from all patients simultaneously 
using NONMEM (Chapter 4), mean binding parameters and their 
variances within the patient population could be determined.
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f i g u r e  6.4 Binding data for a representative patient (14)
A plotted in the form of a modified Scatchard 
plot
B Fitted to the Langmuir isotherm rearranged 
with free concentration as the dependent 
variable
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The results of the NONMEM analysis are shown in Table 6 .6 . 
The population average binding parameters were similar to 
those obtained from the mean of the individual parameter 
values; the inter-subject variability in the dissociation 
constant for the high affinity site was still very large.
If it is assumed that albumin is the major binding 
protein, nP^ and n ? 2  should theoretically be related to the 
concentration of albumin. Using a simple model:
n?i = 0 - 2 .^ a 1 b .......................... (6 .1 )
n P 2 = O 2 . a i b ........................... (6 .2 )
where 9^ and 0 2  are constants which relate the binding 
capacity for the high and low affinity sites to the 
individual albumin concentration (alb), the objective value 
was reduced, indicating an improvement in the 'goodness of 
fit' for the same number of parameters. The results of this 
analysis are also shown in Table 6 .6 . The estimate of the 
inter-subject variability in still relatively large,
but smaller compared to the previous model. The program was 
unable to determine the inter-subject variability in A
plot of free against total concentration using the NONMEM 
binding parameters with a range of albumin concentrations is 
given in Figure 6.5.
(iv) Free naproxen pharmacokinetics
Free drug concentration-time profiles were generated 
using NONMEM binding parameters (adjusted for individual 
albumin concentration) from the total concentrations after 
the single 1000mg dose of naproxen. The program used is 
given in Appendix III.
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FIGURE 6.5 Free naproxen concentration plotted against
total naproxen concentration determined using 
the NONMEM binding parameters over the albumin 
concentration range 34-46g/l
Free concentration-time profiles were best fitted by a two 
compartment model. The fit was improved when a zero order 
input was used instead of the usual first order input (Table 
6.7). The pharmacokinetic parameters for the data fitted to 
this model (Model 4, Appendix II) are given in Table 6 .8 . 
Representative profiles of naproxen (total and free) and 
desmethylnaproxen (DMN) after a single 1000mg dose are given 
in Figure 6 .6 . Although DMN was detected in the plasma after 
the single dose of naproxen, the levels were close to the 
limit of detection and in most cases, could not be detected 
after 12 hours. The kinetics of the metabolite could not be 
determined. The volume of distribution of the central 
compartment for free naproxen was obviously very large as a 
result of the very low free concentrations. The clearance of 
free drug was considerably higher than the clearance of 
total drug, again due to the fact that a large fraction of 
the total drug is bound to plasma albumin.
(v) Correlation between patient factors and naproxen clearance 
The relationship between the clearance of free naproxen 
and various patient factors such as sex, age, creatinine, 
alkaline phosphatase and smoking were investigated using 
general linear regression and correlation techniques. There 
was a weak but significant reduction in clearance with 
increasing age (Figure 6.7a). The clearance also tended to 
be lower in females and in patients on cimetidine. It tended 
to be higher in smokers. There was no correlation between 
the clearance of naproxen and weight in the group as a whole 
(Figure 6.7b).
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TABLE 6.7 Comparison of first order and zero order input on 
the AIC values for free naproxen concentration - 
time profiles fitted to a two compartment model
Patient first order zero order
1 -39.9 -46.3*
2 -47.9 -64.3*
3 -34.1 -64.4*
4 -62.0 -78.8*
5 -24.0 -32.8*
6 -97.2* -96.1
7 -41.1 -50.7*
8 -53.6 - 6 6 . 6  *
9 -47.8* -47.2
1 0 -45.8 -54.6*
1 1 -42.4 -73.8*
1 2 -62.0* -59.0
13 -54.3 -72.0*
14 -44.9 -55.3*
15 -24.7 -54.2*
16 -97.2* -72.6
17 -60.4 -117.1*
18 -34.8 -51.9*
* indicates the lowest AIC value
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FIGURE 6 . 6  Representative profiles of total naproxen, free 
naproxen and DMN in plasma after a single 1000mg 
dose
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FIGURE 6.7 The apparent clearance of free naproxen plotted
against age and weight
(vi) Prediction of free concentrations at steady state
The pharmacokinetic parameters determined for free drug 
were used to predict free trough concentrations at steady 
state (the steady state equation is given in Appendix II for 
the two compartment model) and the error in the prediction 
at each dose was tested using a paired t-test. The 
individual pharmacokinetic parameters gave unbiased 
predictions although the predictions were not very precise 
(Figure 6 .8 ).
(vii) Prediction of tota1 concentration at steady state
The total concentration at steady state corresponding
to the predicted free concentration was determined from the 
Langmuir isotherm (Equation 4.14) with the NONMEM binding 
parameters individualised for albumin concentration. These 
predicted total concentrations were compared to the observed 
total concentrations using a paired t-test. The prediction 
errors for total concentration are given in Figure 6.9. The 
underprediction of the total concentration was most dramatic 
at the lowest dose, suggesting that there is a quantitative 
alteration in the binding of naproxen to the high affinity 
site on albumin. There was no difference in the albumin 
concentration at the end of the treatment periods compared 
to the initial wash-out period. Prediction of total drug 
concentrations at steady state indicated that the binding 
parameters determined with plasma obtained at the start of 
the study were inconsistent with the actual binding during 
repeated dosing with naproxen.
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(viii) DMN concentrations in plasma and binding to plasma 
prote ]n k
There was indirect evidence that DMN does not bind 
significantly to albumin in the presence af the parent drug. 
DMN could be measured easily in buffer after dialysis of 
steady state trough samples. The concentration of DMN in 
buffer was of the same order as the concentration of 
naproxen. DMN was rarely detected in trough plasma samples 
at steady state, even on the 1500mg dose. In one patient, 
however, DMN was detected at concentrations of about 
0,15pg/ml (limit of detection 0.08pg/ml). The concentration 
of DMN in buffer after dialysis was 0.02-0.08pg/ml. Thus if 
DMN is not bound to plasma protein the original 
concentration in plasma was 0.04-0.15pg/ml. However if this 
vmetabolite did compete with naproxen for binding to albumin, 
the free fraction would have been higher in steady state 
plasma samples than in the initial spiked plasma samples.
6.3,2 Dose and concentration-response relationships
There were no significant time or treatment order 
effects. However, one patient appeared to improve 
dramatically throughout the 6 weeks of the study (Patient 
4). The mean (SD) total concentration of naproxen in samples 
taken at the end of each washout period was 6.1 (2.5),
7.4 (2,8) and 7.3 (3.4) pg/ml after 500, 1000 and 1500mg
respectively. As with the fenclofenac study the assessments 
carried out at this time could not be included in the 
analysis to account for any week to week variability in
individual disease activity.
The response data, plotted in terms of dose for each 
response measurement are given in Figure 6.10. Friedman two 
way analysis of variance indicated a significant improvement 
in all clinical effects on 1000 & 1500mg/day when compared 
to the initial washout period (Table 6.9). On average there 
was an improvement in symptoms from 500 to 1000mg/day, but 
there was virtually no further improvement on increasing the 
dose to 1500mg/day. Grip strength showed significant 
improvement on increasing the dose from 500 to 1500mg/day.
In addition, there was no difference between the summed 
efficacy score on any of the three doses. Only 1000mg and 
1500mg produced an effect which was significantly different 
from the baseline.
(i) GLIM analysis
The dose, total and free concentrâtion-response data 
were fitted to the three possible linear models using GLIM, 
with and without baseline measurements included. The most 
appropriate model was chosen on the basis of the F value 
(Chapter 4). Table 6.10 gives the results for the total 
concentration-response data (without baseline measurements) 
fitted to the linear models. As with the fenclofenac data 
the subject effect accounted for a large percentage of the 
total sum of squares, in particular for grip strength and 
the Ritchie Articular Index. The final parameter values 
for data fitted to the reduced model (Model 2, Equation 
4.22) are given in Table 6.11 (with baseline measurements) 
and 6 . 1 2  (without baseline measurements).
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TABLE 6.10 Comparison of different linear models to
describe naproxen total concentration-response 
data (baseline data omitted)
RITCHIE ARTICULAR INDEX
Linear model SSQres dfi,df2 F value P value Cdet
Total SS 9278
Model 1 533 0.943
Model 2 1451 17,17 (1) 1.72 NS 0.844*
Model 3 1653 1,34 (2) 4.73 <0.05 0.822
DURATION OF MORNING STIFFNESS
Linear model SSQres dfi,df2 F value P value Cdet
Total SS 272400
Model 1 18280 0.933
Model 2 67950 17,17 (1) 2.72 NS 0.750
Model 3 70030 1,34 (2) 1.04 NS 0.743*
Linear models:
1. Effect^ = a^ + b^.C
2. Effect^ = a^ + B.C
3. Effect^ = a^
Model for comparison is given in parenthesis 
* denotes the most appropriate model
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TABLE 6.10 Comparison of different linear models to
describe naproxen total concentration-response 
data (baseline data omitted)
MEAN GRIP STRENGTH
Linear model SSQres df^,df2 F value p value Cdet
Total SS 91590
Model 1 1440 0.984
Model 2 4630 17,17 (1) 2 . 2 2 NS 0.949*
Model 3 5923 1,34 (2) 9.50 p< 0 . 0 1 0.935
ANALOGUE PAIN SCORE
Linear model SSQres df j^ ,df 2 F value p value Cdet
Total SS 260
Model 1 52 0.800
Model 2 107 17,17 (1) 1 . 0 2 NS 0.588*
Model 3 128 1,34 (2) 6.95 < 0 . 0 1 0.508
Linear models:
1. Effect^ = a^ + b^.C
2. Effect^ = a^ + B.C
3. Effect^ = a^
Model for comparison is given in parenthesis 
* denotes the most appropriate model
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When baseline measurements were included (Table 6.11), 
the slope of improvement was significant for all response 
measurements when compared to the simplest model (Model 3). 
In general, the reduced model described the clinical effect 
measurements in terms of dose or free concentration best, 
but for analogue pain score, the full model (Model 1) was 
more appropriate. In terms of total concentration, the full 
model was significantly better for analogue pain score and 
grip strength. The coefficient of determination was always 
higher for total concentration than for dose or free 
concentration.
Without the baseline measurements (Table 6.12) for all 
response measures. Model 1 had to be rejected in favour of 
the reduced (constant slope) model (Model 2). As with the 
fenclofenac data, this analysis resulted in a flattening of 
the slope of improvement for response measurements in terms 
of dose or free concentration, in some cases the slope was 
no longer significantly different from zero. The slope was 
significant only for the improvement in grip strength and 
pain score in terms of dose. In terms of free concentration 
only the reduction in pain score was significant. The 
results of this analysis for total concentration were, 
however, very similar to those obtained with baseline data 
included. The slope was significant for all responses except 
the duration of morning stiffness. The analysis of clinical 
effect in terms of total naproxen concentration always gave 
a higher value of the coefficient of determination than dose 
or free concentration.
Articular index, grip strength and analogue pain score
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are plotted against total concentration with the regression 
line indicated in Figure 6.11. These graphs illustrate the 
considerable inter and intra-subject variability in the 
data. On average the GLIM analysis indicated small 
reductions in the analogue pain score and the Ritchie 
Articular Index of 0.94cm and 3 respectively on increasing 
the dose from 500 to 1000mg/day assuming the average total 
trough concentration. The reduction is even smaller on 
increasing the dose from 1000 to 1500mg/day.
A higher coefficient of determination was obtained by 
fitting the response data in terms of log dose or log free 
concentration. Comparison of the residual sum of squares for 
each response index fitted to Models 1 and 2 in terms of 
dose, log dose, total and free concentration and log free 
concentration are shown in Table 6.13. With data fitted to 
Model 2, there is little difference between the SSQres for 
total concentration and log free concentration. The increase 
in the SSQres by removing the individual intercept 
parameter, was in general greater for log dose than for 
total concentration or log free concentration.
(ii) NONMEM ana lysis
As the response data appeared to plateau with 
increasing dose, a hyperbolic or E^^^ model was investigated 
using NONMEM (baseline data were included). For comparison 
the data were also fitted to a linear model. The objective 
value for the response data fitted in terms of dose, total 
or free concentration are given in Table 6.14. It is clear 
that E^2 x model did not offer any improvement over the
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TABLE 6.14 Comparison of naproxen dose and concentration - 
response data fitted to a linear and E^^% model 
using NONMEM
Objective value 
Linear 2 ^ 3 % D
a) ARTICULAR INDEX
c)
dose 397 391 6
total 392 390 2
free 406 390 16
MORNING STIFFNESS
dose 663 657 6
total 656 654 2
free 6 6 6 657 9
GRIP STRENGTH
dose 514 492 2 2
total 499 515 -16
free 521 495 26
PAIN SCORE
dose 180 178 2
total 180 177 3
free 191 182 9
the difference in the objective value for dataD is
fitted to the linear and E^^% models
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linear model for total concentration.
The model appeared to be more appropriate for the
articular index and grip strength in terms of free 
concentration and for grip strength in terms of dose. 
However, although the objective value and examination of 
residual plots indicated an improvement in the fit of the 
data in these cases with the E^g^ model, the parameters were 
in general more poorly defined than the parameters of the 
linear model, especially the estimate of EC^g^. However, the 
residual error (e) was smaller for all responses (except the 
pain score) in terms of dose or free concentration with the 
Emax model.
The parameter values for the responses analysed in 
terms of dose are given in Table 6.15. The value of ECgg% 
was approximately 200-300mg/day. E^^% was -14 (6 ), -78 (31) 
minutes, 37 (9)mmHg and -4.9 (2.7)cm for articular index, 
morning stiffness, grip strength and pain score 
respectively.
The results for the analysis of the response data in 
terms of free concentration are given in Table 6.16. The 
estimate of ECgg% was in general around 2 0 ng/ml (the average 
free concentration of 500mg/day was 34ng/ml). E^^% was 
similar to that for dose.
6.3.3 Side-effects, biochemistry and haemato1ogy
Few side effects were reported during the study. All 
were minor and did not require any change in treatment. One 
patient complained of constipation on all three doses and
1 69
TABLE 6.15 NONMEM parameter estimates (SE) for naproxen dose
- response data fitted to the Emax model
Parameter Articular
index
Morning 
stiffness 
(mi n)
Grip
strength
(mmHg)
Analogue 
pain score 
(cm)
Emax -14 (6 ) -78 (31) 37 (9) -4.9 (2.7)
var ID 0.85 (0.38) 0.35(0.19]1 0.18(0.51)
ECs 0 % (mg) 273 (478) 244 (324) 207 (284) 1 0 2 0  (1180)
var 3.3(11.3) 4.6 (12) 1 0 (2 0 ) ID
Eg (units) 25 (3) 115 (19) 8 6  (6 ) 6.1 (0.5)
var 0.20 (0.09) 0.19 (0.11) 0.09 (0.02) 0 . 0 1 2  (0 .0 2 0 )
e 42 (15) 2200(951) 78 (29) 3.6(0.7)
Key: var = the variance parameter
6 = the residual unexplained error
yjvar xl0 0  gives the coefficient of variation of the 
structural model parameter
yje is an additive error
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TABLE 6.16 NONMEM parameter estimates (SE) for naproxen free 
concentration - response data fitted to the E^^% 
model
Parameter Articular Morning Grip Analogue
index stiffness strength pain score
(min) (mmHg) (cm)
Emax -IE (3) -83 (42) 40 (7) -2.5 (1.0)
var ID 0.30 (0.46) 0 .1 0 (0 .2 0 ) 0 .2 0 (0 .2 2 )
EC 5 0 1  (ng/ml) 2 2  (8 ) 20 (29) 24 (21) 3 (10)
var 4.8 (5.5) ID 5.3 (4.4) ID
Eg (units) 22 (3) 114 (18) 87 (6 ) 6.1 (0.5)
var 0.23 (0.10) 0.22 (0.12) 0 .1 0 (0 .0 2 ) 0 .007(0.020)
e 37(16) 2170(943) 118 (39) 3.9(0.8)
Key: var = the variance parameter
e = the residual unexplained error
Yvar xl 0 0  gives the coefficient of variation of the
structural model parameter 
yje is an additive error
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also complained of insomnia on the 1000mg and 1500mg doses 
(patient 2). The other side effects reported were nausea on 
500mg (patient 18) and 1000mg (patient 4 and 18) and 
lightheadedness on 1500mg (patient 11). There did not appear 
to be any relationship between side effects and dose, total 
or free naproxen concentration. There were no changes in any 
biochemical or haematologica1 measurements on any dose.
6.4 DISCUSSION
The non-linear relationship between the dose and plasma 
total naproxen concentration agrees with the results of 
other studies of the kinetics of naproxen (Runkel et al,
1974 & 1976). The associated linear increase in the free 
concentration indicates that the intrinsic clearance of 
naproxen remained constant over the dose range. According to 
the physiological model proposed by Wilkinson & Shand 
(1975), the nonlinearity can be attributed to the 
concentration dependent plasma protein binding. Saturation 
of the high affinity binding site occured with total 
concentrations of above approximately 70pg/ml. The clearance 
of total naproxen is not constant but increases with 
increasing total concentration. This phenomenon occurs if 
the elimination of a drug is restricted to the free 
fraction. The clearance of total naproxen was considerably 
less then liver blood flow (0.58 1/h) at the free fractions 
encountered after therapeutic doses.
The NONMEM protein binding parameter estimates can be
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compared with those previously quoted after converting to 
molar concentrations and taking the reciprocal of the 
dissociation constant. The values for n, nP and K (the 
association constant) from published data and from the 
NONMEM analysis for patients in this study are given in 
Table 6,17, together with the binding parameters determined 
in a single healthy individual. It is obvious that the 
mean NONMEM binding parameters are not entirely consistent 
with the results of others for the binding of naproxen in 
plasma. This is not entirely unexpected for the reasons 
discussed in Chapter 4. The binding affinity for isolated 
HSA (40g/l) was considerably higher than the binding to 
human plasma. Although in this study naproxen binding in 
patients with rheumatoid arthritis was similar to that in 
one healthy volunteer, the affinity for the primary binding 
site was higher in the healthy individual. Naproxen was 
bound with much higher affinity than fenclofenac (3.29 
compared with 0.54pM” )^ to the primary binding site but the 
affinity for the secondary binding sites was lower than for 
fenclofenac (0.034 compared to 0.135pM"’^ ).
The variability in total naproxen trough concentrations 
was quite small compared to free drug concentration. Total 
concentration is dependent on the individual clearance of 
free naproxen and plasma protein binding. The much smaller 
variability in total concentrations suggests that plasma 
protein binding masks some of the variability in the 
clearance of naproxen. The variability in free drug 
concentrations reflects the inter-individual differences in
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the intrinsic clearance of naproxen. Free drug clearance 
was slightly less than that for a group of male healthy 
volunteers (Upton et al, 1984).
A number of factors appear to affect the elimination of 
naproxen. In this study, the significance of each factor 
could not be assessed due to the small number of patients. 
However the observed reduced clearance of free naproxen in 
older patients agrees with two previous studies (Upton et 
al, 1984 & McVerry et al, 1986). In healthy volunteers, a 
negligible fraction of naproxen is excreted unchanged in the 
urine (Upton et al, 1980b). In the elderly, impaired renal 
function may lead to the accumulation of naproxen glucuronide. 
This metabolite is readily hydrolysed Jji vivo, liberating 
the parent drug. This phenomen may in part explain the reduced 
clearance of free naproxen observed in elderly patients 
(Upton et al, 1980b) and may also be important in patients 
with renal failure. However, the following observations may 
indicate that other factors may be important:
1. The clearance of free naproxen tended to be lower in 
female patients. This could not be explained in terms of 
weight because there was no difference in weight between 
males and females.
2. Cimetidine, which is an hepatic enzyme inhibitor, 
may also influence the elimination of naproxen; two patients 
receiving this drug achieved the highest free concentrations 
and clearance of free drug was low. Both patients, however, 
were female. This may be worth further investigation as 
patients receiving NSAIDs are often prescribed H^-antagonists
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for prophylaxis or treatment of dyspepsia and peptic 
ulceration. Previously, cimetidine was reported to have no 
effect on the kinetics of naproxen, but only total drug 
concentrations were considered (Holford et al, 1981). Plasma 
concentrations of indomethacin, on the other hand, were 
lower when given in combination with cimetidine (Howes et 
al, 1983), In this case, the absorption of indomethacin 
appeared to have been affected.
3. Free concentrations in smokers tended to be lower 
and the clearance of free drug tended to be high. Most of 
the smokers, however, were male. It is not possible to 
distinguish the effect of smoking from sex related 
differences or the effect of age.
Free naproxen concentrations were generated over the 
range of total concentrations encountered in this study using 
the NONMEM binding parameters assuming an average albumin 
concentration of 40g/l. The generated free fractions are 
shown in Figure 6.12 together with the actual free fractions 
measured at steady state. It is clear that the binding in 
control plasma spiked with naproxen is not consistent with 
the plasma protein binding vivo. The reasons for this are 
unclear but it is possible that it is due to differences in 
the patients' clinical state: during a 'flare' (without 
treatment) and during active treatment. There are a number 
endogenous and exogenous factors which might be responsible 
including total protein or albumin concentration, free fatty 
acids, bilirubin and other drugs, especially NSAIDs.
1. If the albumin concentration was lower after
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FIGURE 6.12 The free fraction of naproxen over the
concentration range encountered using the NONMEM 
binding parameters (assuming an average albumin 
concentration of 40g/l) together with the actual 
free fractions in samples taken at steady state
withdrawal of therapy, the free fraction would be higher. 
However, there was no change in the albumin concentration 
between the end of the initial wash-out period and on any of 
the three doses.
2. If free fatty acids were raised due to the 
withdrawal of anti-inflammatory therapy, this might result 
in higher free fractions. Free fatty acids in plasma are in 
general bound to albumin in large amounts and with higher 
affinity than most drugs (Ashbrook et al, 1975). At a molar 
ratio of 4 (palmitic acid to albumin) there was a 50% 
reduction in the affinity constant and number of binding 
sites for the high affinity site resulting in higher free 
fractions of naproxen (Calvo & Dominguez-Gi1, 1983). Under 
normal conditions free fatty acid concentrations have been 
found to fluctuate, the fatty acid to albumin ratio ranging 
from 0.5 to 1.5 (Court, Dunlop & Leonard, 1971). A study of 
the binding of valproic acid indicated that palmitic acid 
reduced the affinity constant but not the number of binding 
sites (Monks & Richens, 1979). Free fatty acid 
concentrations, however, could not be measured.
3. Prostaglandins (PGH2 and TXA^) have been found to 
bind covalently to human plasma albumin (Maclouf et al, 
1980). Prostaglandin synthesis was inhibited during 
treatment periods but not during the wash-out period,
4. Bilirubin has been implicated as another factor 
which will compete with naproxen for binding to plasma 
albumin (Held, 1980). However, in this study there was no 
difference in bilirubin concentrations at the end of the
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initial wash-out period compared to the treatment periods.
5. Other NSAIDs can interfere with the binding of 
naproxen (Kaneo et al, 1981). At a molar concentration of 
3xl0”^M, flufenamic acid produced the largest increase in 
the free fraction of naproxen in a solution of bovine serum 
albumin, followed by flurbiprofen, indomethacin and 
phenylbutazone. Aspirin at this concentration had no effect 
(Kaneo et al, 1981). However, when aspirin and naproxen were 
given together at therapeutic doses, there was an increase 
in the clearance of naproxen which was related to 
displacement of naproxen from binding sites (Segre et al, 
1974). Since patients were withdrawn from previous therapy 
for at least 3 days it unlikely that sufficient 
concentrations of the previous NSAID would have been present 
to cause any significant alteration in the binding of 
naproxen. Patients were allowed to take paracetamol during 
wash-out periods, however, paracetamol is not bound to any 
significant extent in plasma (Gazzard et al, 1973).
It is interesting to note that the binding determined 
in one healthy individual gave better predictions of free 
concentrations in patients at steady state. The binding 
parameters were similar to the mean binding parameters 
determined from the NONMEM analysis of the 18 patients, 
except for the affinity constant for the high affinity site 
(Table 6.17). This requires further investigation: it would
have been helpful, to have determined the binding of 
naproxen in age matched controls. This result taken alone, 
however, suggest thats an endogenous substance which
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interferes specifically with the binding of naproxen to the 
high affinity site was present in higher concentrations when 
patients were withdrawn from therapy.
It was not clear whether the binding of fenclofenac to 
plasma proteins was different in plasma after withdrawal of 
therapy or during treatment. From Figure 5.9 there is a 
suggestion the free fraction was higher in control plasma 
than in trough samples at steady state. However, the mean 
binding parameters were only determined in control plasma 
from 5 out of the 18 patients.
Despite the quantitative difference in the binding of 
naproxen, free concentration-time profiles gave unbiased 
predictions of free concentrations at steady state. Free 
concentration, however, was not predicted with any degree of 
precision. The reasons for this are unclear: it is possible 
again that the binding parameters did not give a good 
description of the actual free concentrations during the 
single dose study.
On average the difference in response on the three 
doses of naproxen was small and comparable with a previous 
study of naproxen where 250, 750 and 1500mg/day were given 
to patients with rheumatoid arthritis (Day et al, 1982). ,
Their results indicated that the average difference between 
the pre-study flare and 250mg/day was much greater than the 
difference between 250 and 1500mg/day. Similarity in this 
study the greatest difference in response was between no 
treatment and 500mg/day.
Since there was considerable inter-subject variability
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in the data, a linear modelling approach was used which 
allowed for individual disease severity. Analysis with 
baseline data included indicated significant improvements 
with increments in dose, total or free concentration.
However since the largest difference in the clinical 
response measurements occured between 'no treatment' and the 
lowest dose, it is certain that the linear relationship 
between dose or concentration and response is weighted by 
this baseline observation. Analysis of response data without 
baseline data indicated that this was indeed the case for 
dose and free concentration (for all responses except the 
analogue pain score) but there was still a significant 
linear improvement in 3 out of 4 response measurements with 
increments in concentration. However, with only three data 
points per individual and considerable intra-subject 
variability, the full model (which includes an individual 
slope for each patient) which was probably more realistic 
had to be rejected.
The significance of the linear relationship between 
clinical response and total concentration should be viewed 
in the light of the non-linear relationship between naproxen 
dose and total concentration. A non-linear relationship 
between dose and concentration appears to parallel a non­
linear relationship between dose (or free concentration) and 
clinical response. As an example, a patient with a grip 
strength of 90mmHg and an analogue pain score of 7.2cm 
before treatment can expect on average to achieve an 
improved grip of llSmmHg and a reduction in the pain score
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to 3.6cm with a trough total naproxen concentration of 
49jjg/ml (mean trough on 1000mg/day), Succesive increments in 
dose from 500 to 1000mg/day and 1000 to 1500mg/day produced 
on average 34,5% and 14.6% increases in the mean trough 
concentration respectively. With a linear relationship 
between the total naproxen concentration and clinical effect 
in this patient, it is obvious that successive increments in 
dose will lead to less than proportional improvements in 
response. For example if the patient above was given 
1500mg/day, assuming that the trough concentration achieved 
was 56^g/ml, a grip of 122mmHg and analogue pain score of 
3 .0 cm could be expected, a small improvement over the 
1 0 0 0 mg/day dose.
In order to compare the analysis for total 
concentration with dose and free concentration, the data 
were also analysed using GLIM in terras of log dose and log 
free concentration. This analysis indicated that the log of 
the free concentration gave a slightly better description of 
the response data than log dose or total concentration.
It is normally assumed that the free concentration in 
plasma reflects the free concentration at the receptor site. 
In this situation it may be assumed that the free /
concentration in plasma at the end of a dosing interval at 
steady state will be in equilibrium with the free 
concentration in synovial fluid. 2 2 . vitro the concentration 
of naproxen required to give 50% inhibition of prostaglandin 
E 2 synthesis was 0.25^g/ml in human synovial microsomes
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cultures (Robinson et al, 1980). In this study the free 
concentration of naproxen in in trough plasma samples ranged 
from 0.009 to 0.25pg/ml. Thus the free concentrations 
achieved clinically in plasma are close to those necessary 
to produce significant inhibition of prostaglandin 
synthesis. However these ECgg^'s for the inhibition of 
prostaglandin synthesis vitro do not compare with the 
estimate determined in this study (20ng/ml). This is not 
surprising due to the variability in the response data.
The oxidative metabolite, DMN, although present in 
plasma in very low concentrations in comparison to total 
naproxen achieves similar concentrations to free naproxen. 
Some metabolites are biologically active and contribute 
sigificantly to the clinical response (Atkinson & Strong, 
1977). The evidence in animal models of inflammation, 
however, suggests that DMN has little pharmacological 
activity (Syntex, personal communication).
There was a linear increase in free concentration as 
the dose was increased up to 1500mg/day, It it is possible, 
however, that as the dose is increased the metabolic 
capacity of the liver may become saturated and there will be 
a nonlinear increase in the free concentration. Although 
this is not evident from the study of large doses of 
naproxen (Runkel et al, 1976), these investigators only 
measured total naproxen concentrations. Although there was 
no significant increases in toxicity with higher free 
concentrations in the present study, caution should be 
exercised especially in the elderly with further increments
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in dose. All side-effects were reported by female patients 
which may be a result of the fact that in general, the 
clearance of free naproxen was lower and free concentrations 
were higher in the female patients.
Day and colleagues (1982) took a different approach in 
order to determine whether there was a naproxen 
concentrâtion-effeet relationship. To reduce some of the 
inter-subject variability in the response measurements, they 
used a non-parametric ranking method to obtain a 'summed 
efficacy score', and by arbitrarily defining.patients as 
responders or non-responders for each dose, the authors 
showed that the proportion of responders increased at higher 
total naproxen concentrations. However, since there was a 
dose response relationship, their analysis did not really 
distinguish a concentration-response relationship from a 
dose-response relationship. The significance of the 
improvement with increments in concentration was uncertain. 
It was interesting to note, however, that while there 
appeared to be a linear relationship between total naproxen 
concentration and the percentage responders, the 
relationship with free concentration appeared to be non­
linear, reaching a maximum effect with free concentrations 
of 0.36;jg/ml. They found that 76% of patients with trough 
concentrations above 50pg/ml had been classed as responders.
In conclusion, the pharmacokinetics of total naproxen 
are non-linear due to saturation of plasma protein binding: 
the kinetics of free naproxen are linear. There was 
considerable variability in the pharmacokinetics of free
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naproxen and increasing age was associated with a decrease 
in the clearance of free naproxen.
There was a linear relationship between clinical 
response and total concentration as both reach a plateau as 
the dose increases. The response in terms of dose or free 
concentration (except the analogue pain score) was described 
better by an model than by a linear model. The
parameters, however, were poorly estimated as there were 
only four data points per individual and the difference in 
effects between doses or concentrations was very small. 
Assuming that the free concentration in plasma is in 
equilibrium with the free concentration at the receptor 
site, these results suggest that increments in the dose of 
naproxen over 1 0 0 0 mg/day will lead to only a slight 
improvement in the clinical response in the majority of 
patients. Finally, there appears to be little advantage in 
taking account of inter-individual differences in the 
pharmacokinetics of naproxen to explain clinical response.
1 84
7.1 INTRODUCTION
In the previous two chapters, the variability in the 
pharmacokinetics of two NSAIDs, fenclofenaO and 
naproxen, were investigated to determine whether the 
response to NSAIDs is more closely related to plasma 
concentration than to dose. More information, however, may 
be obtained by determining drug concentrations closer to 
their site of action.
In inflammatory joint disease, the NSAID site of action 
is in the synovium. Although it is not often possible to 
measure drug 'levels' in the synovium, the synovial fluid 
does provide an accessible sampling site which may represent 
the 'levels' in synovial tissue more closely than plasma. 
Variable patient response to NSAIDs may reflect differences 
in the levels of free or bound drug achieved in this fluid.
The most effective treatment of 'infective arthritis' 
may be based on the determination of antibiotic 
concentrations in synovial fluid. Less attention has been 
directed at the measurement of synovial fluid concentrations 
of NSAIDs, and no studies have attempted to correlate 
clinical response to drug concentrations achieved in this 
fluid. No relationship was found between indomethacin plasma 
concentration and clinical response (Ekstrand et al, 1980) 
and there was no difference in the pharmacokinetics of 
indomethacin in responders and non-responders (Baber et al, 
1979).
This chapter presents a single dose study of a slow
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rel ease preparation of indomethacin (Indocid-R) which aimed
to :
a) quantitate the pharmacokinetics of indomethacin
in plasma and synovial fluid after a single dose of 
Indocid-R.
b) assess whether concentrations of indomethacin in 
synovial fluid can be determined from plasma 
concentrations.
7.2 PATIENTS AND METHODS
7.2.1 Patients
Seven patients with 'definite' or 'classical' 
rheumatoid arthritis (Ropes et al, 1959) and one patient 
with osteoarthritis took part in the study. All had knee 
effusions requiring aspiration. Five were female and three 
were male. Their ages ranged from 40 to 85 years (median 
58). All other patient details are given in Table 7.1. 
Patients were withdrawn from any previous NSAID therapy for 
three days prior to the study. Paracetamol was supplied to 
relieve any pain experienced during this wash-out period.
7.2.2 Indocid-R
This was given as a single Indocid-R capsule, 
containing 75mg of indomethacin in pellet form. 50mg is 
formulated in enteric coated pellets designed for gradual 
release in an alkaline environment and 25mg is contained in 
uncoated pellets available for immediate release in the acid
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TABLE 7.1. Indocid-R plasma and synovial fluid kinetic 
study: patient characteristics
;ient Disease Sex Age
(yr)
Weight
(kg)
Height
(cm)
Albumin
(g/D
p SF
ESR
(mm/;
1 RA F 47 6 6 158 40 19 1 0
2 RA M 78 74 158 33 23 67
3 RA F 40 51 145 39 24 9
4 RA F 54 71 163 41 33 33
5 OA M 61 114 182 41 2 0 6
6 RA M 85 60 170 41 23 57
7 RA F 54 81 158 40 24 -
8 RA F 62 69 158 40 7 28
Key: P = plasma
SF = synovial fluid
RA = rheumatoid arthritis 
OA = osteoarthritis
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environment of the stomach.
7.2.3 Study design
At the end of the three day wash-out period patients 
took a single tablet of Indocid-R with 100ml of water at 
least 2 hours after a light breakfast. Blood (10ml) was 
taken from an indwelling intravenous cannula at 0, 0.25,
0.5, 0.75, 1, 1.5, 2, 3, 4, 6 , 9, 12 and 24 hours and 
collected into heparinised containers. Samples of synovial 
fluid (1 0 ml) were obtained by separate joint aspirations 
carried out under aseptic conditions at 0, 3, 6 , 12 and 24 
hours after the dose.
Blood and synovial fluid samples were centrifuged at 
2 0 0 0 rpm and plasma and cell free synovial fluid were stored 
at -20OC. Indomethacin concentrations were determined in 
plasma and synovial fluid by HPLC as outlined in Chapter 2.
In addition, a standard biochemical screen was carried out at 
the start of the study and albumin and total protein 
concentrations were determined in synovial fluid.
7.2.4 Data analysis
The individual patient plasma and synovial fluid 
concentration-time data were fitted using weighted non­
linear least squares regression analysis (Chapter 4). 
Concentration was weighted proportional to the reciprocal of 
the fitted concentration (1 /c^).
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7 . 3 RESULTS
7.3.1 Plasma pha rmacokinetics
The absorption of indomethacin from the Indocid-R 
preparation was in general rapid after a variable lag time. 
The mean peak concentration was 3.12pg/ml. There was a rapid 
distribution phase, followed by a slower elimination phase 
and the individual data were fitted to a two compartment 
model with zero order absorption and a time lag (Model 4, 
Appendix II). Representative plasma profiles are shown in 
Figure 7.1.
Parameter estimates for individual data fitted to Model 
4 are given in Table 7.2. In some cases the parameters were 
not well defined. If there was a substantial lag time, there 
were fewer data points to provide information on the 
distribution and elimination of the drug. The T^^g ranged 
from 0.24 to 1.45 hours and T ranged from 0.6 hours to 2.5 
hours. The terminal elimination half-life ranged from 3.8 to 
9.8 hours and the average estimate of CL/F derived from the 
parameters was 8.4 1/h and ranged from 3.9 to 9.6 1/h.
There was little evidence that there was a sustained release 
of indomethacin.
There was no correlation between the clearance of 
indomethacin and age or albumin concentration. There was a 
possible relationship between clearance and weight, but this 
was not significant (0.592, p<0.122).
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FIGURE 7.1 Representative indomethacin plasma concentration­
time profiles after a single dose of Indocid-R
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7.3.2 Synovia 1 fluid pharmacokinetics
The synovial fluid concentration-time profiles could be 
approximated to a simple input and output function. The 
indomethacin concentration-time profiles were considerably 
flatter in synovial fluid. The peak concentration in 
synovial fluid occured later and was on average 2 1 % of that 
in plasma. By six hours the concentration in synovial fluid 
exceeded that in plasma. The ratio of indomethacin 
concentration in synovial fluid to that in plasma over the 
24 hours is given in Table 7.3.
There was no correlation between concentrations in 
synovial fluid and synovial fluid albumin concentration at 
any time point. There was a positive correlation between the 
ratio of albumin in synovial fluid to that in plasma and the 
ratio of indomethacin in synovial fluid to that in plasma 
only at 6 hours (patient 8 not included as the albumin 
concentration was suspect; a synovial fluid sample was not 
taken from patient 4 at 6 hours). Representative plasma and 
synovial fluid profiles are shown in Figure 7.2.
Two pharmacokinetic models were proposed to describe 
the kinetics in plasma and synovial fluid and are presented 
in (Figure 7.3). In both cases the plasma kinetics are 
described by a two compartment model with zero order 
absorption: Model 5 assumes that concentrations of 
indomethacin in synovial fluid are representative of the 
profile of drug in the kinetically defined peripheral 
compartment whereas Model 6 assumes that the synovial fluid 
represents a distinct compartment which does not affect the
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TABLE 7.3 Ratio of indomethacin concentration in sync
fluid to the concentration in plasma
Time (h)
Patient 3 6 1 2 24
1 0.09 0.79 1.63 1.63
2 0.39 2.74 3.61 4.34
3 0 . 1 0 1.40 1.17 1.81
4 0 . 6 6 - 1.38 1.36
5 0.60 1 . 1 1 2.24 1.51
6 - 1 . 0 1 - 1.35
7 0.65 1.36 1.85 0.70
8 0.30 1.46 - 0.69
median 0.40 1.41 1.98 1 . 6 8
range 0.09-0.65 0.79-2.74 1.17-3.61 0.70-4.39
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kinetics of indomethacin in plasma. The equations describing 
the concentration in plasma and synovial fluid are given in 
Appendix II (Models 5 and 6 ).
(i) Model 2
Plasma pharmacokinetic parameters determined for the 
fit of individual data (Table 7.2) were used to 
calculate the concentration of indomethacin in the kinetically 
defined peripheral compartment. These calculated or 
predicted concentrations (pred) and synovial fluid 
concentrations (obs) are given in Table 7.4. The correlation 
between observed and predicted concentrations with time was 
tested using GLIM (Chapter 4). The most appropriate linear 
model was;
obs = b^.pred  .............................. 7.1
where b^ is an individual slope. The individual slopes 
ranged from 0.33 to 1.98. If there was no error in the 
prediction of the synovial fluid concentrations, the slope 
should be unity. However, this does indicate that in 
general, concentrations in synovial fluid change in parallel 
with those predicted in the peripheral compartment.
The error in the prediction was also tested using the 
Wilcoxon sign rank test. Although Figure 7.4 indicates that 
there was a trend towards a greater overprediction of the 
concentration in synovial fluid at the later time points, 
there was no significant difference between predicted and 
observed concentrations. This was possibly due to a number 
of factors:
a)the number of individuals was too small and the magnitude
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FIGURE 7.2 Representative indomethacin plasma and synovial 
fluid concentration-time profiles after a single 
dose of Indocid-R
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FIGURE 7.3 Pharmacokinetic models proposed to describe the 
concentration of indomethacin in plasma and 
synoV ia 1 fluid
A Model 5 
B Model 6
TABLE 7.4 Observed and predicted indomethacin 
concentrations in synovial fluid
Time (h)
Pati ent 3 6 1 2 24
1 0 0.339 0.663 0.360 0.088
P 0.663 1.096 0.680 0 . 2 0 0
2 0 0.694 0.784 0.343 0.136
P 0.471 0.431 0 . 2 1 0 0.050
3 0 0.330 0.567 0.272 0.056
P 0.712 0.712 0.375 0.093
4 0 0.820 _ 0.126 0.038
P 0.360 - 0.257 0.091
5 0 0.463 0.345 0.190 0.053
P 0.678 0.563 0.311 0.067
6 0 0.831 _ 0.031
p - 2.480 - 0.096
7 0 0.477 0.308 0 . 1 0 2 0.033
p 0.471 0.426 0.268 0.104
8 0 0.609 0.576 0.050
p 0.188 0.328 - 0.096
Key: 0  = observed synovial fluid concen trati'
P = concentration predicted in the peripheral 
compartment (Model 4)
Concentrations are in pg/ml
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of the errors was large,
b) poorly defined pharmacokinetic parameters.
Since this analysis was inconclusive, the individual 
plasma and synovial fluid concentration - time data were 
fitted simultaneously to Model 5. The results of this 
analysis are given in Table 7.5. In this situation, the 
synovial fluid data are fitted together with the plasma 
data, and therefore influence the estimates of the plasma 
pharmacokinetic parameters. Comparison with the results 
obtained by fitting the plasma data to Model.4 indicates 
that there are some differences in the parameters. On 
average, Cl/F is slightly higher when the data were fitted 
to model 6 . V 2 estimated for Model 5 is similar to that 
derived from the parameters for plasma data fitted to Model
4. In Table 7.5, k ^ 2  and k 2  ^ are the input and 
output rate constants for synovial fluid. The elimination 
from synovial fluid was in general slower (median half-life 
3.7 hours) than the input (median half-life 2.5 hours).
(ii) Model ^
The results for the plasma and synovial fluid data 
fitted simultaneously to Model 6 are given in Table 7.6. 
Comparison of this analysis with that of plasma alone . 
indicates that some of the parameters describing the 
concentration in plasma are slightly different due to the 
addition of the synovial fluid data. The calculated apparent 
clearance, however, was virtually identical. The parameters 
describing the profile in synovial fluid are kgg and k^g/Vg. 
As the volume of synovial fluid was not known, the input
1 9 5
+J
§
•H
+JfO
i
'O■H
3
p*H
4-1
in
4-1
T3
4J
d
r H
OJ
I— I
I— I
C N J
0%
-u
§
• H
- P
fi
in
00
on
( 3
( 3
in
r — 1 1— 1 1 3 1— 4 0 0 1 - 4 ( 3 1
t — 1 r — ( i - H 1 - 4 1 - 4 r - 4
1
< T l r - O ' 0 0 i n O ' - ( 3
1
1
o n k £ ) O k O k O k 1
c r > O k O k O k O k O k O k 1
1
1 3 1 3 I S < 3 ( 3 ( 3 ( 3
1
1 0 4
1
0 4
1— 1 O k 0 4 0 0 0 0 0 4 1  k O ( 3
m 0 0 0 4 1 3 O k ( 3 0 4 1  O ' 1— I
1
0 0 i n ( 3 O k 0 0 O k O k 1  0 0 0 0
I - H 1 O k
kO 
I—I 
( 3
ro
C M
( 304
04
Î 3
( 3
(T i
in
I— I
( 3
00 
r—I
( 3
( 3
CTi 
( 3  I—I
( 3
0 4
( 3
I — I
( 3
in
0 4
kO
( 3
0 4
i n 3 0 0 0 4 O O
0 0 0 0 i n C O n ' O ' O ' -
i n 0 4 0 4 0 4 0 4 0 4 G k
( 3 3 3 3 3 3 3
0 4 0 0
O k k O O ' t—4
3
r - 4 0 0 r - 4 0 0 r - 4 i n i n
'— '—'
( 3 O ' 3 i n 0 0 3 0 4
3 0 0 k D k D 0 0
1—4 0 4 r — 4 0 0 1— 4 0 0 0 4
0 0 k O i n 1— 1 G k 0 4 3
1 - 4 0 4 0 4 0 4 0 4
( 3 3 3 3 t—4 3 3
( 3 3 3 3 3 3 3
1 - 4 O k 0 0 r - 4 in i n i n
i n k O 0 0 3 0 0 k D i n
r - 4 1 - 4 0 4 0 4 r - 4 0 4
1 3 3 3 3 3 3 3
0 0 0 0 k O 3 r— 4
1 3 1 - 4 0 4 1—1 in r - 4 t—1
( 3 3 3 3 3 3 3
1 3 3 3 3 3 3 3
'—
1— 4 3 r - 4 G k 3 0 4 3
( 3 0 4 k D 1—1 G k r - 4 0 4
r - 4 1 - 4 r - 4 r - 4 r - 4 r - 4 1—1
1 3 3 3 3 3 3 3
O k 0 4 3 0 4 k D 0 0
TT 0 0 G k i n G k 1— 1
0 4 r — 4 0 4 0 4 3
3 3 3 3 3 3 3
—
O ' 1—1 0 0 0 0 m i n
k O k O 0 4 3 r— 1 r - 4 0 4
O ' O k 3 G k G k 3 3
f - 4 3 r — 4 3 3 r - 4 0 4
C N f - 4 0 4 0 4 0 4 r - 4 G
r - 4 1 - 4 O O r— 4 0 4 r — 4 0 4
'—
0 4 k O 0 0 0 0 0 0 r - 4
O ' 0 0 k D G k O O G
r— 4 r - 4 r - 4
0 4 00 in kO 00
oo
0 4
( 3
( 3
0 4
in
00
( 3
( 3
0 4
< 3
( 3a^(Tt
( 3
( 3
00
00
m
( 3
I
k O
( 3
in
k £ )
00
4
in
00
( 3
I
r - 4
in
( 3
1 3a\
is
I
( 3
(3
0 4
( 3
0 4
I
in
0 4
k O
( 3
00
k O
I
04
196
4J
i
O
•i-t
4J
tO
Tl
•H
3
rH
MH
I
1
m
(0
a
p
.2
HW
kD
M4
13
-P
CO 
f—I
3
W
CN
'£
0 %
3
kD
C O
G
3
un
3
LO
3
3
3
O-
3
3
3
kD
CN
3
3
kD
kD
3
tn
1—4
3
3
O'-
3
3
r—4
3
3
3
3
IT)
3
3
G
irt
3
G
3
CN
3 3 G 3 r' 3 G 1
1—4 1—C r-4 r-4 1
1
G kD 3 00 O' 00
1
1
G O' O' G G G 1
G G G G G G G 1
1
3 3 3 3 3 3 3 1
11 LO1 Tf
m m LD m r—4 kD kD 1 kD G
LD 00 TT G r—4 iT) 00 1 in 1
r-4
00 un G 00 00 00 1 00 r—4
i Tf
1
CN 00 r—4 IT) f-4 oo 1
3 3 kD 3 r—4 3 3 1
3 3 3 3 3 3 3 !
1
3 3 3 3 3 3 3 1 00
1 CN
1 3
00 CN r—4 O- LD 00 3 1 TP
CN rH CN 3 1—4 3 CN 1 r4 3
3 3 3 3 3 3 3 1 3 1
O-
3 3 3 3 3 3 3 1 3 31 3
1 3
O' kD 3 r-4 1
1—1 r-4 00 CN 00 CN O' 1
3 3 3 3 00 3 3 !
1
3 3 3 3 3 3 3 1 00
1 G
1 00
00 3 CN 00 kD 00 00 1 00
OO 00 kD G CN G 1 t-4 3
1—4 r—4 00 r—4 00 CN 00 1 CN 1
00
3 3 3 3 3 3 3 1 3 00
G 00 00 G G kD
CN r-4 •N’ oo CN CN CN
3 3 3 3 r—4 3 3
3 3 3 3 3 3 3
'— — '
00 r-4 CN 00 G 3 r-4
O- r-" CN G 3 r-4 LD
r—4 r-4 r-4 r-4 t-4 t— 1
3 3 3 3 3 3 3
G r—4 CN 00 t-4 3 CN
1— ! t-4 00 r-4 kD CN r-4
3 3 3 3 3 3 3
3 3 3 3 3 3 3
— '
O- kD UO r- 00
r—4 r—4 00 r-4 G
r-4 r-4 3 r-4 1— 1 3 3
3 3 3 3 3 3 3
t-4 r-4 Tf r—4 00 OO
r-4 r-4 00 r-4 CN 3 CN
3 3 3 3 3 3 3
— '
kD CN 3 00 1— 1
00 r—4 r—4 G 00 G
r—4 r-4 1— 1 3 3 3 f-4
OO kD m 00 00
1-4 3 oo r-4 CN 3 1—1
00 G 00 kD r-4
kD t-4 kD 3 00 CN
r-4 r-4 t-4 r—4 r-4
-P
g"M
4-)COCh
CN 00 in kD
kD
r—I
3
3
3
00
3
CN
3
G
3
3
4
3
OO
G
3
4.
S
3
kD
C O
1
G
in
3
00
I
00
kD
I
197
rate constant K-j^ g could not be estimated. The half-life for 
elimination from from synovial fluid (In 2 /kg 0 ) ranged from
2.3 to 5.8 hours (median 3.7 hours). If the kinetics of 
indomethacin in synovial fluid are equivalent to those in 
the peripheral compartment, a correlation between K 2 1  and 
kg 0 might be expected. There was, however, no correlation 
between these parameters. However, this is perhaps not 
surprising as there was some error in the determination of 
both of these parameters.
A comparison of the 'goodness of fit' for the 
simultaneous analysis of plasma and synovial fluid data 
fitted to models 5 and 6 is given in Table 7.7. There was 
very little difference in the residuals for the two models, 
although Model 5, which has one parameter less, often gave 
a lower AIC value.
7.3.3 Plasma and synovial fluid concentrations at steady
state
The average parameters determined from the individual 
fits were used to predict the indomethacin concentration 
profile in plasma and synovial fluid at steady state on once 
daily dosing. The concentrations predicted at steady state 
were almost super imposable on the the profile after a single 
dose. If the model is appropriate and the kinetics are 
linear, there will be no accumulation of indomethacin in 
plasma or synovial fluid with the envisaged dosing regimen.
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TABLE 7.7 Comparison of the 'goodness of fit' for
indomethacin concentration-time data fitted to 
models 5 and 6
Model 5 Model 6
Patient df WSSOces AIC df WSSQres AIC
1 1 1 0.208 -7.4 * 1 0 0 . 2 0 1 -7.2
2 1 1 0.088 -57.1* 1 0 0.089 -49.7
3 1 1 0.275 -3.8* 1 0 0.229 - 1 . 0
4 1 0 0.437 -3.6 * 9 0.262 -3.3
5 1 1 0.072 -52.0* 1 0 0.071 -50.2
6 8 0.662 19.5* 7 0.663 2 1 . 6
7 1 1 0 . 2 0 0 -33.5* 1 0 0.091 -28.3
8 1 0 0.190 -31.8 9 0.038 -55.0
Key: df = degrees of freedom
WSSQj.gg = weighted residual sum of square:
* indicates the lowest AIC value
1 9 9
7.4 DISCUSSION
It appears that under the conditions of this study 
Indocid-R is not a very efficient slow release preparation. 
While absorption was often delayed, subsequent profiles 
resembled those obtained after a single 75mg dose of 
standard indomethacin (Schoog, Laufen & Dessain, 1981; Yeh 
et al, 1982). The mean peak concentration was slightly lower 
than has been observed in healthy male volunteers after a 
single 75mg dose of standard indomethacin. However, peak 
concentrations after Indocid-R were only 1.47 and 2.14^g/ml 
respectively in these studies (Schoog et al, 1981; Yeh et 
al, 1982). The similarity between Indocid-R and standard 
preparations of indomethacin has been noted previously 
(Adams et al, 1982). Peak concentrations for Indocid-R and 
50mg standard indomethacin were not significantly different 
when corrected for dose. The only noticeable difference was 
a slightly delayed peak concentration.
The apparent clearance or indomethacin determined from 
the fit to the two compartment model was in general s 1 ightly 
higher than that determined in healthy volunteers after 
doses of up to 100mg of standard indomethacin (A 1 van et al, 
1975). This may be due to a reduction in bioavailability of 
the Indocid-R preparation or the lower albumin concentration 
in patients. There was no correlation between the clearance 
of indomethacin and aIbumin concentration.
The analysis of plasma concentrâtion-time data did not 
take account of possible enterohepatic recirculation which
2 0 0
has been reported to range from 24-115% of an intravenous 
dose of indomethacin (Kwan et al, 1976). Although terminal 
concentrations were sometimes erratic, the data were fitted 
relatively well to a two compartment model. In fact, there 
were probably too few data points to identify enterohepatic 
recirculation.
The mean plasma kinetic parameters predict that on 
average, there will be virtually no accumulation of 
indomethacin on multiple dosing with Indocid-R once daily, 
in agreement with the results of others (Schoog et al,
1982; Verbesselt et al, 1983).
The profile of indomethacin in synovial fluid in this 
study was very similar to that observed for standard 
indomethacin (Emori et al, 1973). There was a similar delay: 
peak concentrations in synovial fluid were 25% of that in 
plasma, compared to 2 1 % in this study and concentrations 
exceeded those in plasma after 4 hours.
In all studies investigating the distribution of NSAIDs 
in synovial fluid and plasma, the levels in synovial fluid 
initially were lower than those in plasma and peak 
concentrations were delayed. Free drug in synovial fluid is 
less available for elimination compared to free drug in 
plasma so a gradient develops across the synovial membrane 
during the elimination phase and the concentration in 
synovial fluid remains higher than that in plasma. The 
comparative profiles of indomethacin in plasma and synovial 
fluid are consistent with this general description.
There has been no previous report of the simultaneous
2 0 1
fitting of plasma and synovial fluid data to an integrated 
pharmacokinetic model. Most investigators have assumed that 
the concentration profile in synovial fluid is consistent 
with the profile of the drug in the peripheral compartment 
of a two compartment model. Ray et al (1979), however, in a 
study of carprofen (a propionic acid derivative), suggested 
that the peripheral compartment concentrations (predicted 
from the parameters determined by fitting the plasma 
concentration-time data to a two compartment model) did not 
give a good description of concentrations in synovial fluid. 
However, no statistical test of the difference between the 
predicted and observed concentrations was carried out. In 
addition, it was unlikely that adequate parameter estimates 
determining concentrations in the peripheral compartment 
could have been obtained from the plasma concentration-time 
data available.
Aarons et al (1986) proposed an alternative 
pharmacokinetic model to describe the concentration of 
flurbiprofen in synovial fluid. The total concentration at 
any time could be simulated fairly well by assuming that the 
levels were determined by the free concentration in plasma, 
a diffusion constant (R) for the movement of free drug 
across the synovial membrane, the total concentration of 
binding protein in synovial fluid and the volume of synovial 
fluid. However, the actual value of R was not be determined 
in this study as the volume of synovial fluid was not known 
and the model could not be tested by fitting plasma and 
synovial fluid data as only one synovial fluid concentration
2 0 2
was available per patient.
The rate of input tended to be faster than rate of 
elimination of indomethacin from the synovial fluid (data 
fitted to Model 5). The range of values was quite large. The 
kinetics of NSAIDs in synovial fluid may be related to 
clinical factors such as synovial blood flow, endothelial 
vascular permeability to albumin, diffusion of free drug 
across the synovium, synovial fluid and synovial pH. 
Inflammatory disease may influence both synovial blood flow 
and vascular permeability and it may influence the structure 
of the synovial tissue.
The clearance of ^^^Xenon from the joint is an indirect 
measure of synovial blood flow (Dick, 1972) and it would 
have been useful to compare this with the rate of input of 
the drug into synovial fluid. Alternatively it might have 
been interesting to have determined the disease activity in 
the knee joint since this will affect blood flow. Aarons et 
al (1986) found, however, no correlation between the 
concentration of flurbiprofen in synovial fluid and Xenon 
clearance but there was a weak positive correlation between 
the synovial fluid concentration and a thermographic measure 
of disease activity. The converse was found for 
phenylbutazone: concentrations were lower in patients with 
more actively inflamed joints (Farr and Willis, 1977), These 
relationships, however, were based on single paired 
observations often taken at different times during the 
dosing interval. Aarons et al (1986) concluded that the 
diffusion of free drug across the synovium was an important
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determinant of synovial fluid drug concentration. Acidic 
NSAIDs accumulate in inflamed tissues in animals (Graf et 
al, 1975), and in patients, oxyphenbutazone 'levels' were 
higher in synovial tissue from patients with severe 
inflammation than in those with little or no inflammation 
(Gaucher et al, 1983). Thus greater relief may be attained 
in patients with more severe inflammation.
There have been few studies of the binding of NSAIDs in 
synovial fluid, but the binding of piroxicam was 
equivalent in plasma and synovial fluid for the same total 
albumin concentration (Trnavska, Trnavsky & Zlnay; 1984). 
However, the binding of salicylate was reduced in synovial 
fluid compared to plasma due to a alteration in the binding 
to the high affinity site (Trnavska & Trnavsky; 1980). The 
free indomethacin concentration was not determined in this 
study. If one assumes that the binding constants for 
indomethacin are equivalent in plasma and synovial fluid, 
the free concentrations must be considerably higher than 
those in plasma by six hours after the dose. The measurement 
of free concentrations in plasma and synovial fluid or a 
comparison of the binding profiles of indomethacin in the 
two fluids would have provided useful additional information 
on the distribution of indomethacin. The free drug 
concentration in corresponding plasma and synovial fluid 
samples has been reported to be equivalent for a number of 
NSAIDs (Rosenthal, Bayles & Fermont-Smith, 1964; Whitlam et 
al, 1981). Aarons et al (1986), however, found that the free 
fraction of flurbiprofen in plasma and synovial fluid was
204
the same.
At a total concentration of 2.5pg/ml, the free fraction 
of indomethacin was 5% in synovial fluid and 4% in plasma 
(Wanwimolruk, Brooks & Birkett, 1983). Thus the free 
concentration or indomethacin on average will range from 
2ng/ml at 24 hours to 31ng/ml at around 4 hours. Sturge et 
al (1978) found that concentrations of 14.3ng/ml were 
required to give 50% inhibition of PGE 2 production by 
rheumatoid synovial fragments vitro. Robinson (1980) 
quotes an of 1 .8 ng/ml for PGE 2 production in
rheumatoid synovial cultures. Thus residual concentrations 
in synovial fluid at 24 hours are possibly still sufficient 
to inhibit PGE 2 . Other prostaglandins may contribute to the 
inflammatory response eg PGI 2 and TXA 2 and the production of 
these may be inhibited to a greater or lesser extent.
The rate of elimination of indomethacin from synovial 
fluid is faster than that from plasma. In most previous studies, 
especially with the short half-life NSAIDs, the elimination 
from synovial fluid has been reported to be slower than that 
from plasma (Sholkoff et al, 1967; Emori et al, 1973;
Chalmers, Glass and Marchant, 1980; Glass & Swannell, 1980; 
Caruso et al 1980) and it has been suggested that the drug 
will therefore accumulate in synovial fluid. In many 
studies, however, a comparison was made between the 
distribution phase in plasma and the elimination phase in 
synovial fluid. Others have found that the elimination from 
plasma and synovial fluid was similar (Makela, Lempianen & 
Ylijoki, 1981; Dromgoole et al, 1982).
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The mean kinetic parameters predict that there will be 
no accumulation of indomethacin in synovial fluid with once 
daily dosing of Indocid-R.
In conclusion, this study indicates that the kinetics 
of indomethacin in plasma can in some cases give a good 
description of the profile in synovial fluid. With a larger 
number of plasma samples, a more accurate estimate of the 
plasma pharmacokinetics might have improved the prediction 
of concentrations in synovial fluid. The extended clinical 
response to these short half-life NSAIDs may well be 
explained in terms of the equilibrium delay which will exist 
for free drug between synovial fluid and plasma during the 
elimination phase. Indocid-R, however appears to offer 
little advantage over standard preparations of indomethacin 
in terms of giving sustained plasma concentrations. The 
range of input and output rate constants indicates that 
there is some considerable inter-individual variability in 
the kinetics of indomethacin between plasma and synovial 
fluid and this might explain some of the variability in 
clinical response. The relationship between the free 
concentration in synovial fluid and clinical response should 
be investigated further.
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CHAPTER 8
GENERAL DISCUSSION AND CONCLUSIONS
The number of NSAIDs available to the rheumatologist 
has increased dramatically over the last decade or so. The 
choice and dose of drug remains, however, largely empirical. 
Newer NSAIDs are generally accepted for clinical use if they 
show similar efficacy and reduced toxicity in comparative 
studies with older established NSAIDs. The new drugs are 
seldom investigated with a view to establish a dose or 
concentration-response relationship.
Comparative studies of NSAIDs in rheumatoid arthritis 
suggest that patient response is highly variable and 
unpredictable (Huskisson et al, 1976; Scott et al, 1982).
For example Scott et al (1982) found significant differences 
between patients but no significant difference between 
drugs. In addition, they identified a significant drug- 
patient interaction and they suggested that this indicated 
that some patients are particularly suited to one drug but 
not to another. Two studies were unable to explain this 
variability in pharmacokinetic terms (Capell et al, 1977; 
Baber et al, 1979) but inter-individual differences in 
disease severity were not taken into.account. In other 
studies the response to an increase in dose or concentration 
has been difficult to detect (Orme et al, 1976; Ekstrand et 
al, 1980; Grennan et al, 1983).
This thesis reinforces the view that pharmacokinetic 
information contributes little to the understanding of 
variability in clinical response even when individual 
differences in disease severity are taken into account and
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that there is little to choose between dose, total or free 
concentration in the description of clinical response.
Conventional analysis of the relationship between dose 
and clinical response (using analysis of variance), 
indicated that in general, there was no significant 
difference between the three doses for either naproxen or 
fenclofenac. This reflected the considerable intra- and 
inter-subject variability in patient response and its 
measurement. A much larger number of patients would have 
been necessary to demonstrate a dose response relationship 
with this type of analysis. However, when a linear modelling 
approach was used (GLIM, Baker & Nelder, 1978) the analysis 
indicated that for both drugs there was an improvement in 
response with increments in dose. In the case of fenclofenac 
significant improvement was seen in the duration of morning 
stiffness and the analogue pain score. With increments in 
naproxen dose there was a significant improvement in the 
mean grip strength and the analogue pain score.
Since naproxen and fenclofenac demonstrated 
considerable pharmacokinetic variability it might have been 
expected that concentration would have explained some of the 
response variability. This however was not the case. Using 
the same linear modelling approach, the most appropriate 
linear model for both dose and concentration allowed for 
individual variability in terms of an individual intercept 
(disease severity before treatment). The improvement in 
symptoms with increments in dose or concentration (if any)
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was described by a common slope. In general, the 'goodness 
of fit' to this model was similar for dose and concentration 
but it was possible to show some added benefit from 
concentration.
An improved fit for response when analysed in terms of 
naproxen total concentration was due to the non-linear 
increase in trough concentrations, a consequence of 
saturation of binding sites on plasma proteins. Therefore a 
direct comparison to test for the effect of inter-subject 
variability in the kinetics of naproxen could not be made 
using this analysis. There was, however, a linear increase 
in the free drug concentration and the analysis in terms of 
free drug indicated that there was only slight improvement 
over dose in the explanation of some of the rheumatological 
measures.
The largest difference in clinical response was often 
observed between 'no treatment' and the lowest dose. This 
was more apparent for naproxen than for fenclofenac. It was 
not clear as to whether this indicated that the 
concentrations were close to those necessary to produce a 
maximum response or whether these measures, carried out 
under non-blinded conditions, were exaggerated by their 
subjective nature.
If baseline data were included in the analysis, a 
hyperbolic or model was more appropriate in some cases.
The concentration required to give 50% of the maximum 
response was approximately 70pg/ml for fenclofenac (close to
209
the average concentration achieved on the 1 2 0 0 mg/day dose). 
For naproxen, however, the free concentration required to 
give 50% of the maximum response was estimated as 20ng/ml 
(the average free concentration on 500mg/day was 34ng/ml). 
The errors in the estimate of the parameters of the 
model were large.
The linear model was more appropriate for total 
naproxen concentration. This appeared to be due to the fact 
that total concentration and clinical response moved in 
parallel towards a plateau. Although, it is generally 
assumed that the free concentration of drug in the blood is 
pharmacologically active, the results of the naproxen study 
suggest that clinical response is more closely related to 
total concentration. Support for this notion has been 
provided by Grennan et al (1983) who found that the maximum 
response to ibuprofen occured at a dose of 1600mg/day, a 
dose of 2400mg producing no further improvement. The 
kinetics of ibuprofen were non-linear and these workers 
suggested that binding to plasma proteins might mimic 
binding to the enzyme at their site of action in inflamed 
tissues. Similarly Day et al (1982) found that while there 
was a linear relationship between total naproxen /
concentration and response, the relationship between free 
concentration and response appeared to reach a plateau.
There was some difference in the response measures which 
were able to detect significant differences between doses or 
concentrations for the two drugs. These differences may have
2 1 0
occured, however, by chance or may have been related to 
differences in the patient groups. While the duration of 
morning stiffness (a relatively insensitive measure of anti­
inflammatory activity) showed no difference over the three 
doses of naproxen, there was a linear relationship between 
the dose (or concentration) of fenclofenac and the reduction 
in morning stiffness. Grip strength was also a useful 
measure. The intra-subject variability was in general 
smaller for grip strength, but this was offset by the fact 
that changes in grip tended to be small and dependent on the 
degree of underlying damage to joints. Patients with severe 
deformity showed little response. Despite its subjective 
nature, the analogue pain score in general appeared to be 
the most sensitive measure to detect changes in symptoms 
with increments in dose or concentration.
Some patients in these studies showed wide swings in 
their disease severity throughout the study period making it 
almost impossible to distinguish a dose or concentration 
response relationship. This type of variability in the 
disease may explain why comparative studies of NSAIDs have 
suggested that patient response to different drugs is 
variable and unpredictable (Huskisson et al, 1976; Scott et 
al, 1982). If it is assumed that all NSAIDs share a common 
mode of action, equipotent doses should produce equivalent 
responses in the same patients on a given day.
A number of factors may influence the pharmacokinetics 
of NSAIDs. Differences in protein binding or hepatic
21 1
metabolic activity will affect the total concentration 
achieved in plasma. The clearance of fenclofenac appeared to 
be reduced in older patients and those with raised alkaline 
phosphatase. The clearance of naproxen, on the other hand, 
was reduced in the elderly and appeared to be lower in 
female patients. There were no apparent dose or 
concentration related side-effects, however the small number 
of patients precluded any formal analysis.
In general, pharmacokinetic variability appears to 
contribute very little to the total variability in clinical 
response. This conclusion has been reached by others despite 
different analytical approaches. Grennan et al (1983) 
concluded that there was no advantage in knowing plasma 
concentrations, but their analysis took no account of inter­
individual disease severity. Brooks et al (1975) came to the 
same conclusion; in this case a parallel design was used.
In the future some of the problems encountered in this 
thesis could be overcome by:
1. Normalising the response in different patients with 
a range of disease severity eg expressing response as a 
percentage change from a baseline flare.
2. Using more stringent inclusion criteria to give a 
more homogeneous group of patients in terms of disease 
severity.
3. The inclusion of a placebo period, or an additional 
dose, especially towards the lower end of the therapeutic 
range. A larger number of observations within the same
2 1 2
individual would allow a better description of the data.
If clinical response to NSAIDs in rheumatoid arthritis 
is due solely to the inhibition of prostaglandin synthesis 
and if the factors which affect the pharmacokinetics of the 
drugs are known, it should theoretically be possible to 
determine the optimum dose of a particular NSAIDs for an 
individual patient. In this thesis only eighteen patients 
were studied with each drug and it was not possible to 
determine accurately the contribution of any particular 
patient factor such as age, sex, smoking etc. However, if a 
larger population of patients was studied a clearer picture 
of the important determinants of the elimination of these 
drugs could be established. Together with knowledge of 
protein binding and the distribution of the drug into 
synovial fluid (if it can be predicted from the 
concentration of drug in plasma) the most appropriate dose 
of a particular NSAID could be determined to achieve maximum 
inhibition of the eye 1 o-oxygenase enzyme.
In conclusion, the studies of fenclofenac and naproxen 
indicate that variability in the pharmacokinetics of these 
drugs contribute only a small amount to the variability in 
clinical response and in absence of any concentration 
related toxicity, the doses of these drugs may be increased 
with the expectation that on average a greater response will 
be achieved. In the clinical setting the measurement of 
plasma concentration would appear to be unnecessary. The 
average slopes relating dose and clinical effect tend to be
1 3
shallow and these studies suggest that the doses used 
clinically are close to those necessary to achieve a maximum 
response.
These studies were conducted in patients with 
rheumatoid arthritis who were otherwise healthy and caution 
should be exercised in patients who are less healthy. The 
clearance of fenclofenac appeared to be reduced in older 
patients, and there was a significant negative correlation 
between naproxen clearance and age. This has been noted by 
others (Upton et al, 1984; McVerry et al, 1986). In the 
light of the reports of fatal hepatic toxicity in the 
elderly associated with the use of benoxaprofen (Taggart & 
Alderice, 1982), these observations suggest that particular 
care should be exercised in the use of these drugs in the 
elderly, especially females.
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APPENDICES
APPENDIX I
An example of the form used to record rheumatological 
measures for the fenclofenac and naproxen studies.
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Assessment Form
N a m e :___________________
Visit:
Pre-single ,— , 
(please tick) dose study I I
.M e d ic a tio n  N o :. .D a te ;.
First treatm en t
Start CD Finish CD
Second treatm en t Th ird  treatm en t
Start CD Finish CD S tart CD Finish D
End final washout 
□
1. Ritchie articular index.
2. D uration o f m orn ing  stiffness
3. Grip strength.
m in u tes .
1st try
R ig h t hand
2nd try
Le ft hand
1st try 2nd try
4. G lobal pain
a) Visual an alo gue (ask p a tie n t to  co m p le te )
Pain ' 
b) V erbal rating scale
N one CD M ild  CD M o d e ra te  CD S e v e re
* Pain E ver 
□
5. A ssessm en t o f th erap eu tic  e ffe c t (end o f tre a tm e n t p e rio d s  on ly ).
N o n e Fair G o o d V e ry  G ood
P atient □ □ □ □
D octor □ □ □ □
6. S id e -e ffec ts—  "has the tre a tm e n t u p set you  in an y w ay ? " (end  o f tre a tm e n t periods only). 
If no co m p la in ts  tick here  CD o th e rw is e  c o m p le te  b e lo w .
N um ber  
of days 
sym ptom s  
occurred  
since last 
visit
r e l a t io n s h i p  TO 
TEST DRUG EfFECTO NSTUO r
REQUREO
TREATMENT
is
1
1 1cn II If 113 z ii il Ï zSymptom Date of OnsetOar M ontft Ytar
• * *
• * •
• * •
• • *
'P ro b a b ly  not ra l l ie d — $p«c iIy p robable cause be lo w  "R e q u ire d  trea tm en t: specify d rugs  used, specia l studies o r consulta tions.
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AP PEN DIX II
The equations describing the concentration-time 
profiles of drug in plasma or synovial fluid were determined 
from the differential equations by the method of Laplace 
Transforms (Gibaldi & Perrier, 1975).
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GLOSSAR Y
General variables and constants
D Dose (amount)
F Availability
ka First order absorption rate constant
R Zero order input rate constant
t Time after the dose
*^ lag Time after the dose before drug is detected
T Time from T^^g to the maximum concentration
t' Time after T
X Amount
asma
dX/dt Rate of drug amount 
C Concentration
V Volume
CL Clearance
k First order rate constant
Subscripts
1 Central compartment
2 Peripheral compartment
S Synovial fluid
ss Steady state
el Elimination
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In all equations t is t-T^gg
MODEL J.: One compartment model with first order absorption
D  ^ gut
M Kg
Differential equation:
dX/dt = kgD - kgX (1)
Solution:
C = --    (e”^e^ - e”^a^)
V(ka-kg)
(2)
Estimated parameters: T^gg, kg, V/F, CL/F
Derived parameters: k« = CL/V
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MODEL 2: One compartment model with zero order absorption
gut
R
r
rkg
Differential equation:
dX/dt = R - kgX
Solution:
a) During absorption ( t < T) 
FD
C =   (1 - e-ket)
TVk_
where R = FD/T
(3)
(4)
b) After absorption has stopped (t > T) 
FD
C = ----  (1 - e-ke?) e-ket'
TVkg
Estimated parameters: T, CL/F, V/F
(5)
Derived parameter: = CL/V
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MODEL 3.1 Two compartment model with first order absorption
gut
Differential equations:
dX^/dt = kgD + ^2 X^2 — — ^10^1
dX2/dt — 2^ 1 ^21^2
Solution:
C = Ae-°t + Be-Gt _ (A + B)e"'^ a'^
where A =
F ,D .kg(&—k2^)
B =
C =
V^(a-B)(ka-“)
F ,D ,kg( B— ) 
V^(a-B)CB-ka)
F.D.ka(ka-k2^)
(6)
(7)
(8)
V^Ca-kgXkg-B)
ot and 3 are complex rate constants which relate to k^2» 2^1 ^10
ot + 3 — k^  2 2^1 ^ k^  Q
Estimated parameters: k_, A, a , B, 3
D
Derived parameters: CL/F =
A + B
a 3
V^/F =
A + B
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MODEL J4: Two compartment model with zero order absorption
gut
R
1 2
I 2^1ho
Differential equations:
dX^/dt — R + kg^Xg — ^^2^1 "" ^10^1
dX^/dt — 2^1 *" ^21^1
Solution:
a) During absorption (t < T)
= A(e-°* - 1) + B(e-Gt _ 1)
(9)
(10)
(11)
FD(k2^“ )^ ET^ (3—
where A =   and B =-------------
V^T a(a-3) V^T3(a-3)
b) After absorption has stopped (t > T)
= A(e”*^  - 1)e-"t' + B(e-"T - 1)e-"t') (12)
Estimated parameters: "^ lag» » ^ 21 » 1^
Derived parameters: CL = V^/kg^
^2 = ^1^12^^21 
Vss = Vi + V2
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i lODSL 5: Two compartment model with zero order absorption -
central and peripheral compartment concentrations
D
R
"12,
1 2
21
▼ *<10
Differential equations:
Solution:
dX^/dt see equation (9)
dX^/dt see equation (10)
a) During absorption (t < T)
see equation (11)
Co - C(e-°* - 1) + D(e-Bt _ i) (13)
FDk
where C =
12 FDk
VgTaüi-G)
and D =
12
V2T3(3 -a )
b) After absorption has stopped (t > T) 
see equation 12 
Co = C(e"°^ - 1)e-°^' + D(e-Gf - 1)e-6t' (14)
Estimated parameters: T^^^, T, a , 3 » -2 1> ^1> ^2
Derived parameters: See Model 4
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MODEL Two compartment model with zero order absorption and
a synovial fluid compartment.
10SO
gut
Differential equations:
dX<j/dt — R + 2^ 1 ^10^1
dX^/dt — ^“12^ 1 "* ^21^2
dXg/dt = k^3 - kggXg
Solution:
a) During absorption (t < T) 
see equation (11)
(15)
(16) 
(17)
Cs = — (e““  ^- e-^SO^) + — - (e"^^ - e"^SO^) (18)
(k3o-a)V3 (kso-e)Vs
b) At the end of absorption (t = T)
Cg = CgÇT)
where A and B are as defined previously for equation (11)
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c) After absorption has stopped (t > T) 
see equation (12)
Cg = _________ (e’°^  - 1)(e"^^' - e-ksot') (19)
(k3o-a)V3
+  (e-GT - 1)(e“ ^ '  - e-ksot') + 03(1)6-^50%'
(k3Q-3)V3
stimated parameters: T^gg, T, a , 3, k2 '|, V^ , k3Q, k^3/V3 
erived parameters: see Model 4.
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Multiple do s in;;: steady state
Any equation which describes the time course of a drug after 
a single dose can be directly converted to a multiple dose 
equation by multiplying each exponential term containing *t’ by 
the multiple dosing function (Gibaldi & Perrier, 1975);
1 - enkx
1 - e-kT
(20)
where n is the number of doses, x is the dosing interval and k is 
the first order rate constant.
At steady state, n can be set to infinity and the multiple 
dosing function simplifies to:
1
1 - e-kT
(21)
1. One compartment model with zero order absorption (Model 2)
C =
FD (1 - e-ke?)e-kt 
VTkgd - e " V )
(22)
2. Two compartment model with zero order absorption (Model 4)
FD
C =
V^ T(bt-3)
(!<2i-ci)(e-‘^  -
(1 - e-°^) ( 1  -
(23)
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APP END IX III
For a drug which is bound to two independent sites in 
plasma, the equation relating free and bound
concentrations, assuming the law of mass action is;
nP-| Cu nPo Cu
Cb =  ±____ + — ±....  (1)
Kdi Cu ^d2 Cu
Since: Cb = C - Cu  (2)
nP-| Cu nPo Cu
C = Cu + —  ---  +.— ....   '............. (3)
Kdi + Cu K^2 Cu 
Rearrangement of this equation with Cu as the dependent 
variable and C as the independent variable, gives a cubic 
equation :
Cu^ + (C—Kj2"K^2*nP2 —nP2) Cu^
+ (C.Kji+C.Kj2-Kdi.Kj2-nPi-Kj2-nP2'Kdl) Cu 
- C.K^1.K<32 = 0 ...............................(4)
which cannot be solved explicitly. Rearrangement of Equation 
1 in terms of Cu, gives a quadratic equation which can be 
solved:
A.Cu^ + B.Cu + C = 0 ........................... (5)
and Cu is given by the positive root:
   (6 )
2A
where: A = nP^ + nP2 - Cb
B = nP^.K^2 ^^2*k(31 ~ Cb.K^^ ” Cb.K^2
C = - Cb.Kji.Kj2
-B + V  4 AC 
Cu = ----- Ï---------
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The program used to determine the free concentration in 
plasma from total drug concentration using the binding 
parameters determined from fitting binding data to the 
Langmuir isotherm for two classes of binding sites.
20
DIN Cror (50) ,FR(nO) ,FREE(5</> 
FT P-"££££. f: £££'■■: F2 F ^ = ■•£.]:■:££ |Ç£ " 
i Il’in ==3
t "
sT tes. .
4(.'
Utj 
60 
70 
75 
BO 
90 
105 
110 
120 
130 
140 
150 
200 
210 
250 
260 
270 
280 
290 
300 
310 
31 5
N2
330
; KD2
340
350
360
370
380
PH H IT
INPUT
INPiil
PfTNT
PRINT
INPUT
INPUT
I-=0
1 = 1 F I
I Npu r 
ITER;
'Type 
'I I c j  .  o-f 
‘Pd 1 . .
'Type ; 
'No.of sites,
;N1 
; KD1
;N:
■Kd2............  ";KD2
PRINT;IF I> 50 THEN 300
"Ctotal.........  ";CT:CTOT(I)=CT
1
DELTA=. 05 : F=0 : P 1 =--1 
F=F-t-U£l.TA
F2=Nl*F/(KDlrCT*F) + N2*F/(KD2+CT*F> 
IF f-T< 0 AND F2 >= 0 THEN 200 
F1=F2:GGTG 120
ITER=ITER+1: IF ITER=LIMIT THEN 250 
F=F-DEL TA:DELTA=DELTA/10:GOTO 120 
CF=F*CT: PR(I)=F:FREE(I)=CF
+ F — 1
PRIM r 
AT="V' 
PRINT 
PRINT 
PR I NT 
PRINT 
PRINT 
PRINT
'Free fraction = "; F 
INPUT "Repeat...FY] ;A$:IF A$< >"N" AND A $ 0 " n "  THEN 80
' Summar y ": PRINT ' 
' Class Class 2 ‘
' N o .
PRINT "Kd
PRINT 
PRINT "
PRINT " ====
FOR J=1 TG I 
PR INT J;:PRINT 
: PRINT "
"; : PRINT USING F I T ;N 1 ; ; PRINT ' 
"; ; PRINT USING FIT:KD1 ; : PRINT
; PRINT USING FIT; 
::PRINT USING Fit
Total cone, Free conc. Free fraction"
440
445
450
455
'Switch ON 
"Summary":
'No.
; FREE (.7)
390 NEXT 
400 INPUT 
410 LPRINT 
415 LPRINT 
42'T I FF; 1177 
425 LPRINT 
FIT;N2
430 LPRINT "Kd 
FIF;KD2 
435 I.T P 1 NT 
LPRINT "
I T' R I NT "
FGR J=] TO I 
LPRINT J;:LPRINT " 
NG FIT;FREE(J);:LPRINT 
FR(J)
460 NEXT
";-.PRINT USING F1T;CT0T(J); 
-.PRINT USING F2T;FR(J)
PRINT : PRINT USING FIT
printeîr and 
LPRINT "=== 
Class 1
type key";AT
Class 2"
LPR I NT US I NG F 1 T ; N 1 ; : LF'R I NT ' 
LPRINT USING FIT;KD1 ; :LPRINT
LPRINT USING
; LPR I NT USINIS
Total conc. Fr ee conc Free fraction"
";:LPRINT USING FIT;CTGT(J);;LPRINT 
";:LPRINT USING F2T;
;LPRINT USl
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AP PE ND IX IV
To run the 1980 version of NONMEM (Beal & Sheiner, 
1980) a control file must be provided by the user which is 
specific for the structural model and the data set to be 
analysed. The 'PRED', a Fortran subroutine, contains the 
function for the structural model, together with the 
derivatives of the function (G array) with respect to each 
of the parameters (0). The G functions define the inter­
subject error structure (normal or log normal). The intra­
subject error structure (additive or proportional) is 
defined in the H function.
Examples of control files and 'preds' are given for 
linear and E^^% concentration-response models and protein 
binding models.
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a) The 'pred' and control file for a linear model used to 
describe dose or concentration-response data in Chapters 
5 and 6.
(0001>
(0002)C
(0003)0
(0004)0
(0005)0
(0006)
(0007)
(0008)
(000?)
(0010)
(0011)
(0012)
(0013)
(0014)
(0015)
(0016)
(OOi?) fec£r?ii**
SUBROUTINE PRED(ICALL.NEWIHD.THETA.DATREC.INDXS.F.G.H) 
2 RARAri
PARAM INTERCEPT & SLOPE
OIMENSIuN DATREC(3).THETA(2).G(2).INDXS(1).H(1)
DOUBLE PRECISION T H E TA.F.G.H 
C=DATREC(9)
F=iHETA(1)+THETA(2)TO
G ( D  = 1.0
6(2)=C
Gi1)=G(l)-rKETA(1)
G(2)=G(2)+THETa(2)
H(1)  = 1.0
RETURN
END
( 0 0 0 1 -DATA A K L I B Î .NAP12
(0002)+***
(0003)PR03 CONC EFFECT
(0004)DATA 1 0 71 9
(0005)ITEH 1 8 0 0 1
(OOOÔ)LABL SÜBJ DOSE QRDR CONC EFF1 EFF2 EFF3 EFF4 FR
EE
(0007)FORM
(0008)( 9 F 7.I)
(0009)3TRC 2 2 ! 0 0 1 0 1 0
(OOIO)THTA 9. 0 -0.001
(00:!)3IA0 3.0 0.003
(0012 )DI AG 2.0
(0013)E3TH 02000 4 5 0 0 0 Q . . . . E s t i m a t i o n  p a r a m e t e r s
( O O H ) C O V R 0
(0015)TA3L 2
(0016)3C h T 0 9
(0017)SCAT 9 8
(001G )SCAT 9 10
(0019)SCAT 10 11
(0020)SCAT 10 12
(0021)3CAT 9 11
(0022)SCAT 3 11
( 0 0 2 3 ) V m ^ 8 12
(0024)SCAT 9 12
(0023) SCAT 10 8
(0026)-iEN[i>>
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b) The 'pred' and control file for an Emax model used to 
analyse dose or concentration-response data
)
(0002)C
(0003)C
(0004)C
(0005)C
(0006)
(0007)
(0008)
(0009)
(0010) 
(0011 ) 
(0012)
(0013)
(0014)
(0015)
(0016)
(0017)
(0018)
(0019)
(0020)
I C A L L . N E U I H D . T H E T A . D A T R E C . I N D X S . F . G . H )SüBPuUTINE PRED 
EMAX 3 PARAM
PARAM CMAX. T50
D IMErlS I OH DAT REC ( 3 ). THE T A  ( 3 ). G ( 3 ). INDXS ( 1 ) .H ( 1 )
D OU BL E P R E C I S I O N  T H E T A .F .r 1.G .H
T=D ATR EC (?)
F 1 = T H E T A ( 1 ) * T / ( T H E T A ( 2 ) M )
F= F I +T H E T A ( 3 )
G(1 j=T / ( T H E T A ( 2 ) + T )
G ( 2 ) = ( T H E T A ( 2 ) + T ) * ( T H E T A ( 2 ) + T )
G ( 2 ) = - T H E T A ( D * T / G ( 2 )
G ( 3 ) = 1.0
G ( 1 ) = G ( 1 ) * T H E T A ( 1 )
G ( 2 ) = G ( 2 ) * T H E T A ( 2 )
G ( 3 ) = G ( 3 ) * T H E T A ( 3 )
H ( 1 ) = 1 . 0
RE T URN
END
(0 0 2 1)
( 0 0 0 1 )Dh TA 
( 0 0 0 2 ) k k k
h KLIB 1 .MAPI
(00 03 )P R 03 CONC EF F E CT
( 0 0 0 4 ) DATA 1 0 71 9
( 0 0 0 5 ) ITEM 1 8 0 0 1
(0006)LA BL  
EE
( 0 0 0 7 ) FORM 
(00 0B)(?F7.1 )
SUBJ DOSE O R D R  C O N C
(00 09 ) ST R C 3 3 1 0 0 1 0
( O O iO)THTA -5 .0 50 .0 10.0
( 0 0 1 1 ) DIAG
(0012)IiIAG
10.0
5.0
10.0 10.0
( 0 0 1 3)E3 TH
(0014 ) coyR
(00 15)TA BL
02000 4 
0 
2
5 0 0 0
( 0 0 1 6 ) SCAT 0 9
(0017 ) SC A T 9 8
( 0 0 1 8 ) SCAT ? 10
( 0 0 1 9 ) SCAT 10 11
(0020)3C AT 10 12
(0021)3C AT 9 11
(0 0 2 2)SCAT ? 12
(00 2 3 )S C A T 10 8
(0 0 2 4)SCAT 8 11
( 0 0 2 5 )S C A T,
( 0 0 2 6 ) k k E N D + *
8 12
EFF1 E F F 2 EFF 3 EFF4 FR
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c) The 'pred' and control file for a Langmuir isotherm
rearranged in terms of free concentration used to analyse 
naproxen protein binding data.
SUaaCUTI . N '  P , < E Û ( I C A L L ^ N Ç w I N O , T H £ T A , O A T R £ C / I N O X S / F / G / H )
aiNùI.NG PREO
NI -i N2 prop, to ALE.
DOUBLE PRECISION THETA,H,G,F
DOUBLE PRECISION XN1,XK1,XN2,XK2,A,8/C/D0,0FDA,DF08,0FDC 
0IMENSI0;1 THETA(4),DATREC(4),H(1),G(4),INDXS(1) 
XB=DAT8EC(2)
AL0=DATREC(4)
XNl=THcTA(1) + THETA(5)*ALE 
XK1=THETA<2)
XN2=TH£TA(i) + THETA(6)*ALB 
XK2=THETA(4)
A=XN1+XN2-X3
a = X N 1 * X K 2  f  X N 2 * X < 1  -  X K 1 * X B  -  X K 2 * X E  
C = -  X K 1 * X X 2 + X 3  
DD=8*B-4,*A»C 
OD=SQPT(DO)
F = - a / ( 2 . * A )  + 0 0 / ( 2 . * A )
DFDA=-F/A- C/(A*DD)
OFOa= -1 ./(2.*A)-3/C2.*A*0D)
OFOC=-1./OD
G(1)=0F0A+UFüE*XK2
G(2)=DFD3*(X.N2-Xa)-Dr DC^XK2*X3
G(3)=DF0A+0FDE*Xk1
G(4)=0FDJ^CXn1-X=) -0FDC*XK1^X3
H(1)=F
RETURN
END
DATA F DUN.BIND
NSFO F DUN.MSP2
****
PRO0 BINDING DATA WITH Nl,N2 PROP. TO
DATA 1 0 156 4
ITEM 1 3 C 10 1
INOX 0 C 0 0 0 0 0 0
LABL SUOJ BND FREE ALB
FORM
(4F1Ü.4)
STRC 6 4 1 1 1 1 0 1
THTA 0.000 C.07Q 000.000 6.900
LOWR 0.000 0.050 00.000 4.000
UPPR 000 .000 Q.2CC 000.000 9.000
OIAG 5.QUO 0.025 500.000 2.000
OIAG 0.100
ESTM 0 500 3 1 0 1 1
COVR 1
TABL 1 1
TABL 3 1 0 2 0 3 0
SCAT 1 3
SCAT 2 6
SCAT 3 6
SCAT 4 6
SCAT 5 6
SCAT 2 7
SCAT 3 7
SCAT 4 7
SCAT 5 7
ALB
0
2 . 0 C 0
1 . 5
5 .
12.000
8.0
1 5 .
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